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iv Foreword 
The European Commission  considers  it  a  priority  to  help  in  preventing  death  from  cancer  by  early 
detection through screening programmes. Thus the third action plan to combat cancer, better known as the 
Europe against Cancer programme,  has  helped to  provide  evidence for  European  high  quality  cancer 
screening programmes. A conditio sine qua non to  establish and to monitor the efficacy of any cancer 
screening programme is  the European-wide availability of high quality  cancer registries,  which  is the 
objective of the European Network of Cancer Registries (ENCR), another priority of the Europe against 
Cancer programme. 
While early detection of a specific cancer by screening appears, at first sight, to be a promising method of 
preventing death, conclusive evidence on its efficacy at the public health level must first be established. 
For cancer of the cervix uteri, for example, this was possible, using time trend analyses, based originally 
on data from population-based cancer registries in the Nordic countries. For breast cancer screening using 
mammography, the evidence of benefit is largely based on fairly  small screening trials,  and somewhat 
varying  results  of population based time  trend  analyses.  Overcoming  these  shortcomings  became the 
prime objective  of the  European  Breast  Cancer Screening  Network,  which  has  aided  in  establishing 
European-wide guidelines for more uniform high quality breast cancer screening. In tum, this improved 
the comparability of the available data from different national settings, demonstrating true European added 
value. 
It seems likely that new screening programmes will be implemented as public health policy based upon 
limited screening trials, usually without a  mechanism for evaluation of their effectiveness. However, it is 
not self-evident that the positive results of screening trials will be replicated in a service setting, let alone 
be readily transferable to other countries with different health care systems.  In this instance, one of the 
few tools available to evaluate the results of such new public health interventions is the population-based 
cancer registry. 
A number of factors  may  affect  the  efficacy  of a screening intervention in the  long  term.  There are 
examples  where the anticipated results of a new screening policy  were not achieved,  but where,  after 
critical re-evaluation, the organisation of the programme was remodelled yielding satisfactory results. In 
the era of evidence-based medicine,  this  routine monitoring  of the performance of existing  screening 
programmes is of utmost importance. Population-based cancer registries are uniquely placed to provide 
the data needed for these processes. 
This monograph provides a wide range of experiences from cancer registries in Europe and North America 
in the evaluation and monitoring of existing screening programmes. As such, I hope it will aid researchers 
in choosing the necessary data and  applying  appropriate methods.  The reader should also  realise  that 
despite  more than  30  years'  experience,  there are  still  very  demanding  aspects  in  the  evaluation and 
monitoring of screening programmes. These challenges need very careful consideration in each unique 
setting. 
David Byrne 
Commissioner 
Health and Consumer Protection Directorate-General 
European Commission 
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viii Chapter 1.  Introduction: study design and the potential 
of cancer registration 
D.M.Parkin 
A distinction should be drawn, at the outset, between studies which are concerned 
with the evaluation of screening, and those which aim to monitor the performance 
of  an  ongoing  programme.  Strictly  speaking,  evaluative  studies  should  be 
performed before the introduction of a particular screening programme, in order to 
decide on the likely effectiveness, and possibly also on the resource implications 
(cost-effectiveness).  Normally,  we  are  concerned that  screening  will  reduce  the 
number of new cases of invasive cancer (if  the test detects precursor lesions) or the 
number of deaths from the cancer (if aiming to detect early or pre-clinical invasive 
disease).  It  is  only  with  this  assurance  that  certain  so-called  'intermediate 
endpoints'  - such  as  numbers  of preclinical  lesions  detected/treated,  size/stage 
distribution, and survival in screened vs. unscreened populations- can be used to 
monitor screening programmes. By themselves, they provide no reassurance, as the 
lessons  of screening for  neuroblastoma (see  Chapter  17  in  this  volume)  clearly 
demonstrate. 
Sometimes cancer registries have been a part of evaluative studies on effectiveness 
of screening. Probably more frequently, they are expected to aid the monitoring of 
existing programmes. The methods available depend upon the data to which the 
registry has access. These may be, for example, simply the incident cancer cases in 
a given population in which screening is ongoing. Alternatively, the registry may 
have access to the database of the screening programme itself, so that the screening 
history  of individual  members  of the  population  is  known.  Clearly,  the  latter 
circumstance permits investigations to be better focussed,  than  in circumstances 
where the extent of screening must be inferred from population averages. 
Studies using the registry database alone 
Changesinincutence/~noT!Uduy 
Here the focus  is simply upon  the time trends  in  incidence  and mortality  from 
cancer following the introduction of screening (or changes of screening policy). 
This is analogous to the before/after study design in evaluative research, and like 
all such studies, is fraught with problems in interpretation, largely through lack of 
certainty of what would have  happened in the  absence of screening (no control 
group) with which to compare the outcome. The type of evidence concerning the 
presence  of screening  activity,  and  its  intensity,  is  variable.  It  may  be  simply anecdotal (e.g.,  'screening was introduced in  1988'), be supported by actual data 
from the screening programme (rate of testing- tests per 1000 eligible subjects per 
year), or possibly from the registry itself (registrations of screen-detected disease). 
As  an  example  of the  latter,  many  workers  have  used  registration  rates  of 
carcinoma  in  situ  or of micro-invasive  cancers  as  an  indication  of screening 
activity,  with  which  to  compare  trends  in  symptomatic,  invasive  disease  (e.g. 
Boyes et al., 1981). 
It is only for screening programmes which attempt to prevent the onset of invasive 
cancer that monitoring of incidence provides a direct measure of outcome.  The 
principal example is cancer of the cervix (screening by cytology}, although even 
here (see below) there is an  additional component of benefit due to detection of 
early invasive disease (micro-invasive, or occult/asymptomatic invasive). For oral 
cancer  screening,  too,  at  least  part  of the  potential  benefit  should  be  through 
detection  of pre-malignant  conditions  such  as  leukoplakia,  erythroplakia  and 
submucous fibrosis. However, the appropriate treatment for such lesions is far from 
clear, and so far there is no objective evidence that the rate of invasive disease can 
be reduced by their detection. 
For screening programmes designed to detect early invasive cancers, no reduction 
in incidence should occur. Indeed, the introduction of screening should be followed 
by a rise in incidence (as prevalent, asymptomatic cases are detected), followed by 
a fall,  so that cumulative incidence is  ultimately unchanged over what it would 
have been without screening (Walter and Day, 1983). 
Cancer registry data can be used to monitor the extent of this phenomenon. The 
introduction  of screening  for  breast cancer  has  certainly  led  to  an  increase  in 
incidence in age groups receiving mammography in the USA (Chu et al.,  1996}, 
and the UK (Quinn and Allen,  1995), and the increase in recorded 'incidence' of 
prostate cancer in the USA has been even more dramatic (see Chapter 13  in this 
volume). It remains to be seen whether these increases will be reversed. 
There have been many studies of trends in incidence of cervix cancer in relation to 
screening policies - for example the studies of incidence in the Nordic countries 
with respect to  the date of introduction  and intensity of organised screening in 
different countries, and the trends by age group with respect to those targeted for 
screening (Hakama, 1982; Hakama et al., 1991). 
Trends in size or stage of  tumours 
Many  cancer  registries  attempt  to  record  stage  of  registered  tumours,  and 
sometimes also their size. One good reason for doing so is to study the effects of 
screening,  since  cancers  detected  by  screening programmes  must  have  a  more 
2 favourable stage distribution, and be of smaller size than those detected clinically 
(via symptoms), if  the programme is to have any benefit. 
Using  registry  data  alone,  it  has  been  common  to  examine  the  proportionate 
distribution  of diagnosed cancer cases  by  stage  at  diagnosis,  in  relation  to  the 
presence  of screening  (or  measures  of screening  intensity,  as  above).  More 
meaningful  is  calculation of rates  of disease,  by  stage,  in relation  to  screening 
activity.  In  principle,  screening  should  lead  to  a reduction  in  the  incidence  of 
advanced  cancers.  This  is  usually  in  the  context  of trends  over  time  (see,  for 
example, for cervix cancer: Christopherson et al., 1976; Johannesson et al., 1978; 
for stomach cancer: Hisamichi et al.,  1991; for breast cancer: Chu et al., 1996; for 
colon cancer: Chu et al., 1994). 
An  inevitable  problem  of studying  temporal  trends  in  stage  (without  a  true 
comparison  group)  is  the phenomenon  of stage  migration.  This  occurs  because 
improvements  of investigative  methodology  over  time  result  in  tumours  being 
classified to  higher stages  than  they  would  have  been  in  an  earlier period  (by 
detection of small metastases, for example). 
Comparisons  between  sub-populations  receiving  screening  or not  (or  different 
intensities of screening) (e.g., Taplin et al., 1997) largely avoids problems of stage 
migration,  but  does  raise  other  questions  concerning  the  comparability  of the 
populations being compared. 
Trends in survival 
Cancer registries are increasingly concerned with follow-up of registered cases in 
order to perform survival analyses. Survival is influenced by many factors (Sankar 
and Black, 1999), but size and stage of tumour are powerful predictors of outcome. 
Screening programmes might well expect to be associated with improvements in 
overall survival, therefore. Survival trends, by age, have been studied in relation to 
early diagnosis of breast cancer due to screening (Chu et al., 1996) or to improving 
breast-awareness  (Stockton  et al.,  1997)  and  to  early detection  of colon cancer 
(Chu et al., 1994). In both cases, the favourable trend in survival was due to a shift 
to earlier stage at diagnosis as well as better survival within stage. This latter effect 
is probably the results of improved therapy, although the possibility that some of it 
is due to stage migration should also be considered (Feinstein et al., 1985). 
Ecological (  co"elation studies) 
The idea is to compare rates of disease in different populations, with some measure 
of screening intensity. As far as cancer registries are concerned, the relevant rates 
are incidence rates, or, more usefully, the change in incidence in relation to the 
screening input. This means that studies are confmed to cervix cancer screening, 
with the  'exposure'  being expressed as  the rate  of screening (in  relation  to the 
3 eligible population), or as registrations of in situ cancers (Fouquet and Gage, 1996; 
Bergstrom et al., 1993; Lynge, 1983). 
Studies with linkage to data on exposure to screening 
Generally,  such  studies  will  involve  linkage  to  the  database  of  a  screening 
programme,  in  order to  allocate  individuals  to  different categories  of screening 
exposure. 
The simplest study design  is  the cohort study,  in  which  incidence of disease is 
compared  in  screened  vs.  unscreened  individuals  with,  for  cervix  cancer,  the 
objective of deciding the decrease  in  risk which  might plausibly be ascribed to 
screening. Thus,  in British Colombia the relative risk of invasive cervix cancer, 
adjusted for age, was 6.8 times higher in unscreened women, compared with those 
who had had one or more tests (Fidler, 1968). 
Pettersson et al. (1986) carried out linkage between the screening register and the 
national Cancer Registry of Sweden. They were thus able to calculate incidence 
rates of cervix cancer according to screening history (number of tests, time since 
previous test, result of test)  as  well  as  by  age.  These rates  were compared with 
those  recorded  prior to  screening  (taken  to  represent  'expected'  values  in  the 
absence of screening). 
The  problem  with  these  studies,  as  in  all  non-randomised  comparisons,  is  the 
difficulty in being certain that the groups being compared are similar except for 
their  experience  of  screening.  Women  who  do  not  take  part  in  screening 
programmes (or who  attend few  times,  in contrast to regularly)  are  probably at 
higher risk of cervix cancer than those who do not (Hakama and Rasanen-Virtanen, 
1976). In a more recent linkage study of the screening programme in Sweden with 
the cancer registry, Sparen et al. (1996) found that incidence in unscreened women 
was similar to that pre-screening (Figure 1  ). The authors suggest that this implies 
that  bias  due  to  self-selection  might  be  small,  although  the  curves  pertain  to 
different  time  periods  ( 1958-67  and  1968-92),  and  hence  very  different  birth 
cohorts, so that it is difficult to be certain. 
The  tactic  usually  employed  by  epidemiologists  in  analysing  cohort  studies 
involving  self  selection  into  exposed  vs.  non-exposed  groups  is  to  adjust  for 
potential confounders (in the screening context, this  would be factors  related to 
both screening uptake and risk of cervix cancer). This has rarely been done in the 
cohort-type  of analysis  mentioned  above~ Probably this  is  due  to the relatively 
sparse data on  individuals which can be obtained from the records of screening 
programmes - which do not usually include risk factors for the disease, or for death 
from  the disease.  In  general, this  is  not a problem for evaluating cervix cancer 
4 screening programmes,  where  the  reduction  in  risk  in  screened  vs.  unscreened 
women is simply too big to be ascribed to confounding. But the level of mortality 
reduction  expected in  breast cancer  screening programmes  is  small,  and  could 
easily be obscured by the inclusion of women at higher than average risk of death 
Incidence per 
100,000 women-years 
75~------------------------------------------~ 
50 
25 
Age 
Figure 1.  Age-specific  incidence  rates of cervix cancer in  a  cohort of women  in 
Sweden according to screening status, and for the same geographic area pre-screening 
(1958-67) (Sparen, 1996, reproduced by permission of the author) 
from breast cancer in the screened population. In fact,  it seems clear that women 
who choose to undertake regular breast self-examination (Gastrin et al., 1994) or to 
attend mammographic  screening programmes  (Moss  et al.,  1992;  Taplin  et al., 
1989) do have a higher than average risk (incidence) of breast cancer, by virtue of 
their risk profile (educational level, height, weight, fertility, family history, etc.). 
Thompson  et  al.  (1994)  used  a  case-cohort  study  design,  in  which  detailed 
information on  screening and on risk factors  was  obtained from a sample of the 
entire cohort of women (subjects enrolled in a health maintenance organisation) as 
well as for the breast cancer deaths occurring. Adjusting for confounders (related to 
death from breast cancer)  reduced the risk  of death  from  breast cancer among 
women aged 50 or more and screened within the previous year from 1.08 to 0.61. 
The  introduction  of breast  cancer  screening  in  Finland  was  very  systematic, 
involving  certain  municipalities,  and,  within  these,  invitations  to  women  in 
different (single year) birth cohorts over a five-year period. This population could 
be followed up by the cancer registry and, for a short period after screening (3-4 
5 years), the mortality rates were compared in screened, invited but unscreened, and 
control women (Hakama et al., 1997). Although technically a cohort study, women 
were allocated to screened and unscreened categories by adjacent birth cohorts, so 
there could have been little difference between the groups in terms of confounders. 
A small but significant reduction in mortality  was present in women invited for 
screening (  vs. unscreened controls) at 3-4 years post screening. 
Cancer registration and the randomised controUed screening trial 
Randomised trials remain the established method of evaluating the effectiveness of 
screening (they have no role in monitoring ongoing programmes). The fact that 
they are difficult to perform, of long duration, and expensive, means that few have 
been completed (for the evaluation of screening for breast cancer, and for colon 
cancer). In theory, a randomised trial established in the area which is served by a 
population-based cancer registry, would have the enormous advantage of automatic 
surveillance of the study  groups for  the onset of new  cases  in intervention and 
control populations. The issue of loss to follow up from out-migration would be a 
problem  for  regional  registries,  but  it  would  probably  be  non-differential  if 
randomisation was thorough, and lead to a loss of power, rather than any bias. 
The role of the registry in this context would be to follow  up the screened and 
intervention groups in order to monitor 
a)  overall (cumulative) incidence in screened/control groups (as a check on 
randomisation and/or the presence of any over-diagnosis); 
b)  stage/size of tumours, and survival, in screened and control groups 
(intermediate endpoints, but change in these must be present if  mortality 
reduction is to be achieved); 
c)  deaths from cancer in screenedlunscreened (the outcome measure, collected 
by registries undertaking follow-up of registered cases of all cancers, or the 
cancer under study). 
In fact, most randomised trials of screening in Europe and the United States have 
established their own follow-up  of the  study  populations, rather than rely  upon 
cancer  registration  (although  registries  may  comprise  part  of the  case-finding 
network, e.g. UK Trial of Early Detection of Breast Cancer (1993)). Perhaps this 
reflects the investigators lack of knowledge of registry work (or potential), as well 
as study funding sufficiently lavish to dispense with economies at this stage of the 
investigation.  In  our own randomised  studies  of screening for  breast cancer by 
physical examination in Manila, Philippines (Parkin et al.,  1997), or for oral cancer 
by visual inspection in Trivandrum, India, we depend on linkage between the study 
database  which  contains  details  of each  individual's  screening history,  and  the 
cancer registry database. 
6 Monitoring screening programmes 
Monitoring  of incidence  rates  of cancers  for  which  screening  aims  at  early 
detection (and reduction of deaths rather than of incidence) has  several purposes. 
The interpretation of overall incidence in  screened vs.  unscreened populations is 
not  straightforward.  On  the  one  hand,  any  observed  differences  might  be 
interpreted as  reflecting self-selection for screening as noted.  On the other hand, 
early detection programmes clearly influence incidence of disease, either by simply 
advancing  date  of diagnosis  (with  a  short  term  increase  in  incidence)  or  by 
detecting  cancers  that  would  never  have  otherwise  surfaced  during  life  (over-
diagnosis). The latter effect seems particularly strong for prostate cancer, so that 
incidence  rates  in  a  group  of  individuals  that  has  been  screened  will  be 
permanently higher than the unscreened. 
Day  et  al.  (1989)  have  described  how  information  on  incident  cancers  in 
screened/unscreened individuals may  be used to monitor breast cancer screening 
programmes (Table  1). Cancer registry data are required in order to estimate the 
'expected'  distribution  of cancers  by  stage,  or  the  'expected'  incidence  rates 
(overall, by age group, and/or by stage), against which the results in the screened 
population  can  be  evaluated.  Linkage  of the  cancer  registry  and  the  screening 
programme  is  required in  order to  calculate  incidence  rates  of interval  cancers 
(detected between  screenings)  and incidence of advanced cancers.  The  methods 
concerned are reviewed by Wait (see Chapter 9 in this volume). An example of this 
type of analysis is provided by McCann et al. (1998), who studied the incidence of 
breast cancer, by stage, according to mode of detection, following the introduction 
of screening for breast cancer in East Anglia. By linkage of the cancer registry with 
the data base of the screening programme, cancers could be separated into screen 
detected,  interval  cancers,  cancers  in  non-attenders,  etc.  Schouten  et al.  (1998) 
have  performed  a  similar  analysis  for  the  population  of  Limburg  in  the 
Netherlands. 
The case-control study has  a rather long history of use in  the evaluation of the 
effectiveness of cancer screening programmes (Morrison, 1985). These studies are 
of course  much  more  simply  and  rapidly  applicable  than  the  cohort  designs 
described earlier. They also have the advantage that screening histories need only 
be  obtained  for  a  limited  number  of subjects.  This  may  even  be  done  by 
interviewing the subjects (if deaths from cancer do not comprise the case-group), 
without recourse to screening records, although several studies have suggested that 
interview data may not always reflect that from more objective sources (Gordon et 
al.,  1993).  Although  traditionally  the  case-control  study  has  been  used  to 
investigate the effectiveness of screening, there is no conceptual difference to the 
'audit' of ongoing programmes with the same techniques (Sasieni et al., 1996). For 
cervix cancer, registries should be particularly well placed to provide a list of all 
cases  of invasive  cancer as  the  potential  case  group.  As  in  the  cohort  studies 
7 described  earlier,  the  main  problem  in  interpreting  the  results  of case-control 
studies is selection bias (Moss, 1991; Friedman and Dubin, 1991). 
Table 1.  Monitoring measures for breast cancer screening programmes (Adapted from 
Day et al., 1989, Br J Cancer 59:954-958, by permission of  the publisher Churchill 
Livingstone) 
Measure  Comment  Additional  Evaluation 
information  provided 
Prevalence at the  As a multiple of  'Expected' estimated  Sensitivity, lead 
first screen  'expected' incidence  from incidence in  time, sojourn 
in screened women  non-compliers (  un- time, predictive 
screened) and a  value 
comparable popula-
tion with no screen-
ing programme (e.g., 
historical rates) 
Rate of  interval  As a proportion of  Identify all interval  Sensitivity, lead 
cancers  'expected' incidence  cancers. 'Expected'  time, sojourn 
in screened women,  rate calculated as  time, predictive 
by time since last  above  value 
screen 
Stage/size  Compare to  Stage/size distribu- Indicates potential 
distribution of  'expected' stage  tion in non-compliers  for reduction in 
screen-detected  distribution in the  (  unscreened) and in a  absolute rate of 
cancers  absence of screening  comparable popula- advanced cancer 
(1)  initial screen  tion with no screen-
(2)  subsequent  ing programme (e.g., 
screen  historical data) 
Incidence of  'Advanced' must be  Stage/size distribu- Early surrogate of 
advanced cancers  defined, and majority  tion in non-compliers  mortality 
of  cases classified as  (unscreened) and in a 
early/advanced.  comparable popula-
Compare to  tion with no screen-
'expected' incidence  ing programme (e.g., 
historical data) 
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12 Chapter 2.  Planning and designing of screening programmes 
M.Hakama 
In  the  evaluation  and  monitoring  of  screening  for  cancer,  the  design  of  a 
programme can not be  separated from  the  analysis.  The programme  should be 
designed in  such a way  that it can be evaluated.  This  simple  principle  will  be 
illuminated by the experience from Finland. The programmes considered are for 
cervical cancer and for breast cancer. These are the modes of screening which can 
as  a rule be run  as  public health policies. Much which follows below applies to 
screening  for  other  cancers.  However,  these  other  programmes  are  still  in 
experimental phases. 
Indicators of  effect 
The purpose of screening is to reduce the mortality :from the cancer subjected to 
screening.  Therefore,  the  primary  indicator  of effect  is  the  observed  mortality 
compared  with  the  expected,  assuming  no  screening.  For cervical  cancer,  the 
preinvasive disease is detected by screening and therefore reduction in incidence of 
invasive cancer is also a valid indicator of effectiveness. 
Process  or intermediate indicators  are  also  used  in  the  evaluation of screening. 
They are applicable if there is proof of effect in  terms of reduction in mortality, 
and evidence of a relationship between the intermediate indicators and the outcome 
indicator. The best of these intermediate indicators is  a change in the incidence 
(not proportion) of advanced disease, due to screening. Most process indicators are 
the results of the screening examinations, such  as the numbers or proportions of 
early or preinvasive cancers detected at  screening or the proportion  which such 
cases comprise of all cancers. Short term follow-up  may permit estimates of the 
validity of the screening test. 
The basic measures of validity of a screening test are sensitivity and specificity. 
Sensitivity  is  an  indicator  of the  yield,  and  specificity  that  of the  cost  of the 
screening. For a successful screening programme the performance of the test alone 
is  clearly  not  sufficient.  There  are  other  problems,  e.g.  in  participation  in  the 
programme, and in the referral system (for individuals with a positive screening 
test). 
It is, therefore, useful to consider also the programme sensitivity and programme 
specificity (Hakama,  1984).  The programme  sensitivity is  the  proportion  of the 
13 persons diagnosed as having the disease as a result of  participating in the screening 
programme  out  of the  total  number  of persons  with  the  disease  in  the  target 
population  covered  by  the  programme.  The  programme  specificity  is  the 
proportion of persons not diagnosed as having the disease in the disease-free part 
of the target population. Not diagnosing the cancer will be either due to a negative 
test, or to the test not being applied, i.e. the person was not screened at all, or that a 
person with a positive test did not have diagnostic confrrmation of  the test result. A 
valid test is a prerequisite for a successful programme, but the programme may fail 
even if the test is valid. There may be substantial differences in test sensitivity and 
programme sensitivity,  on the one hand,  and  in  test specificity and programme 
specificity on the other. 
The cancer registry collects data on the incident cases, and provides indicators of 
programme validity through the follow-up of the target population and the linkage 
of cancer registry and screening information. 
Mortality  data  can  be  extracted  from  death  certificates.  There  are  reasons, 
however,  to prefer information  on  cancer deaths  from  the cancer registry.  The 
cancer registry diagnosis is more accurate because more is known of the individual 
at the registry than by the one who signs the death certificate. This is especially 
true for cervical cancer because in the death certificate the diagnosis is often given 
as uterus unspecified. Such diagnoses were common in the early years of cervical 
cancer screening. Furthermore, incidence of invasive disease for cervical cancer 
and sometimes incidence of advanced disease for breast cancer is available at the 
cancer registry before the deaths occur,  so that the process of evaluation can be 
shortened. 
Finally, only deaths occurring in patients for whom the disease was diagnosed after 
the introduction of screening can be prevented by screening. The time of diagnosis 
is reliably available only at the cancer registry. In the following, 'refined mortality' 
is used if  cases diagnosed before the first screening round were excluded. 
Design of a screening programme 
Two main issues must be decided when designing a screening programme. First, 
whether  to  launch  a  special  programme  or  to  implement  the  screening 
spontaneously  in  the  target  population.  Second,  whether  to  advocate  general 
population-based  screening  or selective  screening  targeted  of high-risk  groups 
only. 
14 Organised programmes or spontaneous screening 
Screening can be spontaneously implemented or it can be implemented through 
active  planning.  There  are  several reasons  why  active  planning resulting  in  an 
organised  programme  is  better  than  spontaneous  screening.  First,  only  an 
organised  programme  can  be  evaluated  reliably  and  in  detail.  Second,  when 
comparisons between effects of organised and spontaneous programmes have been 
feasible, organised programmes have been shown to result in larger effects than 
spontaneous ones, as will be described in the next chapters. Third, without active 
planning, there is the danger of an  unpredicTable increase in cost.  Spontaneous 
screening  has  no  inbuilt  mechanism  to  prevent  unnecessarily  frequent  screens 
which result in a high marginal cost. Spontaneous screening is likely to pay the 
greatest attention to high sensitivity without regard for the effect of high sensitivity 
on  reducing  specificity.  For  a  high-technology  screening  programme,  such  as 
mammography  for  breast  cancer,  low  specificity  results  in  high  costs  and 
uncontrolled adverse effects. 
Ages for and frequencies of  screening 
Major organisational considerations of any  screening programme are  the  age  at 
which to start the programme, the interval at which the test is applied and the age 
at which to stop screening. For example, recommended practice for cervical cancer 
screening in western populations, which share about the same risk of disease and 
resources available, ranges from an annual smear from the start of sexual activity 
to a smear every five years from age 30 to age 55. Hence the difference in number 
of tests is tenfold. 
The age range to be screened depends on variation in the risk of disease with age, 
the protective effect of screening by age, and the person-years saved by screening. 
Many cancers are rare at young ages and their incidence increases rapidly with age. 
The  cost-effectiveness  will  be  low  if  screening  attempts  to  prevent  rare 
occurrences at young ages.  The protective effect of a screening test varies  with 
age.  Such variation is  due to the test itself, to the disease or to the subject. For 
example, taking an adequate cervical smear for cancer becomes more difficult after 
the menopause, and the sensitivity of the test will decrease. Also, the results of 
treatment may be poorer at old ages. For clinical cases, survival is better for young 
cervical cancer patients. In many screening programmes the attendance- often the 
most important single determinant of success of a screening programme - goes 
down  with  age.  Therefore,  it  is  likely  that  the  effectiveness  of screening  is 
inversely related to age.  Screening of older age groups  results in fewer person-
years saved because of the competing risk of death from other causes. Again, cost-
effectiveness will be reduced if  older populations are screened. 
15 The variation in the protective effect of screening resulting from changing to the 
interval between the screening rounds  depends on  the length of the pre-clinical 
phase of the disease and on the distribution of sojourn times, and not simply their 
average length. 
For cervical cancer, data on the protective effect have been obtained from several 
screening programmes (IARC Working Group on Evaluation of Cervical Cancer 
Screening Programmes, 1986). It seems that the protective effect after a negative 
smear is high (more than 90 per cent)  and is  only marginally dependent on the 
interval between screenings of up to three years (Table 1). Even ten year intervals 
yield a two-thirds reduction in the risk. This is in sharp contrast with breast cancer, 
for which the sojourn times  seem to  be considerably shorter (Day et al.,  1988). 
Invasive cervical cancer is rare below the age  of 30 and starting the screening 
before that age results in few  prevented cases, whereas many preinvasive lesions 
will be detected and require treatment. Because most of the latter would regress, or 
remain preinvasive until age  30, the benefit is  small, but the harm (in terms  of 
adverse effects and cost) is large. 
Table 1.  Protective effect of  screening for cervical cancer after a negative smear, ages 
3~  (reproduced by permission of  the  BMJ Publishing Group  from  IARC Working 
Group on Evaluation of  Cervical Screening Programmes, Br Med J 293:659-664,1986) 
Interval  between screenings 
(years) 
Selective screening 
1 
2 
3 
5 
10 
Reduction in cumulative 
incidence (%) 
93 
92 
91 
84 
64 
Selective screening means applying the screening test to only a proportion of the 
target population, and is based on  selecting groups at particularly high risk. The 
purpose  of confining  screening  to  high-risk  groups  is  to  reduce  the  resources 
required for the programme, or sometimes to reduce the rate of adverse effects of 
the screening test among the target population. A selective screening programme 
should detect a substantial proportion of the disease in the entire target population 
16 (i.e., only a few cases of the disease are assumed to originate among the low-risk 
groups that are not subjected to screening )  . 
Selective screening has an  effect only on the programme validity but not on the 
test validity. Because the purpose of selective screening is to reduce the cost, the 
programme specificity is increased. Because of the inverse relationship between 
specificity and sensitivity, the programme sensitivity of selective screening will be 
less than that for non-selective screening. 
To decide whether screening of selected high-risk groups may be preferable to 
general population screening, the sensitivity and specificity (i.e., costs and yield) 
of the programmes must be compared. In Table 2, the reduction in cost is given in 
terms of the high-risk group as a percentage of the target population. The yield is 
given as the proportion of all cases of disease in the target population that fall in 
the  high-risk  group.  The  cost  percentage  is  an  upper  limit  of the  programme 
specificity and the yield percentage is an upper limit of programme sensitivity. The 
yield depends strongly on the risk of disease in the high-risk group divided by the 
risk in the low-risk group (relative risk). For example, in order to have 90 per cent 
of the cases in the high-risk group comprising 10 per cent of the target population, 
the relative risk must be almost 100. Very few  such strong risk factors are known 
for any disease. Instead, combination of several risk factors at the same time has 
been attempted. 
Table 2. Proportion of cases belonging to the high-risk group out of  all cases in the 
target population, by percentage of the high-risk group out of total target population 
and by relative risk (high vs. low risk) 
Size of high-risk 
group 
(%) 
1 
10 
50 
2 
0.02 
0.18 
0.67 
Relative risk 
10  100 
0.09  0.50 
0.53  0.92 
0.91  0.99 
Combination of risk factors can be defined in  several ways. Such a combination 
should identify persons exposed to several risk indicators at the same time. There 
17 is good theoretical evidence that the combined effect is usually multiplicative (Day 
and Brown, 1980; Peto, 1977). If  the risk factors are independent, then the size of 
the population exposed to several risk indicators decreases rapidly as the number 
of risk factors  increases. Table 3 gives  an  example of this  inverse relationship, 
which implies that the proportion of the total cases found in each high-risk group 
defmed by  a simultaneous occurrence of several risk indicators is less than that 
found by means of a single risk factor. 
Table 3.  Combining independent risk factors; effect on size of  high-risk group, on 
risk and on yield 
Risk factor 
A  B  c  AandB  BandC  AandB andC 
Size of  high-risk  50  20  10  10  2  1 
group(%) 
Relative risk  2  5  10  10  50  100 
Proportion (%) of  67  56  53  53  51  50 
cases in high-risk 
group of all cases 
On the other hand,  if the high-risk group is identified by  a combination of risk 
factors,  assuming  at  least  one  risk  factor  only  to  characterise  the  individual 
belonging to the high-risk group, then the size of the population to be screened will 
increase. In the hypothetical situation (assuming independent occurrence of A, B 
and C) of Table 3 the high-risk group identified by either A or B or C is 64 per 
cent of the total population. The final reduction in cost will be less than 36 ( 100-
64)  per cent because only  a part of the total cost of the programme is  directly 
proportional to the number of screening tests. Some basic expenses are relatively 
fixed for any programme. 
The best combination of risk indicators can be defmed also in other ways. Multiple 
discriminant  analysis  probably  has  the  widest  applicability.  However,  most 
applications of the method show that, if the high-risk group is small enough to 
result in a substantial reduction in cost, then the cases belonging to the low-risk 
group are too numerous, i.e. the programme sensitivity is unacceptably low. This 
18 seems to be the experience for breast cancer (Farewell, 1977; Soini and Hakama, 
1978) and cervical cancer (Hakama et al.,  1979) and in general the finding is rather 
independent of the disease or defect. 
There are some important exceptions. The definition of high-risk groups does not 
have to be in the terms of known aetiological factors, it is sufficient that the high-
risk characteristics are correlates of the risk, yielding high programme sensitivity. 
Age and sex are used in almost all screening programmes as indicators of high-risk 
groups. Symptoms and diagnostic results based on previous screening may also be 
used to define a high-risk group, although these generally modify the time interval 
between screenings, rather than define an a priori high-risk group. Thus,  women 
with positive mammography or Pap smear followed by a normal histology are at 
high-risk  of breast  cancer and  cervical  cancer respectively  and  re-screening  at 
shorter intervals may be warranted. 
So far,  selective screening based on high-risk populations defined by aetiological 
risk factors has not been useful. The programme sensitivity has been low  and a 
substantial proportion of the disease in the total target population originates in the 
low-risk group that is not subject to screening. In a developing country with very 
limited resources the approach may be feasible, however. 
International comparisons 
If  the effect of screening is large, it may be evident in population rates of disease. 
Perhaps the most convincing evidence for the effectiveness of organised screening 
programmes (Hakama,  1982; Laara et al.,  1987)  stems from the comparison of 
trends  and differentials  in  incidence with  the  screening activities  in  the  Nordic 
countries (Hakulinen et al.,  1986; Engeland et al.,  1993). Only Norway had not 
started  an  organised  screening  programme  by  the  1990's  and  the  reduction  in 
incidence there was much smaller than in the other countries (Table 4). Denmark 
was partly covered by an organised programme and the reduction in incidence was 
largest in areas with organised programme within Denmark (Lynge et al.,  1989). 
Spontaneous Pap smears were common in all the Nordic countries (Hakama, 1982) 
and smears taken within the organised programmes were, in fact, fewer than the 
spontaneous ones except in Iceland.  However,  the decrease in  the  incidence of 
cervical cancer seems to have been proportional to the intensity of the organised 
screening programme.  Such comparisons  are  too  crude to reveal the effects  of 
different intervals between the  screening rounds  or of the age  to start and stop 
screening (Hakama, 1982). 
19 Table 4.  Observed and predicted annual age-adjusted incidence rates (per 100 000) of 
invasive cervical cancer in the Nordic countries in selected time periods. Data from 
the Nordic Cancer Registries (reproduced by permission of APMIS  from Hakulinen et 
al., 1986, and Engeland et al., 1993) 
Observed  Predicted 
Country  1956  1966  1976  1983  1998  2008 
-1960  -1970  -1980  -1987  -2002  -2012 
Denmark  30  30  19  16  11  11 
Finland  14  14  6  4  2  2 
Iceland  16  26  9  13  10  9 
Norway  15  17  17  13  9  8 
Sweden  18  18  10  9  7  7 
Individual level comparison 
The most important characteristics of an  organised screening programme is  the 
personal  invitation.  From the  point  of view  of research,  i.e.  evaluation  of the 
effectiveness of screening, this invitation defines the population to be  screened. 
The  invitees  can  then  be  divided  into  screenees  and  non-responders,  but  the 
reduction in risk should be evaluated in the total target population of invitees, and 
compared with the risk in the invitees before screening, or with an independent, 
apparently similar, unscreened population. 
Screening for cervical cancer in Finland 
Every  woman  in  Finland,  aged  30-55, receives  a personal  invitation  at  regular 
intervals (every 5 years) to attend the organised screening programme for cervical 
cancer.  In the invitation letter she is  given  an  appointment place and time.  The 
result  of the  Pap  test  is  also  given  by  mail,  independent  of whether  normal, 
suspicious or malignant. Approximately 400 000 women with 1 400 000 woman-
years, with information on the actual (participants) or potential (non-respondents) 
participation in the first  screening,  were  followed  up  and  analysed by  a cohort 
design (Hakama and Rasanen-Virtanen, 1976). Among these women were the first 
ones,  under  the  national  policy,  to  reach  the  first  rescreening  after the  5-year 
20 interval. The protective effect, in terms of reduction in the incidence of invasive 
disease among the screenees, was about 80% compared to the national rates before 
the screening started (Table 5). This is not simply due to the responders being a 
selected (low-risk) subset of the target population. If  this were so, risk of cervical 
cancer among the  total  target  population  would  have  remained unchanged.  To 
eliminate bias due to selection, incidence in the total target population should be 
compared to the expected one. The incidence of invasive cervical cancer in the 
target population in our study, responders and non-responders combined, was 32% 
of that  among the  controls  showing,  therefore,  a  68%  protective  effect  due  to 
screening (Table 5). 
Although selection could not explain the protective effect of screening, there still 
was the problem of unbiased choice of controls for the target population. We used 
the incidence for the whole female population of Finland shortly before the start of 
the  national  programme  to  define the expected risk.  It  could  be  argued  that  a 
decreasing trend in the overall incidence was already taking place before the start 
of the programme, and that the estimate of the protective effect was exaggerated, 
due  to  biased expected  rates.  However,  the  lag  between  the  control  rates  and 
screening rates  was  short and,  if anything, there was  an  increasing trend in the 
overall incidence of cervical cancer in all the Nordic countries, including Finland, 
before the start of screening (Hristova and Hakama, 1997) 
Table S.  Annual age-specific  incidence  rates (per 100  000  population)  of invasive 
carcinoma of cervix  uteri among the Finnish population before intense screening 
period in 1962-1966 and after a written invitation to participate in the programme in 
1963-1971  (reproduced  by  permission  of Oxford  University  Press  from  Hakama  and 
Rasanen-Virtanen, 1976, Am J Epidemiol103:512-517) 
Age 
. Cumulative 
risk 
30-34  35-39  40-44  45-49  50-54  55-59 
Before screening  7  20  35  46  47  46  0.010 
Intention to screen 
Screenees  2  2  5  10  12  12  0.002 
Non-responders  19  34  37  82  68  26  0.016 
Total  6  5  7  15  17  13  0.003 
21 Screening for breast cancer in Finland 
The effect of screening on  the risk of invasive cervical cancer is  large.  Many 
routine health services activities have only small effects at a public health level and 
one cannot presume that these effects will be demonstrable by a crude design or 
analysis. Instead, public health policy should be designed in such a way that small 
effects can  be  identified  with  reasonable  accuracy.  Screening for  breast cancer 
will, at best, have a much smaller effect on disease mortality than screening for 
cervix cancer. 
In Finland, nationwide population-based screening for breast cancer was started in 
1987 (Hakama et al., 1997). Women in birth cohorts recommended by the National 
Board  of Health  were  individually  identified  and  invited  for  screening.  The 
programme started with women born in 1928, 1932 and in 1936 and it covers the 
ages of 50 to 59 years and can be continued up to 64. Further birth cohorts were 
invited in subsequent years and the women are rescreened every 2 years (Figure 1  ). 
Individual  municipalities  decide  on  organisation  of  the  activity  with  state 
subsidising and most of them have a special agreement with the Cancer Society of 
Finland or its member societies to run the screening. 
Year of 
screening 
1987 
1988 
1989 
1990 
1991 
1992 
1993 
1994 
1995 
1996 
Figure 1.  Finnish National Board of Health's recommendation of screening rounds in 
an organised screening programme for breast cancer, by birth cohort and calendar 
year (reproduced by permission of BMJ  Publishing Group from Hakama et al.,  1999, J 
Med Screen 6:209-216) 
22 The material first analysed to evaluate the effect consisted of the women born in 
1927-1939 and residing in the municipalities screened by the cancer organisations. 
The invitations  and  screening  mammograms  in  1987-1989  were  recorded,  and 
each invitee was subsequently classified as a screenee or a non-responder. 
The expected mortality  was  estimated,  frrst,  on  basis  of the  preceding national 
mortality from breast cancer as  in the study  on cervical cancer. There were  no 
indications of effect on the age-specific breast cancer mortality in the age group 50 
to 59 years (Figure 2) or in the cohort-specific breast cancer mortality in cohorts 
born in 1928, 1932 or 1936 (Figure 3). As demonstrated later, this approach was 
too crude to disclose any effect. 
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Figure 2.  Age specific mortality rates from breast cancer in Finland in 1956-1995 
(reproduced by permission of BMJ Publishing Group from Hakama et al.,  1999, J Med 
Screen 6:209-216) 
In the  second approach,  individual controls  were  selected. These controls  were 
women in the same municipalities as those screened and they were born in 1927, 
1929,  1931,  1933, 1935,  1937 or 1939 and individually identified at the time of 
identification of the invitees.  Because the  women  born in  1931  and  1937  were 
recommended to be screened for the first time in  1989 they potentially provided 
23 few  person  years  only  and  short follow-up,  and  they  were  excluded from  the 
analyses. Women born in 1936 were also excluded in order to  balance the ages of 
cases and controls. 
Altogether 89 893 women were invited to participate the programme in 1987-1989 
and 76 389 accepted the invitation (Table 6). The number of controls was 68 862. 
Altogether 907 breast cancers were diagnosed among the invitees and 677 among 
the controls by the end of 1992. 
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Figure 3.  Birth cohort specific mortality rates from breast cancer in Finland among 
women born in 1927-1937 (reproduced by  permission of BMJ  Publishing Group from 
Hakama et al., 1999, J Med Screen 6:209-216) 
The total breast cancer mortality was frrst evaluated by comparing the numbers of 
breast cancer deaths in 1987-1992 among the invitees (210) to that expected for 
the  whole  of Finland.  Among  those  screened,  standardised  mortality  ratio  for 
breast cancer was only 0.63 (Table 7). The bias due to self selection of women into 
those  participating  and  into  non-responders  was  eliminated  by  comparing  the 
mortality by the intention to screen. The mortality among non-responders was very 
high  (SMR = 3.67).  Mortality  from  breast cancer among  the  invitees  - those 
screened and those who did not attend combined- was equal to that expected on 
the basis of the Finnish rates (SMR = 1.01). This would point to ineffectiveness of 
the screening programme. 
24 / 
Table 6.  Nation-wide screening programme for breast cancer organised by the cancer 
organisations in Finland in 1987-1989. Cumulative number of cases of breast cancer 
in 1987-1992 (reproduced by permission of the BMJ Publishing Group from Hakama et 
al., 1997, Br Med J 314:864-867) 
Invitees  Controls  Total 
Screenees  Non-responders  Total 
Women  76389  13 504  89 893  68 862  158 755 
Breast cancers  774  133  907  677  1564 
Table 7.  Total number of deaths from breast cancer with standardised mortality 
ratios (SMR): Nation-wide screening programme for breast cancer organised by the 
Cancer Society of Finland in 1987-1989 with follow-up for mortality to 31.12.1992 
(reproduced by permission of the BMJ Publishing Group from Hakama et al.,  1997, Br 
Med J 314:864-867) 
Breast cancer,  Invitees  Controls 
total 
Screenees  Non-responders  Total 
Numbers  114  96  210  175 
SMR  0.63  3.67  1.01  1.12 
However, the risk of death among the controls was higher than expected (SMR = 
1.12), indicating that the municipalities with high risk of breast cancer were more 
likely to have been included in the programme. The problems inherent in selecting 
an  appropriate referee population to  provide  "expected"  rates,  against  which  to 
quantify the effect of screening, is well demonstrated. The use of "national rates" 
was  inappropriate  (too  low).  In  addition,  the  effect  of  screening  was 
underestimated by  the inclusion  of deaths  which  could not possibly  have  been 
prevented  (occurring in  women  diagnosed  with  breast  cancer before  screening 
began). Overall, there was a small difference in the total breast cancer mortality, 
25 which was  favourable to those invited for screening compared to those not invited 
(RR =  1.01/1.12 =  0.90). Finally, the effect was estimated on the basis of "refined 
mortality".  There were  64 deaths  among the invitees  and 63  deaths  among the 
controls from breast cancer diagnosed after the start of screening, with follow-up 
to the end of 1992 (Table 8). The refined breast cancer mortality was lower among 
the invitees than among the controls, RR = 0.76 (SMRs 0.3110.41), indicating a 24 
per cent protective effect due to  screening.  The public  health  programme  was 
effective. The effect was small and was not evident in the national mortality rates 
(not even if classified by year of birth). 
Table 8.  Refined numbers of deaths from breast cancer with standardised mortality 
ratios  (SMR)  from  breast cancer:  Nation-wide  screening  programme for  breast 
cancer organised  by  the  Cancer Society  of Finland in 1987-1989  (reproduced  by 
permission of the BMJ Publishing Group from Hakama et al.,  1997, Br Med J 314:864-
867) 
Breast cancer,  Invitees  Controls 
refined 
Screenees  Non-responders  Total 
Number  49  15  64  63 
SMR  0.27  3.58  0.31  0.41 
The role of the cancer registry 
It  appears  from  the  above  that  design  is  more  important  than  analysis  in 
demonstrating  effectiveness  of  screening.  Design  issues  are  epidemiological 
(whereas many of the quality issues are not). Epidemiological expertise should be 
found  at  the cancer registries,  which  should  be involved  in  the  planning  of a 
screening programme from the very beginning. In Finland the screening for breast 
cancer was initiated by the cancer registry which permitted many optimal details in 
the design. 
The effectiveness  of screening  cannot be  evaluated  solely  on  the  basis  of the 
cancers  found  at  screening.  The  cancer  registry  is  essential  in  identifying  the 
cancers diagnosed among the screenees outside the programme (interval cancers), 
26 among the non-responders, and among the controls or - in absence of a control 
group - in providing the expected incidence and mortality estimates assuming no 
screening. 
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28 Chapter 3.  Evaluation and monitoring of cancer screening: 
theoretical issues 
S.M. Moss 
Methods of evaluation 
Randomised controlled trials 
Ideally,  screening for a disease should be evaluated by means of a randomised 
controlled  trial  to  establish  both  effectiveness  and  cost-effectiveness  before  a 
population-based screening programme is introduced. Randomised controlled trials 
(RCTs)  of cancer  screening  compare  mortality  in  populations  offered  and  not 
offered screening, although  sometimes the randomisation is of volunteers  rather 
than the general population (Mandel et al.,  1993),  and sometimes cluster rather 
than individual randomisation is used (Roberts et al., 1990). It is important to note 
that it is disease-specific mortality which is compared, and that screening for any 
individual cancer site should not be expected to have a demonstrable effect on all-
cause  mortality  (Hardcastle,  1997).  Comparisons  of  all-cause  mortality  are 
however useful to  provide evidence on lack of bias  in randomisation.  Subjects 
diagnosed with cancer before entry to the trial are generally excluded, either prior 
to randomisation or at the point of analysis, since they could not have benefited 
from screening. 
This  evaluation  process  has  taken  place  for  breast  cancer  screening,  where  a 
number of randomised controlled trials were carried out in the 1960-80' s and have 
shown reductions in breast cancer mortality in the population offered screening of 
the order of 25% (Wald et al.,  1994) for  women  aged 50 and over. Population 
screening programmes for breast cancer are now established or being developed in 
a  number of countries.  The effectiveness of screening for colorectal cancer by 
faecal occult blood (FOB) testing in reducing mortality from the disease has also 
been demonstrated by randomised controlled trials (Mandel et al.,  1993; Hardcastle 
et al.,  1996; Kronborg et al.,  1996). Trials are in progress for screening for other 
cancer sites such as prostate and ovarian cancer. 
Randomised controlled trials usually involve the collection of detailed data in order 
to  establish  a  population  register,  and  to  record  information  on  screening 
intervention,  which is generally beyond the scope of cancer registries,  although 
registries  will have  a  role,  for example,  in  providing follow-up  data on  cancer 
incidence. 
29 Alternative methods of  evaluation 
However, other methods of evaluation are sometimes necessary. For example, in 
the case of screening for cervical cancer, no randomised controlled trial has ever 
been performed, yet population screening is widely recommended and carried out. 
Evidence for the effectiveness of cervical cancer screening has come mainly from 
comparisons of trends, both in the incidence of invasive disease and in mortality 
from cervical cancer, as well as from case-control studies (see Chapters 6-8 in this 
volume). Comparisons of trends are made either between time periods before and 
after the introduction of screening, or between similar but geographically separate 
regions with and without organised screening (Louhivouri, 1991), or between areas 
with different levels of intensity of screening (Miller et al.,  1976). The problems 
associated with such comparisons of trends are discussed below under evaluation 
of  population screening. 
Survival analysis 
An improvement  in disease-specific  survival  is  a  necessary,  but not sufficient, 
indicator of a beneficial effect of screening. Cancer registries are generally able to 
produce survival analyses for series of cases registered in different time periods. If 
data on  screening  history/method  of diagnosis  are  held  on  the  cancer registry 
database, then comparisons of survival by method of diagnosis as well as between 
time  periods  will  be possible.  More  commonly,  some  form  of record  linkage 
between registry and screening databases will be required.  However, there are a 
number of  biases, which will affect such comparisons. 
Lead-time is the length of time by which the diagnosis of a case is advanced by 
screening. The survival time of such a case will be increased by the lead-time L 
(Figure 1}, even if the subject in fact dies at exactly the same point in time at which 
they would have died if  diagnosed clinically. 
s  I  no screening 
detection by  diagnosis  death 
screerg 
L  s  I  with screening 
Figure 1.  The effect of lead-time (L) on the total survival time of screen-detected 
patients (L+S) 
30 Such a  case wills  not benefit from  screening in terms of life-years gained,  but 
screening is likely to have a detrimental effect in terms of quality of life, since the 
subject lives longer with the knowledge that they have the disease, and with the 
possible adverse effects of any treatment. However, it is also possible that quality 
of life may be improved. For cases where death from the cancer i.§  delayed or 
prevented, survival will still be increased by length Lover and above the gain due 
to screening. 
Length bias can also affect comparisons of survival. The aim of screening is to 
detect cancers in the 'pre-clinical detectable phase'  (PCDP) before they become 
symptomatic and are diagnosed clinically. For any given cancer site, there will be a 
wide variation in the growth rate of tumours, and hence in the length of the PCDP. 
This in tum is likely to be associated with the prognosis of the case,  with the 
slower-growing,  less  aggressive,  tumours  having  relatively  better  prognosis. 
Screening at routine intervals is more likely to detect slow-growing tumours, which 
spend longer in the PCDP, and hence screen-detected cases may be associated with 
a  better prognosis  (Figure 2).  This is  likely  to be particularly  true for first  or 
prevalent  screens,  where  there  is  a  large  prevalent  pool  of undiagnosed  slow-
growing tumours. Conversely, interval cancers occurring between routine screens 
may be more aggressive and have poorer prognosis. 
It is  worth  noting  that  while  these  biases  will  influence  comparisons  between 
screen-detected and other cases, they will also affect comparisons of survival 
--
Screening 
Length bias 
• 
Slow growing -
good prognosis 
• 
Fast growing~ 
poor prognosas 
Figure 2.  The effect of length bias on the proportions of slow  and fast  growing 
tumours detected by screening 
31 figures for all cases in time periods before and after the introduction of screening. 
In such comparisons the extent of the bias will depend on the coverage of screening 
and the proportion of screen-detected disease. 
Selection bias affects primarily comparisons of cancers detected in acceptors and 
non-acceptors of screening. This can affect comparisons both of incidence and of 
survival or mortality. The effect of selection bias may be in either direction, i.e. 
those  accepting  screening  may  be  at  either  increased  or  decreased  risk  of 
developing and/or dying from the disease, compared with the general population. 
For disease-incidence,  selection bias  may  occur due to an  association  of a risk 
factor  such  as  social class  with both incidence rate and  with  the probability of 
attending for or accepting screening. For example, in the HIP randomised trial of 
screening for breast cancer carried out in New York in the 1960's (Shapiro et al., 
1982), the non-attenders for screening had a 20% lower incidence of breast cancer 
than the women in the control group, implying a 11%  greater risk in the 65% of 
women accepting screening. In this case, the selection bias meant that the actual 
benefit  of screening  in  those  accepting  was  greater  than  would  otherwise  be 
estimated. In the UK Trial of Early Detection of Breast Cancer (1988), there was 
little difference in the observed incidence in the non-attenders for screening and the 
comparison  centres.  However,  the  non-attenders  had  a  significantly  higher 
mortality from breast cancer. This effect of selection bias on mortality can be due 
to those not attending for screening being those more likely in any event to present 
at  a  late  stage  of disease  and  hence  with  poorer  prognosis.  This  bias  is  also 
sometimes referred to as the 'healthy screenee effect' or, where screening is based 
on volunteer participation, as the 'healthy volunteer effect'. 
As discussed below,  socio-economic status can also potentially cause bias  when 
cluster randomisation is used, if  different arms of the trial have different underlying 
risk. This was observed in the Edinburgh RCT of breast cancer screening, where 
the control arm had a higher all-cause mortality, and lower risk of breast cancer 
(Alexander et al.,  1989). 
Selection bias is a particular cause for concern when a case-control study approach 
is used to estimate the effectiveness of screening. In such studies, screening history 
in  cases  and  controls  are  compared.  Although  a  number  of such  studies  have 
attempted  to  adjust  for  potential  confounding,  nevertheless  many  appear  to 
overestimate the benefit of screening (Moss, 1991). 
Selection bias will  also affect cohort studies in which mortality (or incidence of 
invasive disease) in subjects with different screening histories is compared (Lynge 
and Poll, 1986). 
32 Case-control studies 
Case-control studies are  being increasingly used to estimate the effectiveness of 
screening, either in the absence of data from randomised controlled trials,  or to 
provide  additional  information.  They  are  thus  a potential  application  of cancer 
registry data,  since they  will  rely  on  complete  ascertainment of cases,  however 
defmed. However, both the design and interpretation of such studies require some 
care, and there is now a considerable literature on the methodology of such studies 
(Sasco et al., 1986; Moss, 1991; Cronin et al.,  1998; Weiss, 1983).  Problem areas 
include establishing eligibility criteria to ensure that both cases and controls had 
the opportunity to be screened, and were at risk for the study endpoint. 
Sasco et al. (1986) identified two different settings which have implications for the 
selection of cases and controls: 
Tvue A refers to the situation where the aim of screening is to detect cancer at an 
earlier stage than that at which it would present clinically, and thus to reduce the 
risk of dying from the disease.  An example of this is screening for breast cancer. 
Type B refers to the situation where the aim of screening is to detect disease in a 
precancerous state, and to prevent the incidence of invasive disease.  An example 
of this  is  screening  for  cervical  cancer,  where  the  detection  and  treatment  of 
dysplasia will prevent the onset of invasive cervical cancer. 
However, it should be noted that some screening (e.g. for colon and oral cancer) is 
aimed  at  detecting  both  preinvasive  and  early  invasive  disease,  and  that  all 
screening aims ultimately at reducing disease-specific mortality. 
Selection of  cases and controls 
The definition of case subjects should be based on  the event which screening is 
trying to prevent. In Type A screening, cases should be selected as deaths from the 
disease in question (although some studies have used patients with late-stage cases 
of disease  as  a surrogate).  For case subjects to  have  been  able  to  benefit from 
screening,  they  must  have  been  diagnosed  with  the  disease  after  they  had  the 
opportunity to be screened. As in randomised controlled trials, no benefit would be 
expected to be observed until several years of follow-up after the introduction of 
screening.  In  this  situation,  the  screen  at  which  screen-detected  cancers  are 
diagnosed should be included in  the screening history.  However,  it needs to be 
clear that any such test is a screening test rather than a diagnostic procedure. This 
may not always be clear (e.g. in determining the reason for a PSA test for prostate 
cancer). However, it has been pointed out (Cronin et al., 1998) that  exclusion of 
all symptomatic tests may also cause bias if  such tests are likely to be carried out 
for diagnosis of an  associated disease.  For example,  exclusion of PSA tests  for 
33 benign prostate hyperplasia might overestimate the efficacy of the screening test 
for prostate cancer. 
Controls should ideally be drawn from the general population, since other sources 
(e.g. hospital controls) are likely to have different patterns of screening, and not be 
representative  of the  source  population  (Weiss,  1983).  Cancer  registries  may 
therefore be a  source of cases, but they will not be appropriate for selection of 
controls. Controls are generally matched for age, but further matching may result in 
'over-matching'.  Controls  should  be  free  of invasive  disease  at  the  time  of 
diagnosis of the case in order to ensure that the case and control have the same 
opportunity of 'exposure' to screening (Sasco et al.,  1986). The screening history 
of both cases and controls should be measured over the same time period. 
In Type B screening, cases may be selected as patients with invasive disease. The 
screen at which cancer is detected should not be included in the screening history. 
A  potential difficulty is in  differentiating between symptomatic  and 'screening' 
diagnostic tests, if the former are included in the screening history,  a bias will 
result against an effect of screening,  since cases  will  appear to have a  greater 
number of screening tests. One solution is to exclude all tests within a given period 
(e.g. 6 months) prior to the diagnosis of the case. 
Controls should again be drawn from the general population. For cases of invasive 
disease detected by screening, controls should be selected from subjects screened at 
the same time as the case, since they are likely to have a different screening history 
(e.g. in a 5-yearly cervical screening programme, their time since previous screen 
is likely to be approximately 5 years (IARC Working Group on the Evaluation of 
Cervical Cancer Screening Programmes, 1986). 
Evaluation of population screening programmes 
Once a  decision  to  introduce population  screening  has  been  made,  monitoring 
trends in both incidence, and mortality from the disease in question becomes an 
important means of evaluating the effect of screening, since usually no uninvited 
control group is available. 
A  number  of theoretical  issues  in  the  evaluation  of cancer  screening  require 
different  interpretation  according  to  whether  screening  is  aimed  at  detecting 
invasive disease at an earlier stage, or a precancerous state (e.g. cervical smears) as 
discussed above. It is clear that the impact of these two types of screening on trends 
in cancer incidence will be different. The former will cause an initial increase in 
disease incidence. In the absence of overdiagnosis, rates should fall to prescreening 
levels, except in the youngest age-group being invited for the first time. Mortality 
rates should eventually decrease. The latter will theoretically reduce both incidence 
34 and mortality rates, although screening is likely also to detect some early invasive 
as well as in situ disease. 
Screening  for  other  sites  may  work  in  both  ways,  for  example,  screening  for 
colorectal cancer may produce an initial effect by the detection of invasive disease 
at  an  earlier stage,  and  a  longer-term  effect  by  the  detection  and  removal  of 
adenomas, a proportion of which would subsequently have developed into cancer. 
An initial increase in the age-group invited for screening was observed in England 
and  Wales  where  the  incidence  of invasive  breast  cancer  increased  by  40% 
between  1979  and  1992,  with  the  steepest increases  in  the  screened  age-group 
(Quinn and Allen, 1995). ht the United States increases in breast cancer incidence 
were found in line with increased use of mammography (Wun et al.,  1995). The 
size and timing of the observed increase will depend on the speed with which the 
population is  covered by  screening, the prevalence of the disease (reflecting the 
underlying incidence and the duration of the preclinical phase of the disease), and 
the sensitivity of screening. 
Disease-specific  mortality  should  eventually  fall,  and  again  the  monitoring  of 
mortality trends is essential to the evaluation of population screening. However, as 
observed in a number of randomised trials, it will be several years after the start of 
screening before an effect on mortality appears. For example, in the Swedish Two 
County study, a difference in breast cancer mortality between the study and control 
groups emerged 4-5 years after the start of the trial. With population screening, this 
is likely to be compounded by a staggered introduction of screening, so that the full 
impact  will  not  be  expected  until  several  years  after  full  coverage  has  been 
achieved. ht addition, mortality rates in the general population will for some time 
include deaths in cases diagnosed before the introduction of screening, which have 
been excluded in the estimate of benefit from randomised controlled trials. This 
will tend to dilute the benefit of screening for a number of years. 
As for disease incidence, a further problem is the existence of underlying trends in 
mortality unrelated to  screening.  Such trends  may  be related to  changes  in risk 
factors. For example, Hermon and Beral (1996) have observed a levelling-off or 
decline in breast cancer mortality rates in many western countries, which appears 
in part to be due to both cohort effect, for example a reduction in childlessness, and 
a reduction in age at first birth among women born after about 1920. There may 
also be period effects due,  for  example, to  improvements  in the treatment.  The 
observed fall  in  breast cancer  mortality  in  the  UK  in  the  period  1987-1994  is 
believed to be due to the increased use oftamoxifen (Quinn and Allen 1995). 
All the above factors make the estimation of the effect of population screening on 
mortality  difficult.  Record  linkage  with  screening  history  is  an  option,  but 
35 comparison of deaths in cases with different screening histories will be subject to a 
number of the biases discussed above. 
Another use of cancer registry data is to study trends in the incidence of late stage 
disease.  For example,  the  introduction  of screening for  breast cancer would  be 
expected to produce a fall  in the rate of late stage disease preceding any  fall in 
mortality.  A  reduction  in  cumulative  advanced  stage  disease  was  shown,  for 
example, in the Swedish Two County study (Tabar et al.,  1989). However, such 
analyses require complete and accurate data on stage, including data for the period 
before the introduction of screening. 
Interval cancers and sensitivity 
Interval  cancers  are  generally  defined  as  those  cancers  occurring  following  a 
negative  screen,  in  the interval before the  next  routine  screen is  due.  They  are 
potentially a useful means of evaluating the performance of a screening programme 
and the appropriateness of  the screening interval being used. 
Cancer registries  are of great importance in  the  monitoring of interval cancers, 
since accurate estimates of sensitivity require complete ascertainment of interval 
cancers. Reliance on cases which become known to the screening programme from 
other means is likely to be incomplete since, for example, they may not include 
cases diagnosed at  a different  hospital  to  that where  a screening programme  is 
based. There may also be a lack of interest for screening programmes to search out 
interval cases. However, cancer registries alone cannot use interval cancer data to 
produce  estimates  of sensitivity,  since  not  only  is  good  record  linkage  with 
screening  history  required  to  identify  interval  cancers,  but  data  are  needed  to 
provide the denominator. 
Estimating the sensitivity of  screening 
The sensitivity of screening is the ability of a screening test to detect true cases of 
the disease. A number of investigators now differentiate between test sensitivity 
and  programme  sensitivity.  The  former  is  the  probability  that  a  tumour in  the 
preclinical detectable phase will be diagnosed after a positive screening test, whilst 
the latter has been defined as the probability that a case in the PCDP at any time 
during an  ongoing screening programme (and ending at the  last screen)  will  be 
diagnosed following a positive test (Church et al., 1997). 
There are a number of ways in which the sensitivity can be estimated (Day, 1985). 
All require knowledge of the rate of interval cancers following negative screens, 
since these will include those cases missed by screening. However, interval cancers 
36 will also include some cancers newly arising since the last negative screen, and the 
proportion of the latter will increase with increasing time since a negative test. 
The 'traditional' method, in which sensitivity is estimated as  s  where 
( s  +  i) 
s is  the number of cancers  detected by  screening  and  i the  number of cancers 
appearing in a given interval after the screen, is likely to overestimate sensitivity 
since  a  number  of the  cancers  detected  by  screening  may  not  otherwise  have 
appeared in this interval (Day, 1985). 
The 'proportional incidence method' for estimating sensitivity calculates the rate of 
interval  cancers  as  a  proportion  (p%)  of the  expected  cancer incidence  in  the 
absence  of  screening.  The  sensitivity  is  then  estimated  as  (100  - p%).  In 
randomised controlled trials of screening, the incidence in the control group can be 
used  to  estimate  the  expected  incidence  (taking  account  of selection  bias  as 
necessary). For population screening programmes, it is necessary to estimate the 
expected incidence from the historical incidence rates in the period prior to the 
introduction of screening (or for  similar geographical  areas  without  a screening 
programme). 
Mathematical models are now often used to make joint estimates of sensitivity and 
the length of the PCDP. 
The potential for overdiagnosis 
There  are  three  possible  sources  of overdiagnosis  - taken  here  to  mean  the 
diagnosis (and registration) of a cancer which would not have emerged clinically in 
the  absence  of screening.  One  is  the  diagnosis  of slow-growing  disease  which 
would not have  progressed to  clinical  significance in  the  person's lifetime.  The 
extent of such overdiagnosis will depend on the natural history of the cancer. For 
example,  it  is  apparent  that  screen  detected  prostate  cancers  include  some 
proportion of slow-growing tumours, although it is not clear whether there is in fact 
a  latent form  of the  disease  or  a  wide  range  of disease  growth.  Evidence  for 
overdiagnosis comes from autopsy studies, which have shown for example that a 
percentage of men at autopsy have undiagnosed prostate cancer. In addition, high 
prevalence rates at first screen indicate a long mean sojourn time. 
A  second source is  the  inclusion  of non-progressive  disease  (clinically  benign) 
amongst the cancer cases. It is  apparent from  observer variability studies among 
pathologists  that  agreement  is  poorest in  borderline  categories.  Diagnosis  of a 
proportion  of benign  cases  as  malignant  will  affect  incidence  rates  (but  not 
mortality). 
37 The diagnosis of in situ disease is another area of potential overdiagnosis. In situ 
cancer is mainly diagnosed by screening.  For example,  in  the UK NHS  Breast 
Screening Programme 17% of tumours diagnosed by screening are in situ (Moss et 
al.,  1995). Again the natural history DCIS  is uncertain, one study has estimated 
that  50%  may  progress.  Thus  screening  will  increase  the  incidence  of in  situ 
disease, and potentially decrease the incidence of invasive breast cancer. 
The effect  of overdiagnosis  will  show  both  in  incidence  rate  and  in  survival 
analysis,  resulting  in  artificially high  survival rates,  particularly  for early  stage 
disease. 
Su"ogate outcome measures 
In recent years there has been considerable interest in the use of surrogate outcome 
measures, principally in the evaluation of randomised controlled trials. Prognostic 
variables such as tumour size, nodal status and grade in cancers in the two arms of 
the trial are used to predict the outcome in terms of mortality. The advantage of 
using surrogate outcome measures is that the results of the trial become available 
much more quickly, than if it is necessary to wait for mortality results. In addition, 
the sample size required is considerably lower, although this assumes that there is 
no variation in the mortality prediction. A number of potential problems have been 
identified with surrogate outcome measures. Firstly, depending on the number of 
categories used for the prognostic indicators, there will be variation in prognosis 
within each category (e.g., within 'node positive' tumours the number of positive 
nodes will vary). There is the possibility of measurement error, together with the 
possibility that data may be less complete for non-screen-detected cases. Also, the 
possibility  of overdiagnosis,  discussed  above,  is  a  potential  problem  if non-
progressive  cases  detected  by  screening  are  not  correctly  identified.  Lastly, 
treatment differences,  either changes  over time  or a  correlation  with  mode  of 
detection, may affect the results. 
In order for surrogate outcome measures to be useful in monitoring population 
screening, accurate information on the prognostic variables for all cancers would 
be required. Observer variation between pathologists is such that, in most trials so 
far,  all pathology is reviewed in order to produce standardised results. This will 
clearly not be feasible on a population basis. 
The UK trial of one year vs. three year screening interval for breast cancer is using 
surrogate outcome measures, based on the Nottingham Prognostic Index (Haybittle 
et al., 1982), although mortality follow-up is also included. Cancer diagnosed at the 
prevalent screen in each arm of this trial are excluded in order to remove 'length 
bias'. 
38 Analyses of survival by stage and mode of detection in a number of screening trials 
suggest that the pathological information collected has not been sufficient to allow 
accurate  prediction of mortality  (UK Trial  of Early Detection of Breast Cancer 
Group, 1993). 
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41 Chapter 4.  Use of  cancer registry data: prerequisites, limitations 
and solutions 
J.A.A.M. van Dijck and LJ. Schouten 
Introduction 
Periodic screening of asymptomatic persons to detect cancer at an early or even pre-
malignant stage has become an important tool in cancer control. For several malignant 
diseases,  screening  programmes  have  been  introduced.  Cancer  registries  play  a 
substantial role in the evaluation of screening programmes. 
First  of  all,  cancer  registries,  especially  the  population-based  ones,  provide 
background information on the site-, sex- and age-specific incidence rates of cancer in 
a defmed geographical area These regional incidence data may form the basis for 
setting priorities  for cancer control  activities.  Further,  the existence of a  cancer 
registry in a geographical area where a screening programme is ongoing makes it 
relatively easy to monitor incidence rates of that specific cancer, before and during 
the screening programme. However, monitoring the incidence rates will give no 
insight into the effectiveness of the screening. For that purpose, it will be necessary 
to identify  all  cases of cancer in the target population  and separate them into 
screen-detected  and  interval  cancers  and  cancers  among  the  non-responders 
(Schouten et al., 1998). Screen-detected cancers, diagnosed as a result of a positive 
screening test, may be relatively easy to discover even in the absence of a cancer 
registry. However, interval cancers, which are diagnosed clinically after a negative 
screening test and before the next scheduled screening examination, may be very 
difficult to identify without the existence of a cancer registry.  Only population-
based cancer registries have complete coverage of  the screened population. 
The aim of most cancer screening programmes is  to detect the disease as  early  as 
possible. Up to now, the cervix uteri is the only site for which prevention of invasive 
cancer has been demonstrated to be possible. For other sites, the aim is to prevent 
deaths from cancer. Therefore, monitoring of  the incidence according to disease stage, 
as an early indicator of screening effectiveness, may be very useful. As an example, 
Figure  1  shows  the  incidence  of breast  cancer  according  to  tumour  size  in  the 
Netherlands, in the years  1989-1995. The introduction of the screening programme 
started in  1989 and was completed in  1998.  The incidence of small tumours rose 
between 1989 and 1993, and seems to be stable thereafter. However, the incidence of 
larger tumours started decreasing only after 1994. 
43 The detection of cancer at an early stage may influence the choice of treatment. One 
of the secondary benefits of breast cancer screening is that a greater proportion of the 
patients can undergo breast  -conserving therapy. For those registries that do collect 
data on therapy, monitoring trends in treatment may be useful. 
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Figure 1.  The incidence of breast cancer according to tumour size in women aged 50-69 
years (Source: Netherlands Cancer Registry, 1998) 
Cancer registries  must fulfil  several  prerequisites  in  order to be  valuable  in  the 
evaluation of screening programmes. In this  chapter,  the following issues  will  be 
discussed:  quality of cancer registry  data (completeness  and  validity  of the data), 
necessary items, record linkage and timeliness. Some limitations of  the cancer registry 
data and possible solutions will also be discussed. 
Quality of cancer registry data 
One of the  aims  of population-based  cancer  registries  is  estimating  site-specific 
incidence rates by sex, age, and stage, etc. For this purpose, accurate enumeration of 
all incident cases of cancer in the target population is  a basic prerequisite. Further 
requisites are the correct and reproducible classification and coding of the cancer 
cases. In order to be able to calculate (relative) survival, the complete follow-up until 
emigration out of the target population, or death is necessary (Parkin et al.,  1994). In 
addition, accurate and frequent estimates of the population at risk must be available, 
broken down by as many variables of interest to the registry as possible (the absolute 
minimum is by sex and age group). The general aspects of quality control in cancer 
registration have been published before and will not be repeated here (Parkin et al., 
1994).  However,  some  aspects  of completeness  and  validity  deserve  particular 
44 attention  when  cancer  registry  data  are  used  for  the  evaluation  of a  screening 
programme. 
Completeness 
Completeness  of case  ascertainment  in  relation  to  screening  status  may  be 
selective. If so, the degree of completeness is usually higher for screen-detected 
cases than for interval cancer cases, which will lead to an over-estimation of the 
sensitivity  of the  screening.  This  may  occur when  all  screened persons  with  a 
positive test result or the diagnosis of cancer are notified to the cancer registry by 
the screening organisation.  In  this situation,  it is  very  unlikely that any  case of 
screen-detected cancer will be missed.  Interval cancer cases, for whom no  such 
additional source of notification exists, may have a lesser degree of completeness. 
Further, when screened-detected cancers are more likely than interval cancers to be 
present in  the data source  which is  most important  for the  cancer registry,  the 
completeness may be better, e.g.,  when screen-detected cases are more likely to 
have  histological  confirmation  of  the  cancer,  and  pathology  reports  are  an 
important source. This could occur, e.g., in screening for lung cancer. Finally, one 
should remember that because of the screening some cancer cases may be detected 
that would never have become clinically manifest (see also section on validity and 
comparability below). 
Completeness  of  detail  is  another  concern.  For  screen-detected  patients  the 
information recorded in the medical records may be better, or more extensive than 
for clinically detected cancer patients.  This  form  of selective completeness  was 
present in the Maastricht Cancer Registry data of the years 1991-1996 (Schouten et 
al.,  1998).  For  breast  cancer  in  women  aged  50-69  years,  disease  stage  was 
unknown in 2.0 % of the screen-detected patients.  Disease stage appeared to be 
unknown in 4.4 % of the interval cancer patients and in 4.6 % of the unscreened 
patients.  So,  although  a  difference  in  completeness  was  present,  it  was  small. 
However,  in  other  situations  large  differences  in  the  proportions  of missing 
information may be present between screen-detected and other cancer patients. 
Validity and comparability 
Validity  refers  to  the  extent  to  which  the  information  recorded  on  the  different 
variables is true, or accurate. A screening programme may have a great impact on the 
information to be recorded. Many borderline lesions will be detected, such as ductal 
and lobular carcinoma in  situ of the breast or  micro-invasive prostate cancer. The 
clinical significance of these lesions is often not clear. It is very  well possible that 
many of these cancers would never have been detected in the absence of screening. It 
can be discussed if these lesions should be called cancer. Furthermore, there may be 
diagnostic  problems.  The  pathologic  classification  of cancer  and  its  pre-invasive 
45 analogues may change because of the screening programme. The boundary between 
borderline  benign  and  borderline  malignant  may  change.  This  will  hamper  the 
evaluation of time trends. Coding these borderline lesions in an identifiable way by 
using specific codes for stage, morphology or histologic grade makes it possible to 
regard them separately when analysing the data. 
Another problem with the validity of the data is that outcome variables may change 
because of screening.  One  of the  most  important prognostic  factors  for  breast 
cancer is whether the patient has axillary lymph node metastases or not. For the 
evaluation  of breast  cancer  screening,  the  incidence  of cancers  with  positive 
regional lymph nodes is considered one of the (early) outcomes. It is used as  an 
indicator for a future mortality reduction. At the start of the national breast cancer 
screening programme in The Netherlands, the pathologists have been instructed to 
take larger samples of lymph nodes and to look at the resected lymph nodes more 
intensively. Therefore, lymph node metastases can be found in a larger proportion 
of the cases. In the Maastricht Cancer Registry in 1993-1996, the incidence rate of 
node  positive  breast cancer  was  roughly  10%  higher  when  lymph  nodes  with 
micro-invasion (N1a) were included. The clinical implications of N1a are not clear, 
however. Patients with micro-invasion in the axillary lymph nodes  may  have a 
prognosis similar to that of patients with negative lymph nodes. Already 15 years 
ago attention was paid to this phenomenon called stage migration (Feinstein et al., 
1985). With the introduction of new diagnostic tests, patients with any stage may 
have a better prognosis than patients with the same disease stage who had been 
staged with old methods. Had patients been staged with the new methods, many of 
them would have been classified into a worse disease stage. This problem could 
also arise because the introduction of a screening programme has changed the use 
and interpretation of old diagnostic tests. If  screening programmes are evaluated by 
analysing trends in disease stage, one should find out whether new diagnostic tests 
have been introduced since the start of the screening. 
Necessary items 
A discussion of basic and optional items of patient information to be collected by 
cancer registries can be found in Chapter 6 of the Monograph "Cancer Registration: 
Principles and methods" (Jensen et al., 1991). 
For purposes of evaluating screening programmes, the items recorded by the cancer 
registry and the screening programme should be coded in a similar way. Identification 
items should be recorded in such a way that record linkage is possible. Date of birth, 
sex,  name (may  be encrypted)  and address  belong to the  basic  information to be 
recorded. Names can easily contain errors, because names, which are pronounced in 
the same way, may be spelled differently. Further, people may change their name, e.g. 
46 because of marriage or divorce. This will depend on cultural and legal background. If 
a unique personal number is available that is generally used, it should be recorded. 
Especially when this number is permanent and does not change when people get 
married  or divorced  it  is  very  useful.  Tumour information,  such  as  topography, 
morphology,  behaviour and  grade  are  preferably  coded  according  to  the  ICD-0 
classification. However, the ICD-0 coding of topography may not be sufficient for 
screening of skin melanoma, because it is not very detailed. For the definition of date 
of incidence  and  the  most  valid  basis  of diagnosis,  the  IACR  guidelines  are 
recommended. 
Optional items 
Besides the necessary items mentioned in the previous section, recording of the items 
differentiation  grade,  stage,  method  of  detection,  and  treatment  are  highly 
recommended, especially if the design of the screening evaluation includes them. If 
any extra items are collected, they should be available for all patients. 
Differentiation grade could be useful as a prognostic factor. For example, the optimal 
management of ductal carcinoma in situ of the breast has not yet been established. 
Many clinical trials are underway. Differentiation grade is used as a marker to identify 
subgroups requiring different treatment (Holland et al., 1994  ). 
Stage 
Stage is  regarded as one of the early  indicators of the effectiveness  of cancer 
screening for most sites. Therefore, data on stage should be collected by all cancer 
registries that are used for the evaluation of screening programmes. In Table  1, 
several of the available classifications are listed. A classification that is used broadly 
and that is available for all sites is the extent of  disease (BoD). For cancer registries, it 
is relatively easy to collect. A major drawback of the BoD is, however, that it contains 
only one axis. If  metastases are present, no information is available with respect to the 
regional lymph nodes and tumour size. If  positive lymph nodes have been diagnosed, 
the  BoD  contains  no  information  on the  local  tumour extension.  Therefore,  the 
information coded in this classification is limited. In the evaluation of breast cancer 
screening, information on tumour size is important. Further, the BoD is not frequently 
used by clinicians. 
The TNM classification is available for many sites. It has been widely accepted by 
clinicians.  A  major advantage  of the  TNM classification  is  that  local  extension, 
regional  lymph node involvement and  distant  metastases  are coded separately.  A 
disadvantage is that the accuracy and validity are relatively low. For cancer registries 
that  may  not  be  able  to  obtain  all  the  information  necessary  for  the  TNM 
47 classification, the European Network of Cancer Registries has provided guidelines on 
a condensed TNM classification. 
Table 1.  Classification for the coding of  disease stage 
Site  Available classifications 
Breast 
Cervix 
Melanoma 
Prostate 
Colon 
BoD 
BoD 
BoD 
BoD 
BoD 
TNM 
TNM 
TNM 
TNM 
TNM 
Tumour size 
FIGO 
Clark /Breslow 
Dukes 
As an  example,  Figure 2 gives  the  incidence  of breast cancer by  TNM  stage for 
women aged 50-69 years in the Netherlands, were the screening programme started in 
1989. In the years 1990 to 1995, 11%, 25%, 48%, 69%, 77% and 88% of the target 
population had been invited. The attendance was roughly 75%.  In the period from 
1989-1995, the incidence of breast cancer in situ increased threefold, that of stage I 
doubled, that of stage n increased by  16% up to  1993 and decreased almost to the 
level of 1989. Stage ill  or higher decreased by 22% in the observation period. 
150~------------------------------
IL-
.--.t.----.~~-
0  100+---------~~------------------
0 
q 
0 
0  ..-
c  50+--------~~~----------------
0+---~----~--~~--~----~---. 
1989  1990  1991  1992  1993  1994  1995 
Incidence year 
TNM stage 
summarized 
in one axis 
Figure 2.  Trends in stage distribution for breast cancer, ages  50-69  years  (Source: 
Netherlands Cancer Registry, 1998) 
48 Figure 3 shows the same data summarised in a different way. The incidence of distant 
metastases (Ml) is shown separately, and if  MO, the incidence of node negative (NO) 
and node positive (N+) tumours is shown. The incidence ofM1 tumours decreased by 
24% (from 16.9 to 12.9 per 100 000). The incidence of node positive tumours was 
stable, whereas the incidence of node negative tumours increased by almost 60% up 
to  1993,  and  decreased  thereafter.  Figure  3  gives  a  somewhat  less  favourable 
impression of the effects of screening than Figure 2. One of the reasons for this may 
be the increased frequency of  positive axillary lymph nodes with micro-invasion, N1a, 
as mentioned before. 
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Figure 3.  Trends in stage  distribution for  breast cancer, ages  50-69  years  (Source: 
Netherlands Cancer Registry, 1998) 
The TNM classification  provides  a  categorisation  of tumour  size  in  rather  broad 
classes,  when the registration of the exact tumour size may be more useful in the 
evaluation of cancer screening. This item would be rather easy to collect for most 
sites,  at least the pathological size.  For melanoma  screening,  the thickness  of the 
tumour should be recorded (Breslow) in millimeters. For some sites it may not be 
useful  and/or  possible  to  record  the  tumour  size  (e.g.  prostate  cancer),  and  the 
reproducibility and precision of  the recorded tumour size can often be questioned. The 
clinical tumour size depends on the diagnostic tests used to estimate the size, and on 
the reproducibility of these tests,  and even the pathological tumour size cannot be 
measured  very  precisely  in  many  circumstances.  Figure  4  illustrates  this  for  the 
pathologically measured tumour size of  invasive breast cancers (Peer et al., 1996). 
The tumour size often  seems  to  be rounded  to  the  nearest 5  mm,  and for  larger 
tumours even to the nearest 10 mm. An explanation for this is that with the varying 
shapes of the tumours, it may  be difficult to decide  which dimension to measure. 
49 Recording the exact tumour size will give an illusion of precision. For tumours larger 
than 10 mm rounding to the nearest 5 mm may be precise enough. 
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Cancer Screening Study) 
Detection 
The availability  of screening  tests  will  decrease  the  proportion  of patients  with 
symptoms, or it may increase the incidence of  a cancer without decreasing the number 
of patients with symptoms. Registering the  'method of first detection can be very 
helpful in the evaluation of  time series, especially when the diagnostic possibilities for 
a  specific tumour or primary site have changed over time.  h1  many countries, the 
availability of PSA and mammography have given rise to opportunistic screening. To 
evaluate the consequences of this kind of screening, the method of first detection 
would be essential. Since the wide acceptance as PSA as a marker for the presence of 
prostate cancer,  its use has  increased  significantly.  Even for the evaluation of an 
organised screening programme, the item will be helpful in separating screen-detected 
and  interval  cancers  and  cancers  among  non-responders.  This  would  be  very 
important when no linkage between the screening records and the cancer registry 
records can be performed. Also, patients can be identified who have been diagnosed 
outside an official screening programme, for example because they have a high cancer 
risk based on a positive family history. In some situations the coding of this item may 
be difficult due to the lack of detailed history or, e.g., when a patient came to the 
screening examination while having symptoms. 
The experience from a field trial performed at the cancer registries in Maastricht and 
Nijmegen on breast, cervix and prostate cancer was that the method of  detection could 
50 be collected very easily from the medical files. However, a hierarchical order of the 
codes is necessary: 
1.  Incidental finding at autopsy 
2.  Screening examination 
3.  Incidental finding (on examination, at surgery) 
4.  Clinical presentation (with symptoms) 
8.  Other 
9.  Unknown 
In this hierarchical order the higher code is preferred over the lower code, unless there 
is proof for the lower code. So, a patient with symptoms who came to the screening 
would be coded as 4: clinical presentation. 
Although the information could be collected very easily in the Netherlands, it may be 
difficult in other countries. The information necessary to code the item may not be in 
the medical files.  Further, many cancer registries do not collect their data from the 
medical files, but obtain their data electronically or from forms filled in by physicians 
in the hospitals. For these cancer registries it may be difficult to generally register this 
item. However, for special purposes, i.e., for a limited time to evaluate a screening 
programme, additional data can be registered from the clinicians. 
Treatment 
The existence of a  screening programme  may  have  a  great impact on treatment. 
Because of  the screening, tumours should be detected at a smaller size. For example, a 
larger proportion of the breast cancer patients will undergo breast-conserving therapy. 
This can also be seen as a favourable outcome of screening. However, breast cancer 
therapy is only useful if  it is coded with enough detail. So it would be necessary not 
only to code surgery, but also the type of surgery. Also, the frequency of adjuvant 
therapies  such as radiotherapy,  chemotherapy  and hormonal therapy  may change. 
Data on treatment may be valuable when expenses of the screening programme are to 
be evaluated. 
Record linkage 
Record linkage is necessary to match the records of  screening organisations with those 
of the cancer registry, to evaluate the effects of screening on an individual basis. In 
some countries, e.g. the Nordic countries, a unique personal identifying number is 
used to link personal data between different registers. 
51 In most countries, there are no universal personal identifying numbers, so that their 
usefulness is limited. Then, several other identifiers, such as  date of birth, sex and 
family name, have to be used in the record linkage. However, these identifiers are not 
unique and they may contain errors. A name may be misspelled, a date of birth may 
be written incorrectly, even sex may be coded wrong.  Sometimes the patients may 
refuse to have their name registered. In some countries the name and address have to 
be encrypted,  further  hampering  the  linkage  of records.  Small  differences  in  the 
spelling of  names may remain unnoticed because of  the encryption. Further, screening 
records and cancer registry records will  be encrypted differently.  Because of these 
problems, record linkage will almost never be perfect. 
A  probabilistic  method  was  developed based on the calculation of the odds in 
favour of a  correct match  associated  with  a  specific combination of identifiers 
(Newcombe, 1988). The odds of a very common name will be much lower than the 
odds of a rare name. The calculation of the odds can be refined to accommodate 
weights associated with identifier values and coding errors.  A  drawback of this 
method is  that it requires  detailed prior knowledge  about the frequency  of the 
values of identifiers that will be used. 
In the  Netherlands,  a  protocol  was  developed for  use  in  the  Netherlands  Cancer 
Registry 0/an den Brandt et al., 1990). The procedure is a two-stage process. First, a 
computerised linkage is performed with the following identifiers: date of birth, sex, 
family name (first 4 letters) and a part of the postal code. Next, all possible matches 
are inspected visually with additional information. The particular case for which the 
protocol was developed was linkage between the Netherlands Cohort Study on Diet 
and Cancer and the Netherlands Cancer Registry 0/an den Brandt et al., 1990). The 
linkage was performed with the use of several identifiers. When only family name 
was used, the number of possible matches was almost 50 000. The number of missed 
matches was two,  which gave a sensitivity of 98.9%. However, only 0.4 % of all 
matches was true positive (predictive value of positive match [PV  +] =  0.4%  ). Date of 
birth also gave a high number of matches,  with a sensitivity of 98.9% and PV+ = 
3.5%.  When  date  of birth,  family  name  and  sex  were  combined,  sensitivity  was 
slightly lower, 97 .9%, and PV  + rose to 97.9% (Table 2). Including the first initial 
decreased sensitivity to 91.5% (16 matches missed). 
Is  it  possible  to  increase  the  sensitivity  to  100%?  For  linkage  of family  name, 
Soundex could be used. Soundex was developed to index the United States' censuses. 
It codes surnames of the same and similar sounds but of variant spellings. This may 
avoid the problem that differently written names do not match. However, this software 
is developed for the English language, and it is unknown how useful it may be in 
other languages. Moreover, it cannot be used with encrypted data. 
52 Table 2.  Record linkage between the Netherlands Cohort Study (n=8081)  and the 
Maastricht Cancer Registry  (n=8917)  (reproduced  by  permission  of the  author  and 
Oxford University Press from Van den Brandt et al., lnt J Epidemiol19:553-558, 1990) 
Identifiers  Matches  True  False  Sensitivity  PV+ (%) 
positives  negatives  (%) 
Date of birth (DOB)  5276  186  2  98.9  3.5 
F4
1  102 070  186  2  98.9  0.2 
Family name (F)  49808  183  5  97.3  0.4 
DOB+F+Sex (S)  188  184  4  97.9  97.9 
DOB+F+S+  Initial  172  172  16  91.5  100.0 
DOB+F4+S+Postal code (P4)  183  183  5  97.3  100.0 
1 F4= first four characters ofF 
Another solution to increase the sensitivity of linkage is to take into account known 
patterns of errors that may occur. For example, in the date of birth, month and day 
may be transposed, such as 01-11  (1 November) versus 11-01  (11 January). One has 
to keep in mind that all arrangements to increase sensitivity will decrease specificity. 
The  example  in  Table  3  shows  results  from  a  computerised  linkage  of the 
Maastricht Cancer Registry  and  files  with  the regional  breast cancer screening 
programme  (Schouten et al.,  1998).  The linkage  was  restricted to  women.  The 
identifiers  - date of birth, the first 4 letters of the family name and the 4 numbers 
of the postal code - were evaluated two by two, to identify all possible links. 3031 
possible matches were verified manually, with the use of additional items such as 
name  of the  husband  and  initials.  The  result  was  360  true  positive  links.  The 
sensitivity of the combination of date of birth, 4 letters of the family  name  and 
postal  code  was  83%,  PV+  was  100%.  The combination  of DOB  and  F4 gave 
another 61  matches, of which  51  were correct. DOB  and P4 gave 39 matches,  8 
were correct. The combination of F4 and P4 gave only two additional matches at 
the cost of 2632 records to be verified. 
53 Table 3. Record linkage between the Maastricht Cancer Registry and the Breast 
Cancer Screening Programme (Source: Maastricht Cancer Registry) 
Identifiers  Matches  True positives  False  Sensitivity  PV+ (%) 
negatives  (%) 
DOB+F4+P4  299  299  61  83.1  100.0 
DOB+F4  360  350  10  97.2  97.2 
DOB+P4  338  307  53  85.3  90.8 
F4+P4  2931  301  59  83.6  10.3 
Abbreviations: see Table 2 
Timeliness 
Depending on the method of data collection, it may take several years before all 
records of one incidence year have been completed. Thus, for the evaluation of the 
screening  programme  routine  cancer  registry  data  will  be  available  with  a 
considerable delay. 
Figure 5 shows for the Maastricht Cancer Registry the time required to complete the 
records of  the incident cases in 1996. Notifications were received up to February 1997 
from the national pathology registry, the most important source. The small increase in 
the  number of notified  records  after that date  was  due to  notifications  from  the 
national hospital discharge registry. Final data from this source is received after a fair 
delay. All Dutch cancer registries collect their data from the medical records of the 
hospitals and outpatient clinics. The delay is considerable; in 1996 in Maastricht, it 
was at least 6 months. At the end of 1998, the data of 1996 had been completed. In 
December 1997, when the data set for the evaluation of the breast cancer screening 
programme was produced, 85 % of  the records had been completed. So it may take up 
to three years before all data of a specific year are completely registered. Then it will 
take some time before results of the record linkage are reported and the indicators of 
the effectiveness of  the screening programmes are available. Only after this delay is it 
possible to assess whether changes in the screening process are necessary. 
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Figure 5.  Maastricht Cancer Registry for the incidence year 1996 
How to overcome this long delay? The frrst option is to use the notified but not yet 
completed records for the evaluation (Figure 5). In the Netherlands, it will depend on 
the regional situation and on tumour site whether data from the pathology departments 
are reliable enough for this purpose. For  ~reast cancer screening, where the pathology 
report gives reliable localisation and morphology, this may be a good option to speed 
up the evaluation. For other sites, such as the prostate, the clinical examinations 'may 
be necessary to make a reliable diagnosis. In this situation, fast-tracking registration 
may be a solution. This means that priority is given to the registration of the tumour 
site for which the evaluation will be performed. For some sites, such as lung cancer, 
the number of missed cancers may be relatively large when only histologically and 
cytologically notified cancers are used. When a cancer registry obtains notifications 
electronically, the delay may be much less than for registries that collect data from the 
hospital  records.  When  cancer  screening  programmes  are  evaluated  with  rapid 
reporting  systems,  it  should  be  kept  in  mind  that  the  indicators  for  screening 
effectiveness may be selectively biased. As discussed before, the completeness may 
be selective, and this problem will be much larger when rapid reporting systems are 
used. 
55 Mortality data 
The first  outcome  of screening  programmes  should be evaluated by using  cause 
specific mortality data. In cancer registries which use death certificates as one source 
for  identifying  cases,  the  causes  of death  of deceased  patients  are  known.  This 
information can be linked with the screening files. Many cancer registries, however, 
cannot use this source of  notification, because in their country, the death registration is 
anonymised, and it may thus be very difficult to complete the follow up of registered 
patients. Then, mortality data should be analysed on a population level. 
Conclusion 
Cancer registries play an important role in the evaluation of screening programmes. In 
many  countries,  the  existence  of screening  programmes  is  used  as  one  of the 
justifications  for  the  existence  of cancer  registries.  Cancer  registries  should  be 
prepared to adapt procedures to facilitate these evaluations. 
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57 Chapter 5.  Evaluation and monitoring of screening for cervix cancer: 
time trends 
J. Smith and D.M. Parkin 
Introduction 
Cancer of the cervix is an important cause of mortality and morbidity worldwide 
(371  000 new cases in 1990 and 190 000 deaths (Parkin et al.,  1999)). Although 
often perceived as a relatively rare disease in Europe, it certainly was not in the era 
before screening- age  standardised (world)  incidence  was  28.3  in  Denmark in 
1953-57 and 36.5 in Hamburg in 1960-62 (Doll et al.,  1966); these rates are not 
dissimilar from  those in  high-risk countries  today.  Cervix cancer was  the frrst 
malignancy  for  which  an  effective  method  of screening  was  introduced,  and 
although  never  subjected  to  evaluation  via  a  randomised  controlled  trial,  the 
benefits in terms of reduction in invasive cancer (and subsequent mortality) have 
been  quite  clear.  The  data  provided  by  cancer  registries  were  an  important 
component of this evaluation,  and they remain so in the monitoring of existing 
screening programmes,  for  several  reasons.  The  very  success  of screening  has 
rendered cervix cancer a relatively rare disease, so that some commentaries often 
query the benefits in relation to the service infrastructure, and costs, involved in 
maintaining  a  screening  programme.  The  optimal  deployment  of  screening 
resources need to be reviewed, to determine whether different population groups 
(defined geographically or otherwise) are obtaining equivalent benefit (principles 
of equity). 
Much has been made of the importance of organised screening (programmes  in 
which tests are delivered to invited women, in predefined age groups, at predefined 
intervals) in contrast to 'opportunistic' screening (which takes place at the initiative 
of the  subjects themselves,  or of individual  health care providers).  In  fact,  the 
effectiveness  of the  screening  test  itself in  detecting  preclinical  lesions  is  no 
different in the two settings (Gustafsson et al.,  1995). However, it can be easily 
demonstrated that optimisation of a programme. (in terms  of cost effectiveness) 
requires a high level of coverage, with regular tests at defmed intervals in the age 
groups  at  greatest  risk  (Parkin  et  al.,1985;  Van  Oortmarssen  et  al.,  1982; 
Gustafsson and Adami, 1992), and that these are features of organised screening 
rather than of opportunistic testing (Bos et al., 1998). 
Screening  programmes  may  be  monitored  in  terms  of their  level  of activity 
(process measures), or in terms of the outcome sought. Monitoring the activity of 
59 cervix cancer screening programmes is not the role of the cancer registry. At its 
simplest  level,  the  level  of activity  is  expressed  in  terms  of the  number  of 
examinations performed (in relation to the size of the target population), and the 
percentage of which prove to be positive. This type of statistic is readily available 
from the laboratories carrying out the cytological examinations. But it is obvious 
(and easy to demonstrate) that effectiveness of a programme depends also on the 
distribution  of tests  - ensuring  a  high  coverage,  regular  testing,  follow-up  of 
abnormal  smears.  Information  on  these  aspects  requires  a  more  sophisticated 
information  system,  with  linkage  between  a  register  of  women  eligible  for 
screening, and the results of  testing. 
Cancer registries may have information on one aspect of the screening process, 
however - that is, on the numbers of certain pre-invasive lesions which are detected 
by screening programmes. Many cancer registries have recorded in situ carcinoma 
of cervix, along with invasive disease. This used to provide a useful insight into the 
intensity of screening, or even of its effectiveness, given that a proportion of in situ 
cancers would have become invasive if they had remained undetected. However, 
the changing terminology of pre-invasive disease has meant that the utility of the 
information for monitoring screening has been severely compromised. In the UK, 
there was a change in definition in 1984, such that the in situ cancers included all 
the CIN3  cases and in  England and Wales the incidence rate increased by 50% 
compared to 1983 (OPCS, 1993). 
Studies of  age-specific incidence 
The underlying principle is to describe trends in the incidence and mortality from 
cervical  cancer  and  relate  these  to  the  uptake,  or,  if this  is  not  known,  the 
availability of screening. Since the objective of a cervical screening programme is 
to prevent the development of invasive cervical cancer, changes in the incidence of 
the disease should both be seen prior to and be more directly related to screening 
than any effect on mortality. 
The problem in interpreting trends in incidence (or mortality) to screening is the 
uncertainty  of  what  would  have  happened  if  there  had  been  no  screening 
programme, against which to compare the observations. It will generally be over 
simplistic to assume that the underlying risk of disease has  remained unchanged 
over time. It is certainly most useful to examine age-specific trends. This is partly 
because screening effects should be seen in specific age groups (the targets of the 
programme), and affect all of these from the same period of time (when screening 
was introduced). Conversely, changes in disease incidence due to differences in the 
underlying risk (brought about by different exposures to aetiological agents) will 
normally affect successive generations of women, and appear as a "cohort effect". 
60 In order to evaluate trends in age-specific incidence of disease, it is essential to 
appreciate the pattern of age-specific incidence in the absence of screening, in a 
single generation (birth cohort)  of women.  The general pattern of the incidence 
curve is a rapid rise to a peak at a comparatively young age, followed by a plateau 
and a variable decline thereafter. This is a somewhat unusual curve for an epithelial 
cancer, and we are not aware of any obvious explanation for this pattern of risk 
with age. This profile is readily distorted by screening, and, if cross-sectional data 
(from a single time period) are examined, by birth cohort specific changes in risk 
(Ashley,1966; Hakama and Penttinen,1981). 
Since the basis of screening for cervical cancer was recognised in the 1940's, and 
implemented in the 1950s (USA) and 1960s (in Europe), few cancer registries are 
able  to  analyse  trends  in  incidence  and  mortality  before,  during  and  after the 
introduction  of screening.  In  an  attempt  to  define  the  age-specific  incidence 
patterns  of  cervical  cancer  without  any  influence  from  screening  activity, 
Gustafsson et al.  (1997a) compiled incidence data for 28 different populations, for 
long periods of time between 1935 and 1989, and analysed age-specific incidence 
rates from populations unaffected by screening. After scaling the rates (to permit 
direct comparison between countries  with  incidence rates  of differing orders  of 
magnitude), most populations fitted to 1 of 2 reference curves used for descriptive  -
purposes (Figure 1). The first group, comprising Denmark, the former GDR, the 
former FRG, the Netherlands, Norway, Slovenia and Sweden, had an onset at about 
age 25, a rapid rise between 30 and 40 and a peak at ages 44 to 49 years. After the 
peak, the decline was fairly rapid and the 'half peak value' was reached at 70-75 
years. The second group, comprising most American, Asian, and Mrican registries, 
plus Finland and Poland, had onset at approximately the same age, but a slower rise 
to a peak at ages 50-65, followed by a decline similar to that in the first group. Data 
from the UK and China did not fit these curves; for the UK this is almost certainly 
the result of long term variation in risk by birth cohort (Hill and Adelstein,  1967, 
Osmond et al., 1982), and in China the consequence of a low level, and late onset, 
of exposure to aetiological factors, especially HPV. When temporal changes in the 
curves were analysed, in the Nordic countries, the peak incidence shifted with time 
towards earlier ages. This also probably represents the effect of increasing risk with 
succesive birth  cohorts,  since  cross-sectional  analysis  of age-specific  incidence 
showed that  a  3%  annual  increase in  successive  birth cohorts  would  move  the 
shape of the curves seen in the second group of countries above closer towards the 
shape of that seen in the first group. This adds further weight to the other evidence 
that  there  are  strong cohort effects  which  need  to  be  taken  account  of in  any 
analysis of incidence with respect to time. 
61 Modelling time trends 
Modelling techniques have been widely used as a means of determining the nature 
of any temporal changes. Assuming that the effect of age on risk remains constant 
over time, the simplest procedure is to determine whether an age-period model, or 
an age-cohort model, provides the best description of the observed data. Although 
the interpretation of effects observed with using models is difficult and fraught 
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Figure 1.  Scaled age-specific incidence ratios for cervical cancer for time periods 
prior  to  screening.  Reference  1:  weighted  average  from  Denmark,  Germany, 
Netherlands, Norway, Slovenia and Sweden.  Reference ll: weighted average from 
Finland, Estonia, Latvia, Lithuania, Poland, Connecticut, Brazll, Colombia, Jamaica, 
Puerto Rico, Hong Kong, India, Israel, Japan, New Zealand, Singapore, Thailand and 
Africa.  Scaling is by dividing each value by the world-standardized rate for the same 
population (reproduced by permission of Wiley-Liss, Inc., a subsidiary of John Wiley & 
Sons, Inc., from Gustafsson et al.,  1997a) 
with error (Clayton and Schifflers, 1987) they nevertheless allow the investigation 
of time trends when data may not be present for all desirable points in the study. 
Age period models  use log-linear models  to  describe  variations in rates  by  age 
according to calendar period of observation whereas age cohort models use log-
linear models to describe variation within a cohort or generation to which the rates 
apply. The methodology has been extended to develop age-period-cohort models. 
These  are  widely  used  in  comparing  data  across  countries,  as  described  by 
Coleman et al.,  (1993). Even at a national or regional level, the cohort effects are 
so  strong  in  some  countries,  notably  the  UK,  that  the  beneficial  effects  of a 
62 screening programme can be masked. (See Chapter 10 in this volume for further 
discussion on the use of models). 
Studies of trends in incidence 
There have been many analyses of cancer registry data in relation to the possible 
influence of screening programmes on the incidence of cancer, both in developed 
countries (e.g., Anderson et al.,l988) and developing countries (e.g., Aristizabal et 
al.,  1984). 
Pompe  Kim et al.  (1992)  examined trends  for  invasive  and  in  situ  cancers  in 
Slovenia from 1950 to 1986. Increasing registrations of in situ cases was paralleled 
by a decline in invasive disease from to early 1960's until about 1981. The age-
specific  trends  suggest,  however,  that  interpretation  may  not  be  entirely 
straightforward, since there appears to have been an increasing risk of disease in 
recent birth cohorts. 
Marked changes  in birth-cohort  specific  risk  of disease  have  been  a  particular 
problem  in  interpreting  time  trends  in  the  UK.  Quinn  et  al.  (1999)  recently 
completed a comprehensive analysis of incidence in England and Wales, in which 
age-specific trends were compared with the coverage of the screening programme 
(percent  of  women  aged  25-64  screened  in  the  preceding  five  years)  and 
registrations  of in  situ  cancer.  The introduction  of the national  call  and  recall 
system in 1988 had had a clear effect in increasing coverage and was associated 
with a decline in incidence in all age groups under 74. However, quantifying the 
fraction of disease being prevented remains contentious. 
Perhaps the best known studies of time trends in incidence are those undertaken for 
the Nordic countries, where it was possible to compare the trends in incidence (and 
mortality)  across  countries  with  their different policies  in  relation  to  screening 
(Hakama, 1982; Hakulinen et al., 1986). The extent of the decline in incidence and 
mortality is related to the coverage and extent of the organised programmes in the 
respective  countries  (Figure  2).  It  was  not  possible  to  take  account  of the 
opportunistic screening occurring in all countries except Iceland. Nevertheless, the 
decline  in  incidence  appeared  to  be  clearly  proportional  to  the  intensity  of 
organised screening (Sigurdsson, 1999). In Finland, Iceland and Sweden organised 
mass  screenings  have  been  conducted  countrywide  since  the  mid-1960's.  In 
Finland, women between the ages of 30 and 55 years have been invited, women 
aged 30-49 in Sweden, while in Iceland the age range has been wider. In Denmark, 
about 40% of the population have been subject to organised mass  screening, in 
Norway, fewer than 5%. The declines in incidence were most marked in the age 
groups targetted by the organised programmes (Table 1). 
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Figure 2.  Trends in the age-adjusted incidence  rates:  cancer of the cervix  uteri 
(reproduced by permission of APMIS from Hakulinen et al.,  1986) 
Trends by histological subtype 
The importance of studying time trends by histological subtype of cancer has been 
stressed by some workers (e.g. Stockton et al., 1997). Several studies have shown 
rising incidence rates of adenocarcinoma, in populations where- presumably as a 
result of screening  - incidence rates from squamous cell carcinomas are declining 
(Kjaer and Brinton, 1993). The increasing risk of adenocarcinoma appears to affect 
relatively  recent  generations  of women  from  many  countries  (Vizcaino  et al., 
1998), and although there has been no increase in Finland, even in that country the 
relatively  constant  incidence  of  adenocarcinoma  contrasts  with  declines  in 
squamous  cell  tumours  (Nieminen  et al.,  1995).  The  cytological  detection  of 
carcinoma or precursor lesions is undoubtedly less efficient than for squamous cell 
tumours (Fu et al.,  1987; Sigurdsson, 1995) and a case-control study (Mitchell et 
al., 1995) has shown that the risk of adenocarcinoma is not reduced by screening. 
64 Table 1.  Screening for cervix cancer in the Nordic countries (to 1995) (reproduced by 
permission of ©2000 Munksgaard  International  Publishers  Ltd.  Copenhagen,  Denmark, 
from Sigurdsson, 1999) 
Cervical cancer  Iceland  Finland  Sweden  Demark  Norway 
screening 
Start of  organized  1964  1963  1964  1962  1994 
screening (fully  (1969)  (1970)  (1973)  (1975) 
developed in year  ...  ) 
Age range of  targeted  25-69  30-55  30-49  30-50 
population up to 1985 
Screening interval in  2-3  5  4  4 
years up to 1985 
Change in screening  1988  1987  1985  1986 
policy (year) since 1985 
Target age group  20-69  30-60  20-59  23-75  25-70 
Screening interval  2-3  5  3  3-5  3 
Targeted coverage of  100%  100%  100%  45% 
national population in 
1991 
% of smears taken  16-24  66-80  75-80  >80  100 
outside organized 
screening after 1980 
Five-year period with  1966-70  1961-65  1961-65  1961-65  1971-75 
highest incidence rate 
Reduction of overall  67%  75%  55%  54%  34% 
world-adjusted incidence 
rate through 1986-1995 
65 Trends by stage of  disease 
Although the primary objective of cervical screening is to prevent the development 
of invasive cervical cancer, the screening test also detects asymptomatic invasive 
disease, and hence the introduction of cervical screening will also affect the stage 
distribution of invasive disease. However analysis of temporal trends in stage are 
always beset with the difficulties of changes in the precision with which stage is 
determined over time, and the high proportion of unknown stage in earlier years. 
Johannesson et al. (1978) reported on the incidence of cervical cancer in Iceland by 
stage of disease at diagnosis between  1965 and  197 4 and Sigurdsson ( 1993) has 
updated  the  results  to  1991.  The  screening  programme  led  to  a  considerable 
increase in early,  micro-invasive (Stage  1A)  cancers, with a fall  in  incidence of 
more advanced stage disease (stages 11-IV). The authors note that micro-invasive 
disease, like carcinoma in situ, has an excellent prognosis (no cases had died since 
1964) so that detection of these cases should be counted as a beneficial effect of the 
programme  (rather  than  counted  along  with  the  invasive  cancers,  which  the 
programme aims to reduce). 
In British Colombia, screening was introduced early (1949-50) and careful records 
were maintained on screening histories of individual women. The progressive fall 
in the incidence of invasive cancer from the mid-1950's to 1977 occurred despite 
an  increase  in  the  incidence  of micro-invasive  and  occult  invasive  carcinomas 
(Boyes et al.,  1981). Comparing cancers registered in  1969-91  with those from 
1955-59, there was  a higher proportion of later stage disease among the invasive 
cancers (despite a fall in absolute numbers). This was because the invasive cancers 
were  occurring  in  older  women  who  had,  for  various  reasons,  escaped  the 
screening programme and also to the possibly more rapid growth on non-screen 
detected cases. Christopherson et al.  (1976)  had noted the same phenomenon in 
Louisville,  Kentucky,  where,  after  15  years  of screening,  the  increase  in  the 
proportion  of incident  cancers,  which  were  in  older  women  (less  intensively 
screened), resulted in a relative increase in later stage disease. 
Herbert et al.  (1998)  studying the effects of screening in  the south of England, 
demonstrate the importance of following time trends by stage of disease, in their 
evaluation  of  the  effects  of  improvements  to  the  screening  programme  in 
Southampton and SW Hampshire (UK).  Increased registration of screen-detected 
cancers either microinvasive (FIGO Stage Ia1)  or with minimal  invasion (FIGO 
Stage lb) resulted in very little overall change in incidence in the first six years, 
despite a marked decline in incidence of symptomatic invasive disease (Figure 3). 
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Figure 3. Trends in cervicat canser incidence, by stage, Southampton and S\il
Ilampshire (England). Introduc{ion of national screening pnogramme  in 19tt (arrow)
(reproduced by permission of BMI Publishing  Group from Herbert et al., J Med Screen
5:92-98,1998)
Studies of trends in mortality
Although a reduction in disease-specific  mortality is the ultimate goal of cancer
screening, in the case of cervix cancer, this is achieved through a reduction in the
incidence  of the disease. A study of the latter is thus a more direct indicator of the
outcome of screening. kr general, although mortality data are often available over a
longer historical time period than incidence data, and for national populations, they
are less satisfactory for the evaluation of cervical screening  programmes for the
following reasons:
(a) Monality can be affected by improvements in treatment (reflected by better
sunrival) as well as changes in incidence.  It could be argued that improved survival
should follow the detection of invasive cancer at earlier stages (which, as noted
above, is a consequence  of screening programmes),  so that improvement in
mortality may be greater that the reduction in incidence.  However, survival within
stage has also improved over time (Spar6n et al., 1995) implying better results
ffom treatment of invasive  disease.
67(b)  Death certification is less precise in terms of cause of death than incidence 
data recorded by cancer registries. As well as erroneous cause of death statements, 
a varying proportion of cervix cancer deaths  are coded to "uterus not otherwise 
specified". A change in the proportions of "Uterus NOS" deaths over time can lead 
to spurious time trends in mortality from cervix cancer (Figure 4). Some form of 
~~reallocation" of these deaths  to  more  specific  categories is required,  a process 
which is always to some extent arbitrary. 
(c)  There is a time delay of approximately  10 years before changes in mortality 
are apparent. 
There have been many  reviews of trends in  mortality rates from cervix cancer, 
including international comparative studies (La Vecchia et al.  1992; Beral et al., 
1994; Coleman et al.,  1993; Robles et al.,  1996), as  well as  reviews confined to 
single countries. The objective of international comparative  studies  is  generally 
simply descriptive - to draw  attention to  inconsistencies in the pattern between 
countries, as  an  indicator of where more focussed research would be of interest, 
rather  than  to  interpret  the  trends  in  terms  of the  efficiency  (or  otherwise)  of 
specific screening programmes. An exception to this are the studies of mortality in 
the  Nordic  countries  which,  like  the  studies  of incidence  trends,  have  been 
interpreted in terms of the extent of organised screening (Laara et al., 1987). 
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Figure 4.  Trends in recorded mortality of  cancer of the cervix uteri, cancer of the 
corpus uteri and uterus cancer, NOS, in Spain (1955-1995) 
Cook and Draper (1984) examined mortality trends for England and Wales for the 
period 1950-1982. They observed the strong birth-cohort effects, described earlier 
by Hill and Adelstein (1967), and noted that, because of these, it was difficult to 
quantify  the  effect of screening  on  mortality.  However,  by  reviewing  also  the 
trends in incidence (of invasive cancer and carcinoma in situ), they could conclude 
68 that screening was probably responsible for part of the mortality decline at ages 35-
54. MacGregor and Teper (1978), also drew attention to the rise in mortality in 
young women (25-34) in England and Wales between 1968 and 1976; however, in 
Scotland,  there  was  a  decline  in  this  age  group  in  the  two  regions  with  well 
organised screening (but a rise elsewhere). No quantitative data were provided on 
screening intensity, however. 
Devesa  et  al.  (1989)  reviewed  trends  in  mortality  (1950-1985)  and  incidence 
(1969-1985)  in  the  United  States.  Both  had  showed  marked  declines,  with  a 
moderation in the fall in younger women in the more recent years. They noted that, 
considering  that  the  prevalence  of most  other  risk  factors  (related  to  sexual 
lifestyles, contraception, smoking) might have been expected to increase risk of the 
disease, the observed declines might reasonably be attributed to screening. 
De Schryver (1989) noted that the falls in mortality in Belgium had been relatively 
modest, confined to the middle age groups (35-54), and had begun before screening 
was introduced. He drew attention to the similarity to the trends in Norway, where 
screening was also opportunistic, and not very intense. 
Vlasak et al.  (1991)  observed increasing mortality  and incidence (especially  in 
younger  women)  in  Slovakia  (1968-1987);  the  few  cases  of carcinoma  in  situ 
registered suggested that screening was failing to prevent much disease. 
Quantifying the impact of screening: 
The problem of lack of "expected" rates of disease in the absence of screening, 
when  interpreting  observations  of trends  in  incidence  (or  mortality),  has  been 
alluded to earlier. This aspect, often overlooked, has  been approached in several 
ways. 
In investigating the effect of cervical screening programmes globally, Gustafsson 
and  colleagues  (1997a)  determined  age-specific  incidence  patterns  in  several 
populations, as  described above.  They then (Gustafsson et al.,  1997b) compared 
observed incidence in 17 countries (with 15 or more years of follow up) during a 
period after screening was  introduced with the  rates  observed pre-screening.  To 
estimate changes from the baseline period before screening, incidence rates directly 
age standardised to the world standard population were calculated for all ages and 
to the  world population truncated to  35-64 years.  Where age  standardised rates 
decreased  at  least  25%  from  the  baseline  rates,  age-specific  rate  ratios  were 
calculated. Age-standardised incidence rates decreased by at least 25% in 11 of the 
17  studied populations, with an  age-specific pattern demonstrating some common 
features. There was no change in incidence rates below 30 years of age,  a strong 
69 reduction around the peak incidence leading to a flattening of the incidence curve 
with  age,. followed  by  a  less  pronounced  reduction  with  increasing  age.  The 
U-shaped curves of age-specific rate ratios diverged from 1 (no effect) at ages 25-
35, reached a minimum (maximum reduction) at 45 to 55,  and approached  1 at 
higher  ages  (Figure  5).  In  12  of these  populations,  examination  of data from 
periods before screening had demonstrated the presence of pre-existing trends. But 
since  they  were  mainly  positive,  the  authors  noted  that  this  could  only  have 
resulted in an underestimate of the effects of screening. The authors note, however, 
that it is difficult to determine the precise effect of screening without knowledge of 
the intensity of screening. 
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Figure S.  Rate ratios between age-specific incidence rates of cervix cancer for the last 
follow-up and baseline periods for successruny screened populations: (a) Finland, (b) 
Puerto Rico,  (c)  Connecticut (USA),  (d)  Canada (S  provinces:  Alberta, Manitoba, 
Newfoundland, Quebec, Saskatchewan), (e)  Sweden, (f) Denmark, (g)  Slovenia, (h) 
Colombia (Cali), (i) Hamburg, (j) German Democratic Republic, (k) and Norway. For 
each age, the age-specific incidence rate in the last follow-up period is divided by the 
corresponding  age-specific  incidence  rate  in  the  baseline  period  (reproduced  by 
permission of  Kluwer Academic Publishers from Gustafsson et al.,  1997b) 
The approach taken by the East Anglia Cancer Registry in England (Gibson et al., 
1997) takes into account short term pre-existing time trends within age groups (and 
allows for regional variation in such trends) in preparing "expected" values against 
which to compare observed incidence. The "pre-screening" period ( 1981-1990) had 
a rather lower percentage coverage of screening than the observation period ( 1991-
70 93), and the authors considered that the magnitude of the difference in Observed-
Expected  cases  of cancer,  and  the  absence  of effect  in  women  aged  over  70, 
strongly implicated a beneficial effect of screening. 
The problem of estimating expected incidence (or mortality) has been particularly 
acute in UK, because of the marked variation in risk of disease in different birth 
cohorts. This effectiveness of screening has therefore had to be judged against a 
risk of disease increasing in  successive generations of women  born  since  about 
1935  (Osmond  et al.,  1982;  Sasieni  and  Adams,  1999).  In  fact,  evaluating 
underlying  risk  of disease  from  observed  trends  in  mortality  will  result  in  an 
underestimate,  since  mortality  will  itself have  been  reduced  by  screening.  The 
approach taken by Parkin et al.  (1985),  was  to  "correct" the observed incidence 
rates,  making use  of the  information  on  the  number of cases  of in  situ  cancer 
detected as a result of screening activity, and the proportion of these which would 
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Figure 6.  Annual age-specific incidence rates (per 100 000 uteri) of carcinoma of the 
cervix uteri in England and Wales in 1962 and 1978. For 1978, the estimated incidence 
in the  absence  of screening  (A)  is  also  shown.  The  shaded area  represents  the 
reduction in incidence due to screening (reproduced by pennission of Blackwell Science 
from Parkin, 1997, in Franco & Monsonego (  eds) New Developments in Cervical Cancer 
Screening and Prevention; originally from Parkin et al.,  1985, Br J Obstet Gyn 92:150-157) 
have been expected to progress to invasive cancer. The rates were also corrected 
for the women  who  would  cease to be at risk of the  disease by  virtue  of them 
71 having a hysterectomy. In this way the expected incidence of invasive cancer was 
estimated and compared to the observed rates. This demonstrated that the reported 
increase in younger women (aged under 35) between 1963 and 1978 was the result 
of cohort specific increases in risk for generations born since 1931; screening had 
reduced the potential increase in  incidence by 50%  and prevented a  significant 
increase  in  older  age  groups  (Figure  6).  This  at  least  partly  explains  the 
observations of the UK data in Gustafsson's paper. However, using this model to 
quantify the effect of well established programmes of long standing would require 
some estimates of both the incidence and the rate of progression of CIN2 lesions 
which is not easy to acquire on a national basis. 
Conclusions 
Cancer  registries  can  make  an  important  contribution  to  the  evaluation  and 
monitoring of cervical cancer screening programmes by the analysis of trends over 
time in  the incidence of,  and  to  a lesser extent mortality from,  cervical cancer 
within  defined  populations.  Such  analysis  has  identified  strong  cohort  effects 
which, if not taken into account in the evaluation of a screening intervention, can 
lead to incorrect conclusions about the effectiveness of a screening programme. 
Ideally  trends  in  cancer incidence  should  be  analysed  over  the  period  before, 
during and after the introduction of a screening programme and are of maximum 
value when screening is undertaken as part of an organised, structured programme. 
The usefulness  of cancer registry data can be enhanced by  statistical modelling 
techniques,  both  if cancer  registry  data  is  not  available  for  all  of the  period 
required, and by facilitating comparison with the observed cancer incidence and 
that expected in the absence of screening. Cancer registries should maximise the 
opportunity for using registration data in the evaluation and monitoring of cervical 
screening programmes by developing links with the screening programme itself, 
modifying the cancer registration dataset to include detailed staging information, 
and analysing time trends in cancer incidence alongside screening activity data. 
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76 Chapter 6.  Cervix cancer: geographical correlations 
A. Anttila and E. Liiirii 
Background 
There is nowadays no big divergence from the opinion that adequately performed 
Pap smear screening can markedly reduce cervical cancer incidence and mortality. 
In  spite of widespread application, there is  still disagreement on the size of the 
overall  effects  of  Pap-screening  programmes.  Factors  affecting  the  overall 
effectiveness include a high and evenly-spread coverage, regular compliance of the 
target population, including high-risk populations at the defined intervals, adequate 
sample taking  and handling  practices, combined with  well-controlled diagnostic 
work in the cytological analysis of the smears; and the adequacy and completeness 
of the subsequent follow-up  and treatment of the precancerous  lesions  detected 
(Coleman et al., 1993). Lack of one or more of these characteristics might explain 
the relative failure of some screening programmes. 
The evaluation of a screening programme should not only be organised in terms of 
the screening activities and outcomes, but also include follow-up of incidence and 
mortality data among attenders  and non-attenders  as  well  as  at  the  level  of the 
overall target population (Hakama et al., 1985; IARC, 1986; Coleman et al., 1993). 
Variation in opinion has  resulted in differences in  screening policies adopted in 
different countries or centres - between different options for organised screening 
programmes, and between organised and spontaneous  screening modalities.  The 
scope of this review is to summarise the results of the studies on the overall impact 
of Pap-screening activities in decreasing cervical cancer incidence and mortality. 
Estimation  is  based on  the  associations  between  screening indices  and  invasive 
cervical cancer endpoints in different geographical areas.  Variation in  screening 
policies  has  made it possible to compare their overall  effectiveness in different 
settings. We also describe briefly the methods and designs used in these studies and 
discuss their limitations. 
Methodological considerations 
Studies  of  geographical  correlations  as  an  epidemiological  approach  can  be 
subsumed  under the  so-called  ecological  studies  (Morgenstern,  1998).  In  these 
studies,  the units of study  are  groups,  aggregates  or populations of individuals, 
often citizens living within the same administrative region. This is in contrast with 
77 the  common  cohort  and  case-control  designs,  in  which  the  study  units  are 
individuals themselves. In individual-based studies, the measurements of both the 
outcome and the exposure variables can be linked at individual level within the 
entire study population. 
In ecological studies, the measurements of exposure and outcome variables refer to 
a whole group  or population of individuals. The outcome is represented by the 
incidence  or  mortality  rate  aggregated  over  the  individual  occurrences  of the 
disease in the group during the same follow-up  period. The ecological exposure 
variables can be of three types:  (a)  aggregate or summary measures (averages or 
proportions) of individual values, (b) environmental characteristics shared by the 
members  of the  group,  or (c)  global  measures  that  are  attributes  of the  group, 
organisation, or place for which there is no distinct analogue at the individual level, 
e.g.,  population  density,  type  of health  care  system.  As  a  consequence,  in  an 
ecological  study,  information  exists  only  on  the  marginal  distributions  of the 
exposures and the outcome within a group.  Another important statistical feature 
present in these studies concerns the nature of random variation. In addition to the 
unsystematic variation across individuals in a given population group affecting the 
statistical  precision  of the  incidence  rate  in  that  group,  there  is  an  important 
variance component in an ecological study due to the random variation between the 
groups. If  one takes into account only the individual variation within a group, the 
resulting standard errors and confidence intervals of the ecological estimates are 
likely to be too narrow. 
Ecological studies can be divided into the following designs:  <n  multiple-group 
design, in which the disease occurrence is studied in different populations during 
the  same  limited  period  in  time,  (IT)  time-trend  design,  in  which  the  disease 
occurrence is investigated in one selected population over various periods in time, 
and (Ill) mixed design, in which several populations are followed-up over the same 
periods of time. 
Geographical correlation studies are generally considered within design category 
(n,  and  they  are  sometimes  described  as  "descriptive",  i.e.,  quantifying  the 
statistical associations between aggregate exposure variables and disease incidence, 
in order to  give  clues  to  aetiological  relationships  to  be further  investigated in 
"analytical" case-control and cohort studies at the individual level. The above view 
on geographic or ecological studies is too restricted. Many interesting aetiological 
questions can readily be studied on group level. In fact, there are important causal 
hypotheses  which can only be tested at this  level.  The effectiveness of a given 
health  care  policy,  like  a  screening  programme  targeted  to  a  demographically 
defmed population, is  such a causal question,  the answer of which demands  an 
ecological design, because a population-based intervention should also be analysed 
in terms of population-based outcome. 
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is generally studied by investigating the outcome incidence in a target population 
under  the  implemented  screening  policy  (like  a  defined  organised  screening 
programme)  as  compared  with  the  incidence  one  would  have  observed,  if an 
alternative policy (like no organised screening programme at all) were adopted. At 
best  an  'analytical' ecological  study  is  a  randomised  experiment,  in  which  the 
different aggregate units forming the meta-population of the study are randomly 
divided into two sets: in the intervention set of units, the screening programme is 
implemented to cover the whole target population, and in the control set of units, 
there is no such organised intervention. 
The label 'geographical correlation' should not be interpreted too narrowly to mean 
that only correlation coefficients  are used to  describe  the statistical  association 
between ecological exposure variables and the outcome. A correlation coefficient 
(whether Pearson or Spearman)  may  not be informative  at  all  about the causal 
association  of interest.  It  merely  tells  whether an  exposure  variable  is  linearly 
related  to  the  outcome.  Certain  other  statistical  measures  and  methods,  like 
appropriate contrasts (absolute or relative) of the incidence rates between screened 
and non-screened units, may better describe the effect of an intervention. 
In  this  paper,  we  focus  on  non-experimental  ecological  studies,  in  which  the 
intervention programme is  not randomised across  the groups forming the  meta-
population;  i.e.,  the  characteristics  of  the  screening  programme  are  varying 
between the groups. As in individual-based studies, biases due to misclassification 
and  confounding  are  also  present  in  geographical  studies.  Therefore,  the 
interpretation of the results of these studies is not straightforward at all. A special 
form of bias prevalent in ecological studies is the ecological bias: the association at 
the group level is qualitatively different from that at the individual level, which is a 
consequence of heterogeneity of exposure level and covariate levels within groups. 
This heterogeneity  cannot be captured  with ecological  data because of missing 
information on the joint distributions of the exposures and outcome at individual 
level. An example of  an ecological bias is the association between the income level 
and  incidence  of  cancer  of  the  cervix  (Hakama,  1982).  At  the  level  of 
municipalities  one  can  observe  a  positive  association:  the  higher  the  average 
income  in  a  municipality  the  higher  is  the  incidence.  On  the  other  hand,  at 
individual  level,  the  association  is  negative:  women  with  higher  than  average 
income have a lower incidence than women do at lower income levels. The results 
imply that a woman with a low standard of living in a well-to-do environment has a 
high risk of cervical cancer. 
In a non-experimental ecological evaluation of a screening programme one would 
preferably  use  the  mixed  design  (III).  For  several  populations  defined  by 
geographical region there should be outcome data from a period before there was 
screening  programme,  and  from  a  period after an  appropriately  long  time  had 
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design  allows  a  before-after  analysis  (Morrison,  1998)  relating  the  change  in 
incidence or mortality to the existence and properties of a screening policy. Each 
region, thus, serves as its own control. However, one cannot rely on before-after 
analysis of incidence trend in one population only, so there should also be control 
regions or populations with different screening policies at the outset. 
Screening policy is not an ali-or-none variable. When evaluating the effectiveness 
of an  organised  screening  programme,  one  should  have  data  at  least  on  the 
following important characteristics: (i) target age range, (ii) screening interval, (iii) 
certain  organisational  aspects  (information,  invitation,  attendance,  and  referral 
procedures), (iv) diagnostic and clinical aspects and (v) quality control procedures 
in the whole screening process. Changes in these characteristics over time should 
also be taken into account. 
In the context of evaluating a cervical (or any) screening programme, coverage and 
compliance are of utmost importance: what proportion of the target population are 
actually invited or offered screening, and what proportion of those invited have 
smears taken according to the scheme. These are of course important determinants 
of the ultimate outcome,  i.e.,  the incidence of (or mortality  from)  the invasive 
disease. However, coverage and compliance are not intrinsic fixed properties of a 
programme, but they are dependent on the characteristics of the programme. Thus, 
they can be viewed as  an intermediate outcome. Compliance is  also,  to a  large 
extent, dependent on certain socio-economic features of the target population. It is 
also related to the availability of spontaneous smear taking in the region. These 
aspects may vary over time. The actual compliance and coverage must of course be 
taken  into  account  in  the  interpretation  of  ecological  analyses  of  screening 
programmes. A straightforward 'blind' adjustment for them might sometimes give 
a misleading estimate of  the actual effectiveness of  the programme, however, if  e.g. 
the individual screening histories in the population were not considered adequately. 
Materials and methods 
We found 27  references reporting data on geographical correlation or ecological 
association between Pap-screening activities and invasive cervical cancer incidence 
or mortality rates (summarised in Table 1). In a single report the multiple-group 
design  (I)  was  adopted  such  that  the  incidence  and  mortality  figures  were 
correlated with the intensity of screening in different districts during a single period 
only (Fouquet and Gage 1996). Moreover, in this study the outcome was obtained 
from a simultaneous or even a partly earlier time period than the screening data. 
The time-trend design <m  was  applied in  13  studies in  which the incidence or 
mortality rates before and after the initiation of screening activity were compared 
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the mixed design (Til) allowing evaluation of the temporal changes of incidence or 
mortality  related  to  screening  in  many  populations.  Yet,  most  of these  were 
restricted to comparing different regions in one country, but in three studies several 
countries  were  included  (Hakama,  1982;  Laara  et al.,  1987;  Gustafsson  et al., 
1997; additional follow-up  material available in  Engeland et al.,  1993;  Hristova 
and Hakama, 1997; Parkin et al., 1997). 
In most of the studies, the association between screening and incidence or mortality 
was  analysed  in  a  rather  informal  way.  In  comparisons  between  the  Nordic 
countries (Hakama,  1982; Laara  et al.,  1987)  summary  statistics  on  certain key 
characteristics (target age range, screening interval, coverage,  attendance) of the 
screening programmes in the five countries were described to aid the interpretation 
of changes in the outcome. More common were studies in which important details 
on  the  organisational  aspects,  coverage,  attendance  and  other  properties  of 
screening in the study populations were inadequately described. For example, in 
the article by Gustafsson et al.  (  1997) the incidence of cervical cancer after "the 
introduction of a screening programme" was  compared to that before the era of 
screening in several populations without any information on what these different 
"screening  programmes"  actually  contained.  Interpretations  of  the  observed 
changes of incidence are therefore difficult to make from this study. In contrast to 
that, Gibson et al. (1997) performed a more focused before-after analysis in which 
the trends of incidences in the districts of East Anglia were related to the timing of 
the well-documented changes in the organisation and management of the national 
screening  programme  in  England  occurring  in  1988-1989.  A  special 
methodological feature in this study was the appropriate statistical treatment of the 
variability between districts. 
A  few  studies  performed  a  formal  analysis  in  terms  of correlation  coefficients 
between  measures  describing  the  screening  activity  and  percent  change  in  the 
incidence or mortality rate since the onset of the screening activity (Cramer, 1974; 
Miller  et  al.,  1976;  Murphy  et  al.,  1988).  In  general,  though,  besides  the 
information on the extent or intensity of screening, not much historical details on 
the organisation and clinical aspects of the different screening centres were given. 
Usually the proportion (rate)  of screenings done per female population during a 
one- to five-year period were described, the length of the period depending on the 
targeted screening interval  within the region.  These do  not necessarily describe 
well the screening histories of individual women. In some study areas there might 
have  been  screening  activities  at  least in  a limited extent  also  during  the  time 
considered 'unscreened' (noted by Miller et al.,  1976). So far only one study has 
reported  systematically  the  details  on  the  quality  assurance  in  cervical  cancer 
screening (Sigurdsson, 1995). 
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the  impact  of screening  by  simultaneously  adjusting  for  other  ecological-level 
variables (for example, on the social and demographic characteristics, population 
flows,  prevalence of hysterectomies,  proxies  on  sexual  life,  smoking  habits,  or 
some other behavioural  risk factors)  using  multiple  regression  methods.  A  log-
linear Poisson model was applied by Lynge et al. (1989) in estimating the impact 
of the  initiation  of an  organised  screening  programme  in  Denmark  where  the 
various  administrative  regions  adopted  different  policies  concerning  organised 
screening. 
Results 
After the introduction of the cervical cytological smear in the early 1940s, it took 
several years before the test became widely available (Ayre, 1964; Cramer, 1974; 
Gardner and Lyon, 1977). There were some early screening programmes launched 
in limited areas in the United States and Canada already in late 1940s, but it was 
not until the late 1950s or in 1960s that cytological screening became widespread 
in these countries. The cervical cancer mortality rates had started to decrease to a 
minor degree already before the introduction of the screening programmes, with 
little if any  evidence of a further contribution of screening (Miller et al.,  1976; 
Gardner and Lyon, 1977). In limited areas in the United States, decreases between 
40% and 66%  in the incidence of invasive cervical cancer and in mortality were 
reported, following an expansion of the· programmes to one-year coverage of 25% 
to 45% in the late 1960s (Dickinson et al., 1972; Cramer, 1974; Christopherson et 
al., 1976, Table 1). In Canada, the intensity of screening was related to the fall in 
death rate between 1960-1962 and 1970-1972 at the provincial, county, and census 
division  levels  (Miller  et  al.  1976).  The  frrst  large-scale  centrally  organised 
screening programme  had  been  launched  in  the  province  of British  Columbia, 
Canada in 1949. The lifetime coverage of smears increased up to 85% from 1970s 
onwards (Boyes et al.,  1981; Anderson et al.,  1988). The age-specific incidence 
rate  of squamous-cell  carcinoma  of the  cervix  uteri  in  the  British  Columbia 
decreased  from  28.4 cases  per  10
5  woman-years  in  1955  to  6.4  cases  per  10
5 
woman-years  in  1985,  i.e.,  78%,  among  women  over  age  20  years.  The 
corresponding mortality rate decreased from 11.4 deaths per 10
5  woman-years in 
1958 to 3.1 deaths per lOS woman-years (decrease 72%). 
In the United Kingdom, the screening activities started to expand in the early 1960s 
(Parkin et al., 1985; Fouquet and Gage, 1996; Gibson et al., 1997; Table 1). There 
was  some  decrease  in  the  registered  incidence  and  mortality  rates  related  to 
screening  intensity  also  in  the  UK,  at  least  among  the  35-54  years  old  target 
population (Parkin et al., 1985, Gustafsson et al., 1997). The rates in younger age 
groups had increased in a birth cohort-wise manner. There appeared to be no clear 
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screening  activities  (Fouquet  and  Gage,  1996;  Gustafsson  et  al.,  1997).  The 
screening  programme  has  been  re-modelled  since  1988  by  introducing  a 
computerised call and recall system for invitations, new quality standards, and new 
guidelines  for the  follow-up  of women  with  abnormal  smears.  According  to  a 
report,  using data from East Anglia, the coverage of smears  has  increased after 
these changes rapidly to 80% of the target population and the incidence of invasive 
cervical  cancer has  started  to  decrease  (Gibson  et al.,  1997).  The  decrease  in 
incidence was 34% in the age group of 20 to 69 years in 1991-93, compared to the 
expected incidence  based on  the  age- and  district  -specific  trends  in  the  period 
1971-90.  In  whole England, the age-standardised mortality from cervical cancer 
has decreased from 6.1  deaths per 10
5 woman-years in 1987 to 3.7 deaths per 10
5 
woman-years in 1997 (Quinn et al., 1999). 
In  the  Nordic  countries,  organised  screening  programmes  based  on  personal 
invitations  were  started  in  the  early  1960s.  Spontaneous  smears  were  not  in 
widespread  use  before  the  introduction  of  the  organised  Pap-screening 
programmes,  but  since  then  they  became  increasingly  common.  In  Finland, 
Sweden, and Iceland the programmes became nation-wide in the early 1970s. The 
coverage  of invitations  was  close  to  100%  at  the  target  age  groups  and  the 
participation rate was 70% to 80% in each invitational round in these countries. In 
Norway,  the  organised  programme  was  introduced  in  one  county  only.  In 
Denmark, the organised programme was introduced in some counties, leading to a 
population  coverage  of about 40%  at the  national  level.  In  Denmark  in  1986, 
however, only 25% of women in the target age range had actually been covered by 
an organised screening programme (Lynge, 1998). The coverage of the organised 
screening programmes has increased in Denmark, as well as in Norway, during the 
1990s.  In  Finland  and Iceland,  the  nation-wide  programmes  were  administered 
centrally,  whereas  in  Sweden  and  Denmark  the  organisation  has  been  de-
centralised within autonomous counties. Finland has been the only country over the 
decades  where  the  opportunistic  and  programme  smears  have  not  been 
'coordinated', i.e.,  where  all  the  women  at target age  groups have  been invited 
irrespective of any recent spontaneous smears. There have also been differences in 
the screening interval and target age range between these countries. 
Before the introduction of the programmes there had been slight increases in the 
incidence  of cervical  cancer  in  each  of the  Nordic  countries,  reflecting  more 
intensive  detection  or  registration,  or  an  increased  background  risk  (Hakama, 
1982). The programmes were started in the period 1963 to  1967 in most of these 
countries.  Up to the mid-1970s,  soon  after the introduction  of the  programmes, 
there were large decreases in cervical cancer incidence and mortality rates in each 
of the  countries  with  a  large-scale  screening  programme  (Denmark,  Finland, 
Iceland, and Sweden; Hakama,  1982; Laara et al.,  1987; Figure 1). The decrease 
was confined largely to the age groups 30 to 59 years, i.e., to those groups targeted 
83 in the programmes (Figure 2). In Norway- almost completely without organised 
activities- incidence rates continued to increase, particularly among those below 
60 years  of age  (i.e.,  among  the  potential  target  population).  The  slope  of the 
decreasing  trend  in  incidence,  as  well  as  in  mortality,  was  steepest  in  those 
countries with the highest coverage of the organised programme (Finland, Iceland, 
and  Sweden).  During  that  time  in  Denmark,  comparison  of the  county-based 
incidence and mortality rates suggested an effect of about 33% associated with the 
presence of organised screening (Lynge, 1983, Lynge et al., 1989). 
The five-year period-specific age-adjusted rates of cervical cancer published from 
all the Nordic countries can be extended up to the year 1992 (Engeland et al., 1993; 
Hristova and Hakama,  1997; Parkin et al.,  1997). Large differences in the trends 
have emerged (Figure 1). The decrease in age-adjusted cervical cancer incidence 
has been largest in Finland, 77% overall, whereas it was 68% in Iceland and 56% 
in  Sweden  (Table  1).  In  Denmark,  the  overall  decrease  has  been  52%,  and  in 
Norway,  during the  latter half of the  follow-up  period between  20%  and  30%. 
Interestingly, the slope in the incidence trend in Denmark and Sweden has been 
almost identical. The relative reductions in the incidence rates have extended in the 
Finnish patterns also to older women  with the aging of the screened population. 
The incidence rates have increased in Finland during the  1990s in the youngest 
target ages (Anttila et al., 1999). A high incidence appears to correlate with a low 
attendance rate  in  the  screening  programme  within  the  municipality  level.  The 
percent decreases in the age-adjusted mortality in the Nordic countries have been 
almost of similar magnitudes to those seen in the incidence (Hristova and Hakama, 
1997; Figure 3). 
There is a unique report available on  the impact of the screening programme in 
East Berlin, former German Democratic Republic, during 1973 to  1982 (Ebeling 
and Nischan,  1986). The coverage of the programme appeared high, up to 90%. 
The cervical cancer rates had been very high at the start of the programme. In the 
ten-year period up to 1982, the incidence had decreased by about 33%. In another 
nation-wide programme in Cuba, no clear decrease in cervical cancer incidence has 
been  observed  (Fernandez  et  al.,  1996).  The  coverage  of the  well-controlled 
screening activities appeared to be limited in the latter programme. 
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Figure 1. Cervical cancer incidence rates in the Nordic countries, 1958-1992. Whole 
female  population,  five-year  period specific  rates  adjusted  for  age  to  the  world 
standard population (Hakama, 1982; Engeland et al., 1993; Parkin et al., 1997) 
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female population, adjusted for age to the world standard population (Laara et al., 
1987; Hristova and Hakama 1997) 
86 Discussion 
We reviewed 27  studies on the impact of organised activities for cervical cancer 
screening. All but one of these studies showed clear decreases in cervical cancer 
incidence or mortality after introduction of Pap-screening activities. Evidence of 
the largest effects in terms of percent decrease in the age-adjusted cervical cancer 
incidence rates (68o/o  to 78%) come all from areas with high coverage of smears 
taken in a centrally organised screening programme, i.e., Finland and Iceland, and 
British Columbia, Canada (in the latter the squamous cell carcinoma rates  were 
reported).  As  these  relatively  large  effects  emerged  rapidly,  within  few  years, 
among women in the target ages of the organised activity, it is unlikely that any 
other factor would explain the findings.  Some organisational differences between 
these most effective programmes, e.g., in the target ages  and  screening interval, 
apparently  affect  the  overall effectiveness  in  a minor degree.  Those differences 
may affect the efficiency in a greater extent. The impact of less centrally organised 
activities vary roughly from  10% to 60%  depending on the period and length of 
follow-up, and age groups reported. All in all, the present-day evidence based on 
geographical  correlations  of the  effect  of large-scale  organised  Pap-screening 
programmes can be considered reassuring. 
In  addition  to  the  organisational  design  in  screening  (considered  the  major 
determinant for the rapid reductions in incidence and mortality patterns) there are 
fluctuations  which  might  also  have  affected the  trends  in  a minor degree.  Any 
increased  intensity  of a  spontaneous  activity,  possibly  simultaneously  with  the 
organised  programmes,  might  contribute  or  modify  part  of the  overall  impact. 
Changes in  sexual life, e.g.,  in  age  at first  intercourse,  in the number of sexual 
partners,  or  in  the  proportion  of unprotected  intercourses  may  relate  to  the 
prevalence  of some  potentially  oncogenic  infections  (such  as  oncogenic  HPV 
types). Changes in smoking habits among women might conceivably also affect the 
trends.  If these  risk  factors  have  become  more  prevalent  during  the  last  few 
decades,  the  changes  would  favour  an  increase  rather  than  decrease  in  the 
background risk. This could lead to underestimation of the overall screening effect 
in some areas (think, for example, highly urbanised areas in comparison with more 
remote areas). 
Inadequacies in the coding and coverage of the registration of invasive cervical 
cancer  incidence  or  mortality  might  have  affected  country-specific  data, 
particularly  concerning  the  effects  of the  early  programmes.  For  example,  a 
proportion of cervical cancer cases might have been coded to  'uterus, unspecified 
or NOS' in earlier years. The invasive tumours might not have been separated from 
the in situ tumours. There were efforts to correct for these kinds of errors, e.g., by 
re-analysing the diagnoses from hospital records in limited areas (Dickinson et al., 
1972;  Cramer,  1974;  Christopherson  et al.,  1976).  Concerning  the  present-day 
diagnostic  accuracy  and  registration  practice,  one  would  expect  only  minor 
87 differences between the developed countries. There are not many data available on 
direct comparisons of histological samples, and therefore potential differences in 
the diagnostic criteria may complicate international comparisons. For example, the 
age-adjusted  incidence  to  mortality  ratios  appear  to  be  somewhat  higher  in 
Denmark than in Finland, suggesting that the diagnostic criteria in incidence may 
differ between these countries. Nevertheless, the country-specific percent decreases 
have been the same whether estimated from incidence or mortality figures in these 
two countries. 
There  are  differences  in  the  prevalence  of hysterectomised  women  between 
countries. In the US, where hysterectomy rates are higher than in most countries in 
Europe, cervical cancer incidence rates, if left uncorrected, have lead at least 10% 
errors in the trends since 1960s (Lyon and Gardner, 1977; Marrett, 1980). These 
errors vary between age groups, being most prominent in the postmenopausal age 
groups. 
One  of the  main  limitations  in  the  evidence  on  how  to  attain  the  maximal 
effectiveness in Pap-screening programmes is that not much detail is available on 
the organisational, diagnostic, and clinical aspects in screening centres in relation 
to the trends.  Diagnostic criteria in the cytological Pap-screening test or in the 
histological  diagnosis  of the  precancerous  lesions  may  differ  greatly  between 
different centres or countries. In those countries where there exist well-established 
screening and cancer registries and archives it should be a rather simple procedure 
to document the quality assurance, including a systematic audit of the screening 
histories,  and  to  compare  directly  the  diagnostic  or  clinical  aspects  between 
different areas or countries. These could add much new evidence on the overall 
effectiveness of the Pap-screening activities. 
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 Chapter 7. Cervix cancer: case-control studies on screening 
M. Zappa and S. Ciatto 
Introduction 
Case-control studies (as well as other observational studies) had a crucial role in 
assessing the efficacy of Pap smear as no randomised controlled trial has ever been 
conducted. The case-control  approach  allows  screening efficacy to  be measured 
and the natural history of cervical cancer to be investigated. In the present paper we 
will describe the main characteristics and results of case-control studies published 
since 1986 (The IARC monograph on the evaluation of cytological screening was 
published in 1986 and we assume that after that publication screening efficacy was 
widely accepted) (Hakama et al., 1986). These studies were aimed at evaluating the 
effectiveness  of  specific  screening  programmes,  essentially  for  monitoring 
purposes. The importance of these studies will be discussed, as well as their limits. 
We will also describe 'audit' studies of cervical cancer, an  approach analysing the 
natural history of cases of invasive cancer, particularly useful  in  identifying the 
weak phases of a screening programmes: 'audit' studies do not use the case-control 
approach,  but  use  a  similar  retrospective  reconstruction  of screening  history. 
Finally, we describe a recent attempt to monitor the screening process by a case-
control study which considers the different phases of the process as determinants of 
outcome:  although  such  a  methodology  has  its  limits,  the  approach  is  quite 
interesting  as  it  allows  the  identification  of  areas  of practice  susceptible  to 
improvement. 
Case-control studies: some methodological aspects 
Case-control  studies  have  been  used  in  the past to evaluate  screening efficacy, 
particularly for screening programmes for which randomised field trials had not 
been performed either for ethical or logistic reasons. The rationale of these studies 
is the comparison of the prior use of a screening test in two groups of subjects, 
namely  (1)  those  who  have  suffered the  adverse  outcome  that the  screening is 
expected to prevent (cases), and (2)  subjects sampled from the source population 
from  which  cases  were  drawn,  whose  screening  history  reflects  that  of the 
population (controls). Such a study design estimates the occurrence of an adverse 
outcome in subjects who had a screening test as compared to those who had not. 
The case-control approach has a number of advantages  over other observational 
studies. First, screening history is not required for the whole population, but only 
99 for cases (developing invasive cancer or dying of it)  and controls. Furthermore, 
limiting  the  study  to  a  relatively  small  number  of  subjects,  collection  of 
information on relevant confounding variables is also feasible. 
Two study variants have been described, according to whether the screening test is 
aimed at detecting early stage cancers or precancerous lesions (Sasco et al.,  1986). 
In  the case of cytological  screening for  cervix cancer (as  well  as  screening for 
colorectal cancer), both outcomes may be considered: in fact screening is aimed at 
preventing the occurrence of invasive cervical carcinoma (CC) and thus at reducing 
mortality from CC, but it is also possible that death from CC may be prevented by 
detecting early and curable invasive CC. It is also possible that mortality reduction 
is  determined by  a better quality  of medical care of screen-detected cases  with 
respect to  not  screen-detected cases:  it could be argued that  this  fact  is  also  a 
favourable  effect  of screening,  but  the  assumption  that  the  benefit  is  due  to 
screening could be biased. The validity of this type of study in the evaluation of 
screening has been the object of a wide debate  (Morrison, 1992; Parkin and Day, 
1985; Sasco et al., 1986; Moss, 1991; Weiss, 1994; Gill and Horwitz, 1995; Cronin 
et al., 1998). 
Definition of  cases and controls 
Cases are subjects who experienced the adverse outcome. If the source population 
is population-based,  cases  are  identified by  means  of a cancer registry  or of a 
pathological archive collecting all cases occurring within a geographical boundary. 
If cases are identified from hospitals or clinics (hospital-based) the corresponding 
source population is defined as all the subjects who would attend that clinic if they 
had the disease of interest (hospital catchment population). The choice of hospital 
series may be convenient for practical reasons but it is a source of possible bias in 
the selection of controls. 
If cases (as well as controls) are drawn only from a screening programme archive 
(nested  case-control  study  within  a  cohort)  the  effect  of  screening  could  be 
underestimated, since being screened at  a given date is  generally correlated with 
previous  screening  attendance.  This  approach  may  be  useful  for  evaluating  the 
relative benefits of a previous smear performed at different times in the past. 
If the adverse outcome of interest is death, some additional problems may occur. 
One is related to the quality of death certification. For example, in Aorence District 
more than 30% of deaths from CC were coded as  ICD-9  179 ( =  cancer of uterus 
not otherwise specified) (Barchielli et al.,  1990). Moreover, it is difficult to judge 
only from the death certificate if the woman died from or with CC. To avoid the 
latter  bias  it  has  been  suggested  that  medical  records  should  be  reviewed  in 
addition to death certificates and a panel of experts should be set up for blinded 
case  review.  (Weiss,  1994;  Gill  and  Horwitz,  1995).  The  inclusion  of screen-
100 detected cases tends to underestimate the benefit of screening since the effect of 
lead-time bias may lead to a surplus of such cases (Moss, 1991). 
Controls must be an unbiased sample of the source population. In the selection of 
controls an equal chance of 'exposure' to screening must be ensured for cases and 
matched controls. If migration to and from the study area is relevant, it must be 
verified that cases and controls have been resident for the same period in that area 
(and/or received the same number of invitations to screening). In fact, a bias may 
arise if migrating people are at different baseline risk. 
Definition of  screening history 
The definition of screening history presents several problems. All screening tests 
(negative  or positive)  must  be  included  in  the  analysis  of screening  efficacy. 
Considering only negative tests makes sense only if the objective is to evaluate the 
negative predictive value of a screening test with respect to the adverse outcome 
(Weiss, 1994). 
A  method  should be established to  distinguish  true  'screening' tests  from  tests 
performed for diagnostic purpose in symptomatic subjects, although it may not be 
easy  to  decide  this  retrospectively.  If smears  taken  because  of symptoms  are 
included, this will lead to an underestimate of the screening benefit, as  cases are 
more likely than controls to have had such tests. Within an organised programme, 
with active invitation, this is not a major problem as only smears performed as  a 
consequence of an invitation may be considered. 
When  this  information  is  not  available  (opportunistic  screening  and  organised 
screening without invitation at a fixed date) some studies have tried to identify and 
exclude smears taken because of symptoms. Gill and Horwitz (1995) suggest that 
this  uncertainty  is  addressed  by  using  'clinical' confidence  intervals  (a  sort  of 
sensitivity analysis), by  varying the criteria for  excluding possible diagnostic or 
follow up tests. Many case-control studies have excluded smears taken within 6 or 
12 months before the date of diagnosis of matched case in an attempt to exclude 
diagnostic tests. This choice causes a bias of its own, as cases cannot have a true 
screening smear for the whole length of the excluded period, whereas controls can. 
If the preclinical invasive detectable phase is longer than the excluded period, then 
the effect of screening will be overestimated (Weiss,  1998). To minimise such a 
bias, some studies included only advanced carcinomas as cases (van der Graaf et 
al.,  1988) or estimated the length of the preclinical invasive phase and excluded 
tests  performed  within  that  interval  (Berrino  et al.,  1986).  Unfortunately  it  is 
difficult to obtain a good estimate of that phase on either an individual or group 
basis. Matching screen detected cases with controls screened at the same date has 
been suggested (Moss, 1991). This is  a good choice if we admit that the interval 
between tests is longer than the preclinical detectable phase. 
101 Another problem arises when timing cancer diagnosis in relation to the availability 
of the screening test. Cases occurring immediately after the start of the programme 
may be useless to evaluate screening effectiveness, as the benefits of screening are 
expected only after several years. This is particularly true if the outcome is death. 
Another problem is  represented by  the  so-called  'healthy  screenee bias' i.e.  the 
potential bias in using the frequency of screening tests as measure of 'exposure' to 
screening. Indeed, a subject receiving multiple screening tests is necessarily disease 
free  at  several  points  in  time,  whereas  cases  had  less  opportunity  to  perform 
screening tests. To avoid such bias it has  been proposed to use as  'exposure' the 
ever/never screened condition during a given time period (i.e. the period in which a 
smear can detect a precancerous lesion). If we are interested in the study of the 
predictive value of a negative test (i.e.  how long the subject is  protected after a 
negative test), we must take into account the relatively low sensitivity of cytology. 
After two negative tests the probability of being a false negative is quite low. In 
fact, we observed a considerably longer protection for subjects with two or more 
negative smears with respect of  those with one smear only (IARC, 1986). 
Comparability of  information and comparability of  populations 
The comparability of information is always a relevant issue in retrospective studies. 
In  particular a  serious  bias  (recall  bias)  can  arise if the  recall  of the screening 
history  is  correlated  with  the  current  status  of the  subject  (case  or control)  -
differential  misclassification.  As  far  as  the screening  history  is  concerned,  this 
problem can be avoided using an  independent archive (or administrative data) of 
screening tests. In this instance, however, the problem remains for the collection of 
confounding variables. If  a complete screening archive is not available, studies on 
the validity of the collected information (by interview, questionnaire, etc.) must be 
undertaken. 
Problems  in  'comparability  of population'  (selection  bias)  may  arise  if non-
attenders are per se at higher or lower risk of developing (and or dying of) CC as 
compared to attenders. 
All the above mentioned methodological problems can be minimised if 
(a)  the  screening  programme  under  evaluation  is  centralised  and  an  active 
invitation at a fixed date is used; 
(b) a cancer registry (or pathological archive ) as well as a complete archive of all 
invitations  (for  matching  cases  and  controls  to  date  of  invitations)  and  all 
preventive  smears  (i.e.  the  tests  performed  as  a  consequence  of  a  screening 
invitation) is available; 
(c) the screening programme has been going on for some time. 
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scrutiny of all design aspects as well as of result interpretation is needed. 
The role of  case-control studies in assessing the emcacy of  cytological 
screening in reducing CC incidence 
Case-control studies (as well as other observational studies) had a crucial role in 
assessing the efficacy of screening as no randomised controlled trial has ever been 
carried out.  In 1986 the conclusions  of the IARC  Working Group  on  Cervical 
Cancer Screening were drawn from the overview of several studies performed in a 
number of countries with widely different approaches. Among them, the results of 
five case-control studies were analysed; two (Macgregor et al.,  1985; Geirsson et 
al.,  1986) carried out within organised programmes in Aberdeen and Iceland and 
three (Clarke and Anderson,  1979;  Berrino et al.,  1986;  Raymond et al.,  1984) 
from areas  where screening was  not centrally organised (in Toronto, Milan and 
Geneva respectively). 
The studies in Iceland and  Aberdeen  were  case-control  studies  nested  within  a 
cohort and were designed to investigate the reduction in risk of invasive CC among 
women with a previous negative smear, in terms of time elapsed since the smear 
was taken (Macgregor et al.,  1985; Geirsson et al.,  1986). In fact in such studies 
cases and controls were both derived from the screening archive and controls must 
have had their first negative smear prior to the date of diagnosis of the case. The 
combined analysis of two studies showed a relative protection (RP) of more than 
ten-fold (RP=11.1, 95% confidence intervals (95% Cl) 2.4-52.2) for women with 
their last negative smear performed 0-11 months before the diagnosis of the case as 
compared to  women  who  had had their last negative  smear ten  years  or more 
before. The RP remained significant if a smear was performed within 71  months 
(RP=2.0 95% CI 1.1-3.7) The number of previous negative smears increased the 
RP by approximately 1.5-fold. No clear effect of age was observed. 
The other three case-control studies were addressed to evaluate the effectiveness of 
cytological screening for invasive CC. Differences existed among these studies in 
the criteria for case and control selection and in the definition of screening history. 
Nevertheless, such differences did not affect the results. The odds ratios (OR) for 
ever vs. never screened tended to be similar in these studies, ranging from 0.26 to 
0.37. Furthermore, the effect was similar to that observed in the other studies when 
time elapsed since the last screening and number of previous tests were analysed. 
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Since the publication of the IARC monograph (Hakama et al., 1986) on Pap smears 
efficacy  in  1986,  several  case-control  studies  have  been  carried  out  within  a 
process of evaluating current screening programmes. In the present review  only 
studies published after 1986 and aimed at evaluating screening effectiveness are 
considered. Three were carried out in North America: Manitoba, Canada (Cohen, 
1993), Maryland, USA (Celentano et al., 1988), and Washington, USA, (Shy et al., 
1989); two in Central America: Panama and Costa Rica (Herrero et al., 1992) and 
Mexico  city,  Mexico  (Hernandez-Avila  et al.,  1998);  four  in  Asia:  Thailand 
(Wangsuphachart et al.,  1987), Jingan, China (Zhang et al.,  1989); Osaka, Japan 
(Sobue et al., 1990), Miyagi, Japan (Sato et al.,  1997); four in Europe: Nijmegen, 
The Netherlands (van der Graaf et al.,1988), Denmark (Olesen,  1988), Florence, 
Italy  (Palli  et al.,  1990),  Aberdeen,  Scotland  (Macgregor et al.,  1994),  United 
Kingdom (Sasieni et al.,  1996). Table  1 summarises the main  characteristics of 
these studies. 
About  half  of  them  were  carried  out  within  organised  programmes  (i.e. 
programmes with an active invitation of women). In all studies CC incidence was 
chosen  as  the  outcome.  Two  studies  also  considered  in  separate  analysis  CC 
mortality.  Most  studies  limited  the  selection  of CC  to  the  squamous  subtype, 
whereas two studies made a separate analysis for squamous- or adenocarcinomas 
(Herrero et al., 1992; Sato et al., 1997). In some studies the histological type of CC 
was not specified. In some studies attention was paid to the stage of CC and/or only 
advanced stages were considered (van der Graaf et al.,  1988; Zhang et al., 1989) or 
separate analysis was carried out for different grades of invasion (Herrero et al., 
1992).  In fact,  we  would  expect  the  strongest  protective  effect  for  advanced 
carcinomas. About half of the studies were designed on a population basis, whereas 
the others were hospital-based. 
In one study (Herrero et al.,  1992) controls were selected partly from population 
census lists and partly from hospital admission lists; in other studies (Zhang et al., 
1989; Sato et al., 1997) cases and controls were selected from screening archives. 
In population-based studies, the source of CC cases was the local cancer registry or 
archives, which were supposed to collect all the cases occurring in a given area. In 
hospital-based  studies  the  source  of  information  on  cases  were  the  hospital 
admission records. 
Table 2 summarises the main results of these studies. The proportion of controls 
'ever screened' give us an overview of the coverage of Pap smear practice in the 
general population (although it must be considered that in  most studies controls 
were matched to cases for several covariates so that the actual coverage cannot be 
directly estimated from such figures). The comparison of the proportion of ever-
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last three years, if not otherwise specified) gives us an idea of how regularly Pap 
smears are performed. In fact, in a situation where all subjects have a Pap smears 
every three years (or more frequently) these values would tend to be similar. It is 
worth noting that these data differ substantially from one study to another. In fact, 
the proportion of ever-screened controls ranges from 20 % in Osaka, and 37% in 
Bangkok to 88%  in  Miyagi  and 93%  in Maryland.  Such a fmding  is  important 
when  evaluating the result  of a case-control  study;  in  fact,  if the  proportion  of 
never screened is  small  (or large)  the  problem of comparability of populations 
becomes less trivial. The observed differences can be partly explained by different 
attitudes in different periods and geographical areas, as well as by different criteria 
in selection of controls or in collecting screening histories. Most studies tried to 
identify and exclude smears taken because of symptoms by means of exclusion of 
smears taken within 6 or 12 months before the index date. In some studies, controls 
were  selected from  subjects  with  a  negative  smear  at  the date  of diagnosis  of 
matched  case  (Macgregor et al.,  1994);  in  another  study  (Sobue  et al.,  1988) 
controls for screen-detected cases  were selected among subjects with a negative 
smear taken the same year of the index date; otherwise controls were subjects with 
no smear during the same year. 
In spite of the above listed differences (eligibility criteria for cases and controls, 
modality of screening history collection, adjustments for confounding variables), 
the results are quite similar (with respect to reduction in risk of invasive CC), ORs 
ranging from 0.27 in the Danish study to 0.43 in the Canadian study. Some studies 
are out of this range, with lower risks in the studies in Miyagi, Japan and Jingan, 
China (0R=0.16) and the higher risk observed in Mexico City (OR=0.76). In the 
latter  study  the  OR  becomes  0.38  (95%  CI=  0.28-0.52)  when  only  smears 
performed without gynaecological symptoms are considered. 
When death from CC is assumed as the end point, the protective effect of screening 
tends to be slightly higher. In fact, in the Scottish experience the OR for mortality 
was 0.25 (95% CI 0.11-0.48) and for incidence 0.35 (95% CI 0.25-0.50), and in the 
Osaka study 0.22 (95% CI 0.03-1.95) and 0.41 (95% CI 0.13-1.29) respectively. Of 
course, a direct comparison with incidence is not possible as these figures refer to 
different groups of women, but nevertheless such results are to be expected if we 
assume a beneficial effect of  early detection of invasive CC. 
The  combined evidence from  these  studies  confirms  the  IARC  working  group 
statement on screening effectiveness in reducing CC incidence and mortality and 
emphasises the strength of the association between exposure to Pap smears  and 
(reduced) risk of developing CC. 
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programmes? 
The  above  mentioned  case-control  studies  are  focused  on  the  epidemiological 
relationship between screening history and invasive CC incidence and/or mortality. 
However, it is worth noting that these studies answered also some other interesting 
questions. The frrst concerns the magnitude of the protective effect of screening 
from  cancer  other  than  squamous  cervical  carcinoma,  i.e.  adenocarcinoma  or 
mixed cancer. The first results (Herrero et al.,  1992,  Sato et al.,  1997)  seem to 
indicate a lower impact (but anyway  an  impact;  OR= 0.5;  95%  CI 0.3-0.8  and 
OR=0.45;  95%  CI  0.1-3.7  respectively)  for  adenocarcinoma  as  compared  to 
squamous cell carcinoma. Also in the Danish study· (Olesen, 1988) a reduction of 
OR was observed when only squamous cell carcinoma patients and their controls 
were  analysed.  When  evaluating  these  results  one  must keep  in  mind  the  low 
statistical power of such analysis, as adenocarcinomas are relatively rare. A recent 
large case-control study carried out in Victoria, Australia (Mitchell et al., 1995) on 
the relationship between negative cervical cytology and risk of adenocarcinoma 
(113 cases and 452 controls) showed a very modest benefit from screening. Again, 
when  evaluating this  result,  one  must  consider that  endocervical  brushes  were 
introduced into routine use in that area only after 1989, and that most cases in the 
study occurred before that date. Further studies are needed, but anyway the fmding 
of a lower protection of cervical cytology for adenocarcinomas may be explained 
by problems in cell sampling and by difficulties in  cytological assessment.  The 
evaluation  of the  screening  history  of such  carcinomas  may  justify  efforts  to 
improve specific screening (sampling) techniques. 
The second issue concerns the role of risk factors (in particular human papilloma 
viruses (HPV) type 16-18) for CC in screening policies. The presence of HPV does 
not modify the protective effect of screening because virtually all cancers are HPV 
positive (Herrero et al.,  1999). Only one of the above mentioned studies (Herrero et 
al.,  1992) has considered the presence of HPV. In that study a smear was obtained 
from  all control  women.  Although details  are  not given in  the paper, no effect 
modification was observed according to the presence of HPV infection. However, a 
different screening policy (with shorter screening intervals for women with HPV 
and  longer intervals  for  HPV  negative  women)  might  be  proposed in  order to 
increase the efficacy of the programme. 
To date the protective effect of a well conducted screening programme is totally 
accepted and  further confirmations  are  of limited interest for the evaluation  of 
specific  screening  programmes.  On  the  other  hand,  serious  methodological 
problems exist with the case-control approach and even if recommended methods 
were  followed,  several  difficulties  arise  in  practice.  Thus  results  obtained  in 
different situations, with different methodological assumptions, may be not easily 
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centralised and most smear taking is opportunistic, this approach may still play an 
important role. It could provide information on the coverage, stratified by different 
covariates.  Furthermore,  if an  unexpectedly  high  OR  were  observed,  it  could 
indicate (as in the study carried out in Mexico City) problems in quality control of 
smear taking,  smear reading or in other phases of the screening process. In  this 
perspective, it is important to obtain a population-based recording of CC cases and 
a cancer registry or a pathological archive must be available. For monitoring and 
evaluating a screening programme the analysis of trends in incidence and mortality 
are  essential.  But,  particularly  in  small  areas,  these  trends  may  be difficult  to 
interpret due to statistical fluctuations of figures. Furthermore, such analysis could 
become quite complicated if we suspect a spontaneous, not screen-related change 
in  baseline risk of CC,  as  suggested by  some recent  studies  (Macgregor et al., 
1994, Cecchini et al.,  1995). 
For  monitoring  a  screening  process  several  issues  must  be  considered.  The 
occurrence of CC (any incident CC should be regarded as a potential failure of the 
programme) could be the consequence of several factors, namely: 
a)  Inadequate coverage of the population 
- non-attendance 
- too long interval since last smear (more than five years might be the 
cut-off?) 
b)  False negative cytology 
- inadequate smear taking 
- inadequate smear processing (fixation and staining) 
- errors in smear interpretation 
c)  Inadequate follow-up of abnormal smears 
- requiring repeat smear 
- requiring colposcopy 
d)  Inadequate colposcopy and/or biopsy 
e)  Inadequate treatment 
To monitor all these aspects, a list of process indicators (with the relative reference 
standards)  has  been  proposed  (Coleman  et  al.,  1993).  The  most  important 
indicators  to  control  for  are  the  coverage  of the  population  and  the  screening 
history  of  CC  cases.  With  respect  to  the  latter,  there  have  been  several 
investigations. In the Florence (Italy) experience (Ciatto et al.,  1993) 42 CC cases 
were considered. No or irregular attendance (negative smear-to-diagnosis interval 
>5 years) was recorded in 25  women (59%); in seven (17%) cases assessment or 
treatment  inadequacy  was  found;  false  negative  smears  by  the  local  screening 
programme  were  recorded  in  four  cases  (10%).  In  the  Swedish  experience 
(Stenkvist and SOderstrom.,  1996), 38 cases reported as CC by the central Cancer 
Registry were examined. Out of them, 11 cases had not been classified correctly as 
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were revised as carcinoma in situ after double blind examination of the specimens. 
After  linkage  with  the  computerised  archive  55%  of patients  with  invasive 
squamous carcinomas had no previous smear, 23% had had only one smear more 
than five years before the diagnosis, and 36% had had no diagnostic work-up after 
an  abnormal  smear.  In  Scotland  (Macgregor  et  al.,  1994),  83%  (234/282)  of 
invasive  cancers  occurred  in  unscreened  or inadequately  screened  women;  an 
inadequate smear interpretation was found in 32 (11 %) slides, and recurrence after 
treatment at  colposcopy  occurred in  eight  women  (3% );  for  nine  women  (3%) 
information was  not available.  In  the Icelandic  study (Sigurdsson,  1995)  among 
120 women aged 25-64 registered at the Cancer Registry with invasive cervical 
cancer during the period 1980-1989, 49% were screen detected, 21% were interval 
cancers (i.e., cancers occurred within three years of a negative tests) and 30% had 
never been screened. For squamous and adeno/adenosquamous carcinomas, these 
percentages  were  54%,  15%,  31%  and  29%,  46%,  25%  respectively.  In  the 
experience of Connecticut  (Janerich  et al.,  1995),  the  screening  history  of 481 
women  with CC  was  ascertained by  means of direct interview to the patient or 
physician. 28.5% of CC occurred among women who had never been screened, and 
another 23.5% occurred among women whose last Pap test was taken more than 
five years before diagnosis, 7%  had a misread negative smear and 9%  were not 
followed properly. These results give us relevant information about the weak points 
of the programmes but do not tell us the weight of each cause of failure in terms of 
preventable fraction. 
An  interesting  monitoring  modality  has  been  established  recently  in  England 
(Sasieni et al.,  1996). The screening histories of all 348  women diagnosed with 
invasive CC (included 89 microinvasive cases - FIGO stage1A) in 24 Districts of 
England, Wales and Scotland in 1992 were examined and compared with those of 
677  age- and  residence-matched  controls.  Cases  were  obtained  from  local 
pathology  laboratories.  Controls  were  randomly  chosen  from  the  computerised 
registry held by the local family  health services authority. Women with previous 
hysterectomy were excluded. The screening histories  were determined, for cases 
and controls, from the same computerised archive. The analysis excluded (in both 
cases and controls) any smear performed 6 months before the case's diagnosis. A 
conditional logistic regression was  made and the population attributable risk was 
calculated using the techniques appropriate to matched case-control -data  (Kuritz 
and  Landis,  1988).  Forty  one  percent  of  invasive  CC  cases  vs.  30%  of 
microinvasive and 24% of controls had never had a Pap smear or had no test within 
five years. As far as the adequacy of follow up is concerned, 13 % of all CC cases 
(17%  among  microinvasive  and  11%  among  invasive)  had  screening  histories 
indicative  of inadequate  follow  up  of smears  requiring  colposcopy.  The  same 
percentage among controls was 1%. Analysis using this method of the adequacy of 
treatment of precancerous lesions is in progress. The interesting aspect of this study 
is  that  it  is  oriented  towards  monitoring  (rather  than  evaluation)  and  several 
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such as  the quality of cytology, the adequacy of follow-up  and treatment.  More 
generally, this kind of approach allows identification of areas of current practice 
for improvement. 
Some problems emerged from this study: the authors do not discuss selection bias 
and,  as  mentioned above,  the choice of excluding  smears  performed  within  six 
months of diagnosis is questionable. Furthermore, the statistical power of the study 
should have  been taken into  account for  the precision of the  estimate,  e.g.,  we 
would  have  expected  quite  a  low  percentage  inadequately  treated  or  followed 
among controls. 
The role of cancer registry in monitoring cervical screening programme 
In order to monitor a screening programme, it is essential to have: 
- a complete registration of all CC cases which occurred in the target 
population; 
- a complete archive of all performed preventive smears and all further 
assessment performed after a positive test in the target population; 
- a valid key for linking the two archives. 
Cancer registries provide a universal registration of all cases occurring in a defined 
area and almost all cases occurring in the target population (if strong migratory 
effect is not present) will be available. The importance of the universality of the 
registration  must  be  stressed  when  monitoring  screening  programmes.  The 
correlation between type of hospital where women are admitted for diagnosis and 
socio-economic  status  is  well  known;  and  the  latter  could  be  correlated  with 
screening  history,  so  that  a  bias  could  occur if only  a  selected  proportion  of 
incident cases is considered. Furthermore, interval cancers (i.e. cancers occurring 
some years after a negative test) or cancers occurring after inadequate colposcopy 
or treatment, may be referred to gynaecological practices different from those for 
cases  managed  by  the  screening  authority.  Such  types  of cancers  are  of key 
importance in  evaluating screening activity,  and any  lack of information  of the 
screening history of such women deprives us of a lot of information on the weak 
points of the programme. A cancer registry collects all cases occurring among the 
residents  of a  given  area.  From  a  public  health  point  of view,  a  screening 
programme should be addressed to all subjects living in that area. As a matter of 
fact,  especially  in  the  great  metropolitan  areas,  an  increasing proportion  of the 
population has no legal residence (students, temporary workers, immigrated people 
and  so  on).  It is  suggested  that  storage  (in  a  separate  file  from  that  used  for 
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area (resident or not) would provide better monitoring of all screened people. 
One  problem  is  common  when  a  cancer  registry  is  used  as  a  database  for 
monitoring screening: cancer registry data should be available within a relatively 
short time after incidence date. Otherwise if, for example, data on interval cancers 
were available only several years after their occurrence, retrieving negative slides 
for slide review might be rather difficult and the consequent corrective action could 
be ineffective. 
Delay in reporting official figures is a problem in some cancer registries. In such a 
situation, the development of processes  whereby the pathology  archives can be 
rapidly  utilised,  to  provide  a  raw  list  of all  incident  CC  cancers  is  strongly 
recommended. The histological subtyping of CC is important, since the protective 
effect of screening differs for squamous or adenocarcinomas, and this information 
should  be  available  from  cancer  registries.  Nevertheless,  misclassification  and 
misinterpretation have been reported (Sigurdson et al.,  1995). 
Finally,  problems  may  occur in  recording  of stage.  In  fact,  microinvasive  CC 
(FIGO  stage  1A)  cannot be considered as  a failure  of the  programme since its 
detection is  often a consequence of a preventive smear and may be regarded as 
early detection, and it is associated with extremely high cure rates. Information on 
histologically  confirmed  cervical  intraepithelial  neoplasia  (CIN)  is  not  directly 
important  in  evaluating  the  effectiveness  of  a  screening  programme.  The 
occurrence of CIN is  highly dependent on features of the screening programme, 
such as referral rates for colposcopy, and the colposcopy directed biopsy rate (CIN 
are asymptomatic lesions), as well as on screening frequency. Nevertheless, their 
collection by cancer registries could be useful if an archive of screening smears is 
also available. In fact, the detection rates of CIN2 or more severe lesions in women 
at their first smear give us an estimate of the baseline risk of the disease and allow 
a better analysis of trends in CC incidence and mortality. 
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 Chapter 8.  Cohort studies in evaluation of cervix cancer screening 
E. Lynge 
Introduction 
In  1941,  Papanicolaou  and  Traut  (Papanicolaou  and  Traut,  1941)  presented  a 
"simple, inexpensive method of diagnosis  ... which could be applied to a large 
number of women in the cancer-bearing period of life". The authors clearly stated 
that they were "not yet in a position to offer a statistical proof of the reliability of 
this method of diagnosis, but we can say that in our experience it yields a high 
percentage of correct diagnoses when checked by tissue biopsies. There is evidence 
that a positive diagnosis may also be obtained in some cases of early disease". 
If the Pap  smear worked for  early  detection  of invasive disease,  a decrease  in 
cervical cancer mortality was to be expected in screened populations. If the Pap 
smear  worked  also  for  detection  of preinvasive  lesions,  a  decrease  was  to  be 
expected  in  cervical  cancer  incidence  (Lynge,  in  press).  However,  the 
understanding of the need for randomised controlled trials of medical procedures 
was new (Chalmers, 1998), and no one waited for the statistical proof, as the Pap 
smear was adopted widely throughout the world in the post war decades. 
Only observational data have therefore been used for evaluating the outcome of the 
widespread cervical cancer screening. Evaluations have been based on  both time 
trends,  geographical  comparisons,  cohort  studies,  and  case-control  studies.  The 
purpose of  the present chapter is to give an overview of the cohort studies. 
Cohort study data requirements 
In most historical cohort studies, the observed number of deaths or incident cancer 
cases in the exposed cohort has been compared with the number expected, given 
that the exposed cohort had experienced the same mortality or incidence as  the 
national population, i.e., standardised mortality or incidence ratios (SMR or SIR, 
respectively) have been calculated. This comparison is of course a valid estimation 
of the risk associated with the exposure only if the cohort members are similar to 
the national population, apart from the exposure considered. 
119 In cohort studies for evaluation of cervical cancer screening, the exposure has been 
defmed  as  either  invitation  to  screening  or as  participation  in  screening.  Both 
approaches have their advantages and disadvantages. Invited women will normally 
be a representative sample of the national population, the observed cervical cancer 
incidence or mortality among the invited women will, however, reflect both their 
background  risk,  the  effect  of  the  screening,  and  their  participation  rate. 
Participating women will on the other hand be a biased sample, but the observed 
cervical cancer incidence or mortality among these women will reflect only their 
background risk and the effect of the screening. The appropriate study design will 
depend on the questions addressed in the cohort study. 
Both types of cohort studies of cervical cancer screening require that the individual 
screening histories are known and can be linked to the individual follow-up  for 
incident  cases  of invasive  cervical  cancer  and/or  deaths  from  cervical  cancer. 
Cohort studies can thus be undertaken only when: 
- all Pap smears and biopsies are registered by date and personal identification for 
all women for a well defmed cohort in a given time period; 
- all women in the cohort can be followed up for deaths, emigrations, cause of 
death and/or incident cases of invasive cervical cancer; 
- the two sets of data can be linked at the individual level. 
In  most circumstances, the use of Pap  smears  started  spontaneously  within  the 
clinical setting and not as  organised screening programmes.  Pap smears from  a 
given  area  were  often  read  in  many  different  private  laboratories  with  no 
requirement  for  systematic  and  long-term  record  keeping.  The  follow-up  for 
occurrence  of invasive  cervical cancer requires  the  presence  of comprehensive 
cancer registration or other case ascertainment systems. The linkage of screening 
history data with follow-up data requires use of personal identification numbers or 
other unique personal identification. With this background, it is not surprising that 
the effect of cervical cancer screening has been evaluated in relatively few cohort 
studies. 
Included here are only the long-term cohort studies originally set up for evaluating 
the effect of screening on the cervical cancer incidence or mortality. Not included 
are short-term follow up studies aimed at evaluating, e.g. progression of cervical 
dysplasia  (Richart  and  Barron,  1969)  or importance  of endocervical  cells  in  a 
smear (Mitchell and Medley, 1991). 
120 Cohort studies 
British Columbia, Canada 
The British Columbia cervical cancer screening project started in  1949. In  1959, 
about  8%  of women  above  the  age  of 20  were  screened  annually,  and  this 
proportion increased to 44%  in  1971. Two cohort studies  have been undertaken 
here. First, based on the population data and the individual screening records from 
1958  to  1966,  women  in  British  Columbia  were  divided  into  those  previously 
screened or not. In 1965, 13 clinical invasive carcinomas were detected among the 
screened women where 81.2 cases were expected based on the incidence rates from 
1955-1957 (SIR 0.16). For the unscreened women the numbers were 67  and 62.1 
respectively  (SIR  1.08).  The  effectiveness  of the  programme  could  thus  be 
estimated for the total population:  80 observed vs.  143.4 expected (SIR 0.56). It 
should be noted, however, that preclinical invasive cases were not included among 
the observed cases (Fidler et al., 1968). 
Second, two cohorts of women born 1914-1918 and 1929-1933 were formed. The 
size of the cohorts over time was estimated from the population data. Data on Pap 
smears used by the cohort members during the period  1949-1969 were extracted 
from the British Columbia Central Cytology Laboratory. The original publication 
from this study reported the results for detected cases of "carcinoma in  situ and 
worse", complicating comparison with other data sources (Boyes et al., 1982). 
Ostfold, Norway 
Organised screening was offered in Ostfold County, Norway, from the first round 
in  1959-1965 to the fifth  and last round in  1974-1977. A cohort study has been 
undertaken of all 45 960 women invited to the first screening in the age-group 25-
59  years  and  not  previously  diagnosed  with  cervical  cancer.  The  cohort  was 
followed  up  to the end of 1982, and the observed incidence and mortality  were 
compared with that of women in five neighbouring counties not offered organised 
screening. During the period 1959-1982, 267 new cases of invasive cervical cancer 
were observed in the cohort, where 341.5 cases were expected, SIR 0.78, and 103 
deaths from cervical cancer were observed where  124 were expected, SMR 0.83 
(Magnus et al.,  1987). 
121 Finland 
In  Finland, an  organised screening programme started in  1963  and it gradually 
developed to become nation-wide.  Pap  smears  were offered every fifth  year to 
women aged 30 to 55.  In  1971, 414  164 women had been offered at least two 
rounds of the programme, and the incidence of cervical cancer was followed in this 
cohort to the end of 1972. In the age group 30-59, the probability of contracting 
microinvasive carcinoma after the frrst Pap smear was 0.002 and the probability for 
frankly invasive carcinoma was 0.002, compared with a probability of 0.010 for 
invasive cervical cancer in Finnish women before the screening, and with 0.016 
among women who did not attend the screening. The participation rate in Finland 
was  85%,  and  the effectiveness  of the  programme  was  thus  SIR 0.42,  if only 
frankly  invasive carcinomas are considered, and SIR 0.58 if both microinvasive 
and frankly invasive carcinomas are considered (Hakama and Rasanen-Virtanen, 
1976). 
Manitoba, Canada 
A  province-wide  cervical  cytology  screening  programme  with  a  registry  was 
initiated in Manitoba in 1963, and the registry was used to estimate the percentage 
of women  in  the province who had been screened during the years  1963-1972. 
Cases of cervical cancer were known from the Manitoba Cancer Registry (Choi 
and  Nelson,  1986).  The  data  were  included  in  the  study  performed  by  the 
International Agency for Research on Cancer (IARC study), see below. 
Sweden 
From 1964, several counties in Sweden gradually introduced organised screening 
for women aged 30-49 every fourth year. By 1973, the programme covered all of 
Sweden,  except  the  municipality  of Gothenburg.  All  smears  taken  inside  the 
organised programme were reported to the National Board of Health and Welfare, 
where 930 127  women were registered with at least one smear taken during the 
period 1967-1975. This cohort was followed up for incidence of invasive cervical 
cancer to the end of 1980 (Pettersson et al., 1986). The data have been included in 
the IARC study, see below. 
In a later series of studies incorporated into the doctoral thesis of Sparen (Sparen, 
1996), an open cohort of 118 890 women in the county of Uppsala was followed up 
from 1969 to 1988 for in situ cancer of the cervix. The authors reported that the 
difference  in  efficiency  between  organised  and  opportunistic  screening  in  the 
detection of cancer in situ was slight, if any, based on the comparison of detection 
rates. Their conclusion was that the dogma that organised screening is significantly 
122 more efficient than the opportunistic type needs reconsideration (Gustafsson et al., 
1995a). It should be noted that 75%  to 80%  of all  Pap smears taken during the 
study period were opportunistic, i.e. taken outside the organised programme. Their 
results have been challenged by other researchers (e.g. Nieminen et al., 1999) 
They further reported a low efficiency of cytological screening for cancer in situ of 
the cervix in older women based on decreasing detection ratio by age in the same 
cohort (Gustafsson et al.,  1995b). They also combined the women resident in the 
Uppsala and Gavleborg counties into a cohort of 386 990 women. This cohort was 
followed  up  for  invasive  squamous  cell  cancer  of the  cervix.  The  women's 
screening history was ascertained in computerised registers of Pap smears taken in 
the  area and record-linkages enabled complete follow-up  with  regard  to  cancer 
incidence, out-migration and survival from 1968 to 1992. They compared the age-
specific incidence of squamous cell cancer in ever vs. never-screened women and 
found a relative risk (RR) of 0.55 with 95% confidence interval of 0.51-0.61. The 
age-specific relative risks followed a U-shaped curve with lowest risks among the 
screened  women  in the  age  group  of 40 to  59  years  (RRs  from  0.27  to 0.38) 
(Sparen, 1996). 
Iceland 
Cervical cancer screening started in Iceland in 1964 and was extended to the entire 
country in 1969. Women aged 25-59 were invited every 2-3 years, later extended 
to women aged 25-70. In 1974, close to 90% of women aged 30-49 had had at least 
one Pap smear. In all Icelandic women  aged 25-59,  the mortality from cervical 
cancer changed from 20 per 100 000 in  1955-1959,  to  21  in  1960-1964,  32 in 
1965-1969, and 15 in 1970-1974. The rates in never screened women were 30 in 
1965-1969 and 23  in  1970-1974 (Johannesson et al.,  1978). In a later study, the 
mortality was reported to have fallen by 60% between 1959-1970 and 1975-1978, 
with a corresponding fall in the incidence of advanced tumours. The mortality rates 
among the unscreened population were more than ten-fold greater than among the 
screened.  The  greater  part  of the  fall  in  mortality  was  attributed  to  the  mass 
screening programme (Johannesson et al.,  1982). 
Maribo, Denmark 
An  organised  screening  programme  started  for  women  aged  30-49  in  Maribo 
County, Denmark, in 1967. The 16 187 women invited to the first round in 1967-
1970 have been followed up for  incident cases of cervical cancer to the end of 
1984, and the observed numbers have been compared with the expected number 
based on  rates  for  all  Danish  women.  In the  87%  of the  invited  women  who 
participated, 115 cervical cancer cases were observed compared with 217 expected 
(SMR 0.53), whereas the numbers were 63 and 35.96 (SMR 1.75) among the 13% 
123 of women  who  did  not  participate  (Berget,  1979;  Mellemgaard  et  al.,  1990; 
Mellemgaard et al., unpublished data,  1990). The effectiveness of the programme 
estimated by the  SIR for  the total population  was  0.70 (178/253).  It should be 
remembered  that  the  comparison  group  was  the  total  population  of Denmark, 
where  there  was  extensive  spontaneous  screening  and  some  other  organised 
programmes as  well. The Maribo cohort was later extended to include all women 
screened in the area 1967-1982, see IARC study below. 
Use of cohort data 
Although several of the cohort studies were originally established to evaluate the 
effect of the Pap smear screening on the cervical cancer incidence and mortality, 
the best known evidence for this effect in the end came not from the cohort studies, 
but from the  analyses of time trends in cervical cancer incidence and mortality 
(Christopherson et al., 1970; Miller et al., 1976; Hakama, 1982; Laara et al., 1987). 
The reasons for the limited impact of the cohort studies in assessing the effect of 
screening were probably the often small numbers of cases in the cohort studies, the 
selection bias implied in the comparison of rates for participants with rates in the 
total  population  not  offered  screening,  and  the  complicated  ways  in  which  the 
cohort data were often presented. 
The importance of the cohort studies therefore comes mainly from the secondary 
use of the data in the study of the natural history of cervical cancer. It is desirable 
to know the regression, persistence and progression of preinvasive lesions in order 
to optimise the screening for these lesions.  As  observation without treatment of 
preinvasive lesions has been considered unethical for many years, such data on the 
natural history of cervical cancer are available only for small groups of women 
(Ostor, 1993). Modelling studies of the cohort data have been used therefore to fill 
this information gap. These studies were the International Agency for Research on 
Cancer study on risk of cervical cancer following a negative Pap smear, and the 
'MISCAN' modelling studies on transition probabilities. 
International Agency for Research on Cancer, IARC, study 
In the 1980's, the data on time trends indicated a beneficial effect of screening for 
cervical  cancer.  Few  data  were  available,  however,  on  the  effect  of different 
screening  schedules,  the  key  question  being  whether  screening  was  needed 
annually  or  whether  a  similar  protection  could  be  obtained  with  less  frequent 
screens  (Editorial,  1981).  The  IARC  study  was  established  to  evaluate  the 
incidence of invasive cervical cancer by number of previous negative smears and 
124 time elapsed since last negative smear, Figure 1 (Day, 1986; IARC Working Group 
on Cervical Cancer Screening, 1986a). 
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Figure 1.  Anticipated incidence of invasive cervical cancer following  one or more 
negative smears, by time since last negative smear, assuming sensitivity <100%  (from 
Walter and Day, 1983) 
Data were collected from ten areas with  well established screening programmes 
(IARC Working Group on Evaluation of Cervical Cancer Screening Programmes, 
1986b  ). The data collection was organised either as case-control or cohort studies. 
The cohort studies being the above listed from British Columbia (van Oortmarssen 
and Habbema, 1986), Manitoba (Choi and Nelson, 1986), Sweden (Petterson et al., 
1986),  Ostfold,  Norway  (Magnus  and  Langmark,  1986)  and  Maribo,  Denmark 
(Lynge and Poll, 1986a; Lynge and Poll, 1986b). The cohort studies estimated the 
incidence of cervical cancer in women with negative smears by time since the last 
negative smear and by number of negative smears. Comparison was made with the 
incidence expected given that no screening had taken place. While the observed 
incidence could be  calculated accurately from the  screening and the population 
data,  the  expected  incidence  given  no  screening  was  estimated  based  on  the 
incidence in the area prior to implementation of the screening programme. 
The IARC study showed that the cumulative rate of invasive cervical cancer in 
women  aged  35-64 could be reduced  by  93.5%  with  screening every  year,  by 
92.5% with screening every second year, and by 90.8% with screening every third 
year, see Table 1. 
125 Table 1.  Per cent reduction in cumulative rate of invasive cervical cancer in women 
aged 35-64 with different frequencies of screening (IARC Working Group on Evaluation 
of  Cervical Cancer Screening Programmes, 1986b) 
Interval between 
screening 
(years) 
1 
2 
3 
5 
10 
Per cent reduction in 
cumulative incidence 
93.5% 
92.5% 
90.8% 
83.6% 
64.1% 
Number of  tests 
30 
15 
10 
6 
3 
Assuming that a woman is screened at age 35 and that she had at least one negative screen 
previously. 
These results could not directly be applied to any public health policy as they were 
based on the conditions, that 
1)  the background incidence used in the analysis was a valid reflection of what 
the incidence would have been given no screening; 
2)  a 100% participation rate in the screening programme; 
3)  all detected non-negative smears were appropriately followed up; 
4)  the women entering the programme were essentially disease free, having had 
one or more previous negative tests. 
However, the data provided a useful guide, as they indicate that almost the same 
protective effect could be achieved with three  year screening intervals  as  with 
annual screening. The IARC study has formed the basis in many countries for the 
recommendation of  three or five year screening intervals. 
126 Transition probability from preinvasive to invasive disease 
The  'MISCAN'  simulation model  of cancer screening has  used the cohort data 
from British Columbia (van Oortmarssen and Habbema, 1991; van Oortmarssen et 
al., 1992; van Oortmarssen and Habbema, 1995) and from Maribo, Denmark (Bos 
et al.,  1997)  as  the  basis  for  estimation  of the  proportion  of non-progressing 
cervical intraepithelial neoplasias and estimation of the duration of the preclinical 
phase in progressive lesions. Data on these parameters are needed in order to avoid 
overtreatment  of  cervical  intraepithelial  neoplasias  detected  in  screening 
programmes. 
Of the women screened in  Maribo County,  1.5%  had a positive smear,  and one 
third of these women had a negative diagnosis at follow-up, whereas two thirds had 
a histologically confirmed cervical intraepithelial neoplasia.  The analysis  of the 
Maribo  data  showed  that  at  least  half  of  the  confirmed  cases  of  cervical 
intraepithelial  neoplasia  would  not  have  progressed  into  clinical  cancer  in  the 
women's lifetime. 
The modelling of the cohort data has  indicated that screening with  a short time 
interval and with a high proportion of smears classified as non-negative will imply 
treatment of many preclinical lesions which, if undetected and untreated, would not 
have progressed to invasive disease. 
Conclusion 
Collection of cohort data for evaluation of cervical cancer screening requires that 
high  quality  register  data  are  available  on  the  screening  history,  the  incident 
cancers  and  the  deaths.  Relatively  few  cohort  studies  have  therefore  been 
undertaken. The cohort studies were not decisive in establishing the effect of Pap 
smear screening on cervical cancer incidence and mortality, as the time trend data 
from national populations were less biased and easier to understand. Data from the 
cohort studies have, however, later formed an  important basis for evaluating the 
optimal interval in cervical cancer screening and for studying the natural history of 
cervical cancer. 
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131 Chapter 9.  Cancer registries in evaluation of  breast cancer 
screening programmes 
S.H. Wait 
Introduction 
Over the past 30 years, the effectiveness of mammography as a screening tool for 
breast cancer has been established through over 11  randomised clinical trials and 
case-control studies (Wald et al.,  1994). In these studies, screening mammography 
allowed for a reduction of up to 30% in breast cancer mortality in women aged 50-
65  or 50-69  years.  Screening programmes  have  been  set up  in Europe,  North 
America and parts of Asia with the objective of reproducing this breast cancer 
mortality reduction in their target populations. 
The  ultimate  measure  of  the  effectiveness  of  screening  programmes  is  the 
reduction  in  breast  cancer  mortality;  however  this  benefit  may  only  become 
apparent some 7-10 years after the introduction of screening (Day et al.,  1989). 
This  time  period is  incompatible  with  the  needs  of public  policy  makers  and 
screening units  alike,  who  require early,  reliable  measures for  the  purposes  of 
programme evaluation. Thus intermediary indicators have been developed to help 
assess  the  quality  of mammography  as  a  screening  test  and  the  efficacy  and 
potential impact of screening programmes on breast cancer mortality (Day et al., 
1989). Many of these measures rely on the existence of a cancer registry which 
systematically records all cancer cases in the population targeted by screening. 
The purpose of this  chapter is  to describe the role  of cancer registries  in  the 
evaluation  of  existing  breast  cancer  screening  programmes.  This  paper  frrst 
highlights some general issues related to data linkage between cancer registries, 
screening  databases  and  other  potential  sources  of data  for  the  purposes  of 
programme evaluation.  Secondly,  measures that require  a  cancer registry  to be 
assessed  are  described in  terms  of how  they  are  derived  and  what  they  may 
potentially contribute to the assessment of screening. 
It should be noted that this chapter is meant as a  general overview of potential 
measures for the evaluation of breast screening programmes within the specific 
context of cancer registries. Thus it offers only limited critical comment on the 
comparative  value  of  each  measure  in  evaluating  screening  programmes. 
Moreover, target rates for these measures, and the comparative success of different 
screening programmes in achieving them, are not discussed. For further guidance 
133 on  this  topic,  readers  are  recommended to consult the  Europe  Against  Cancer 
epidemiological guidelines (Broeders et al.,  1996). 
Data linkage in the evaluation of breast cancer screening programmes 
The evaluation of breast cancer screening programmes requires the combination of 
data from various sources and thus raises important issues of data linkage. Aspects 
of screening which need to be evaluated on a routine basis include: adherence to 
screening by the target population (compliance rate); the quality of screening as a 
preventive measure; the efficacy of screening and its impact on the epidemiology 
of breast cancer. Measures that may be used to evaluate each of these facets  of 
screening programmes are listed in Table 1.  Quality of screening should include 
quality of diagnostic procedures used in the assessment of screen-positive cases, 
and is measured in terms of false positive rates, sensitivity and specificity. Efficacy 
parameters allow determination of how effective screening is at fmding cancers 
and detecting them early. Measures of the impact of screening allow assessment of 
the potential effect of screening on reducing breast cancer mortality, and require 
the positioning of screening results within the overall epidemiological picture for 
breast cancer in the target population. 
As is described in Table 1, cancer registry data are needed in order to evaluate the 
impact of screening on the entire target population. Screening programmes must 
have a comprehensive dataset of all persons targeted by the screening programme, 
as  well  as  comprehensive follow-up  information on the outcome of the persons 
screened, and analysis  of these data may  allow determination of the quality  of 
screening itself. However, the limitation of this perspective is that it provides no 
indication of the overall impact of screening on the epidemiology of breast cancer 
in  the  target  population  and  restricting  the  evaluation  of screening  to  screen-
detected cancers may overestimate the actual effectiveness of screening. 
Cancer registries and screening programme databases are usually run completely 
independently, so that linkage may only be possible if a unique identifier is used. 
Moreover, data from the screening units may or may not be contained in a single 
database.  The easiest  and  most reliable  identifier for  record  linkage  remains  a 
unique national identifier (e.g., social security numbers). However, some countries 
prohibit  its  usage  in  cancer registries  or screening  databases  due  to  issues  of 
confidentiality and data anonymity. If a unique identifier cannot be used, linkage 
requires computer matching of files from the screening database by last name, first 
name, and date of birth with cancer cases recorded in the cancer registry. In some 
studies,  postal  code  is  used  as  an  additional  identifier  (van  Dijck et  al.,  this 
volume).  Manual checking of positive matches between the two data sources is 
necessary, to rule out any double occurrences, check for multiple cancer diagnoses 
per individual, and ascertain correct diagnosis dates. Some authors have advocated 
134 Table  1.  Early  indicators  that  may  be  used  in  the  evaluation  of breast  cancer 
screening programmes (Adapted from Schaffer et al.,  1996, Rev Epidem et Sante Publ, 
©Masson Editeur) 
Measure  Screening  Cancer 
database
1  registry 
Impact of screening 
attendance rate
2  ../ 
Quality of screening process 
recall rate  ../ 
false positive rate at screening  ../ 
screening sensitivity
3  ../  ../ 
screening specificity  ../  ../ 
biopsy rate  ../ 
positive predictive value of  biopsy  ../ 
cancer detection rate  ../ 
Screening efficacy 
screening prevalence/expected incidence ratio  ../  ../ 
proportion of  in situ cancers4  ../ 
proportion of invasive cancers <10 mm4  ../ 
proportion of  invasive cancers >20 mm4  ../ 
proportion of  cancers with positive nodal status  ../ 
(N+)4 
proportion of advanced cancers (Stage II or 
more)4 
../ 
Impact of screening on cancer epidemiology 
interval cancer rate  ../  ../ 
absolute rate of  advanced cancer detection  ../  ../ 
absolute rate of small cancer detection  ../  ../ 
evolution of  prognostic factors in target population  ../ 
over time 
1  For the measurement of certain indicators, additional data linkage with population 
registers, census population lists or other data sources may be required. 
2  In programmes where women may also have access to  screening outside of the 
organised programme, rates of individual or spontaneous screening should  also be 
assessed. 
3  This indicator may also be used as a measure of the impact of screening on cancer 
epidemiology, namely in terms of the rates of interval cancers. 
4  Although the optimal description of these  counts is  as  cases per  1000  women 
screened, it is customary to also present these data as a percentage of the total number 
of  cancers detected by screening. 
135 doing this by  manually checking the validity of women's address details in the 
source files used (McCann et al., 1998, Woodman et al., 1995). 
Screening programmes may  also require access to other sources of data such as 
target population  lists  derived  from  local  health  authorities,  mayor's offices  or 
other population census bureaux. In the UK national programme for example, the 
names of addresses of women within target age groups for screening are obtained 
from local family health service authority listings. In  France, local sickness fund 
lists  are  used  (Wait  and  Allemand,  1996).  Problems  reported  with  such  data 
sources are frequent and include the finding of "ghosts" (persons who no longer 
live at the indicated address) (Chamberlain et al.,  1993) or of missing women from 
invitation  lists.  All  efforts  should  be  made  to  correct  for  inaccuracies  in  the 
invitation  lists,  as  these  translate  into  under- or  over-estimation  of the  target 
population for screening. Although these calculations do not directly rely on cancer 
registry data, the rates obtained (screening uptake rate, cancer detection rate,) are 
important measures of the impact of the screening programme and understanding 
of all other screening parameters hinges on their accuracy. 
Counting cancer cases 
Cancer registries typically  measure rates  in terms  of the number of cancers,  as 
opposed to the number of individuals affected. If  one is linking cancer registry data 
to screening attendee data, one may argue that the denominator should reflect the 
number  of women  with  breast  cancer,  as  opposed  to  the  number  of cancers 
detected.  Thus  women  who  present  with  more than  one  cancer should  only  be 
counted once.  Conventionally,  one would then  record data reflecting the cancer 
with the worst diagnosis or stage (Schouten et al.,  1998) or detected using the most 
invasive  diagnostic  technique.  This  convention  is  especially  relevant  when 
measuring the impact of screening on stage or size distribution. 
Measures dependent on cancer registry data 
As  was  presented in Table  1,  a subset of evaluation measures requires a cancer 
registry for calculation. Table 2 briefly describes the significance of these measures 
to the evaluation of a screening programme's overall quality and effectiveness. The 
remaining part of this paper will describe each of these indicators in more detail. 
Prevalence/incidence ratio of  screen-detected cancers 
One of the most important contributions of cancer registries to the evaluation of 
screening  programmes  is  to  show  the  evolution  of  breast  cancer  incidence 
following the introduction of screening.  The underlying premise of screening is 
136 Table 2.  Description and significance of selected effectiveness  measures  requiring 
cancer registries in breast cancer screening programmes 
Measure  Dermition  Significance 
Screening  Ratio of number of screen- Measures the number of  cancers 
prevalence/expected  detected cancers at 1st  detected by screening which (in the 
incidence ratio  round to the expected  absence of  overdiagnosis) should 
incidence in the absence  have been detected clinically at 
of screening  some later point in time. 
Interval cancer rate  Number of  cancers  Measures ability of screening to 
appearing in between two  advance the diagnosis of  cancer as 
screening rounds in  well as screening sensitivity. 
women who screened  Interval cancer rates are inversely 
negative at the previous  proportional to the expected 
screening round (as % of  reduction in breast cancer 
expected incidence)  mortality. 
Absolute rate of  Percent change in  Evidence of ability of screening to 
small cancer  proportion of small  advance the diagnosis of  cancer to 
detection  cancers (=:;10 mm)  an earlier stage. May indicate 
detected as compared to  overdiagnosis due to screening. 
before the onset of 
screening 
Absolute rate of  Percent change in  Early predictor of  the impact of 
advanced cancer  proportion of advanced  screening on breast cancer 
detection  cancers (Stages II-IV) as  mortality. The assumption is that a 
compared to before the  decrease in the rate of advanced 
onset of screening  cancers will allow for a reduction 
in breast cancer morbidity and 
mortality. 
Evolution of  Evolution of  tumour size,  The more favourable the 
prognostic factors in  nodal involvement, stage,  distribution of  prognostic factors in 
target population  and presence of metastases  screen-detected cancers with 
over time  in the screened and  respect to clinically detected 
unscreened population  cancers, the larger the potential 
over time.  impact of  the programme. 
137 that it allows for the detection of more cancers at an earlier stage, thus causing an 
apparent  increase  in  cancer  incidence  at  the  "prevalent"  or  initial  rounds  of 
screening. Day (1989) devised a helpful formula to demonstrate the link between 
prevalence  at  1st  round  of  screening,  expected  incidence  in  the  absence  of 
screening, screening sensitivity and sojourn time of cancers, that is the preclinical 
time period during which  a cancer is  detectable by  screening The formula is  as 
follows: 
prevalence at 1st screen/expected incidence rate= 
screening sensitivity x sojourn time 
The above formula highlights the relationship between the quality of screening, its 
effectiveness and the natural history of breast cancer. This relationship is  further 
illustrated in  the  following  diagram  (Figure  1  ).  The efficacy  of mammography 
hinges on  its ability to detect cancers during their preclinical phase, thus before 
they would have been detected clinically. Hence one uses the rate of small cancers 
(~10  mm)  as  an important efficacy measure for breast cancer screening, although 
one must be conscious of the fact that high rates may reflect overdiagnosis through 
screening and overestimate the actual efficacy of the screening process. 
First 
cancer 
cell  I 
! 
I 
Non-detectable  1 
preclinical phase I 
Detectable preclinical phase, 
i.e., sojourn time 
Clinical 
diagnosis 
Clinical 
phase 
Figure 1.  Early detection of breast cancer through screening (adapted from de Koning 
1993) 
138 Interval cancers 
Significance of  interval cancers 
Interval  cancers  may  be  defined  as  cancers  that  present  symptomatically  in 
between  two  screening  rounds  in  women  who  were  screened  negative  at  the 
previous screening mammogram. Interval cancer rates are an important indicator of 
the  quality  of mammography,  as  well  as  of the  potential  impact  of screening 
programmes  on  breast cancer mortality.  Based on  the  promising  results  of the 
Swedish  Two-County  trial  (Tabar  et  al.,  1987),  Day  and  colleagues  (1995) 
established  a  formula  for  estimating  the  expected  reduction  in  breast  cancer 
mortality from interval cancer rates. When they applied this formula to their data 
from East Anglia, they found paradoxical results, namely that their programme met 
targets  for  cancer  detection,  yet  reported  unexpectedly  high  rates  of interval 
cancers. These results were also reported in the analysis of interval cancer rates in 
the Northwest region screening programme (Woodman et al.,  1995). The authors 
attributed the high interval cancer rates, especially those in the 24-36 month period 
after screening, to the long interval between screens and to the single reading of 
screening mammograms. These results have sparked the debate over the need to 
shorten the screening interval from 36 months to 24 months in the UK (Field et al., 
1995) and in France (S.  Wait, personal communication). They suggested that the 
much lower interval cancer rates observed in the Swedish trial was partly explained 
by the fact that interval cancers were calculated based on an interval period of 33 
months on average, as opposed to 36 months in the UK. However, this explanation 
does  not  shed  any  light  on  differences  observed  in  the  periods  0-11  or  12-23 
months  after  screening.  Moreover,  analysis  from  the  Limburg  and  Nijmegen 
programmes in the Netherlands, both based on a 2-year screening interval and with 
systematic double reading of all mammograms, demonstrated similarly high rates 
of interval cancers to the UK programme 12-24 months post-screening (Schouten 
et al.,  1998). A special working group on interval cancers has been set up  in the 
UK to explore means of reducing interval cancer rates and to reassess targets set 
for  existing  screening  programmes  (Moss  and  Blanks,  1998).  Further research 
needs to be conducted to determine the optimal balance between interval cancers, 
screening interval and resource levels  (e.g.,  double reading)  required to achieve 
screening targets. 
Data linkage with interval cancers 
The ascertainment of interval cancer cases  may  be done  using  various  sources, 
namely  population  registers,  cancer  registries,  pathological  registries,  clinical 
records, and death certificates. The most recommended source remains the cancer 
registry, as this avoids both the reporting bias problematic in clinical records, and 
139 allows for more completion than death certificates, which vary significantly from 
one country to another. In districts in which no cancer registry exists, a pathology 
registry  may  provide  an  acceptable  alternative,  although  its  completeness  will 
depend on the compliance of pathology laboratories, the quality and uniformity of 
their data recording and diagnostic patterns in the region. 
There is an inevitable lag in the recording of cancer cases in registries, which poses 
some  challenges  to  assessing  specific  interval  cancer  rates  and  may  lead  to 
underestimating  of the  most  recent  year.  Several  programmes  have  tried  to 
overcome this lag by instituting a system of "fast tracking" breast cancers in their 
districts (McCann et al.,  1998, Woodman et al.,  1995). Nonetheless, some interval 
cancer cases may be absent from the registry either because they are too recent to 
be registered or they occur in women who may have moved away from the area or 
are treated outside of the district. Record linkage between screening unit databases 
and registries may be complemented by specific searches at the level of screening 
units for interval cancers missed by the cancer registry. McCann et al. (1998) as 
well as Woodman et al. (1995), who retrieved some data directly from screening 
units before the cases had been recorded in the registry,  took this  approach.  In 
screening programmes which have both a cancer registry and a pathology register, 
cross-verification  of these  two  sources  of data  may  also  allow  for  increased 
completeness of recording of interval cancers. Schouten et al.  (1998) chose to limit 
their  dataset  to  those  cancers  recorded  in  the  registry,  running  the  risk  of 
underestimating interval cancer rates in the latter year of their analysis. However, 
they  argue  that  using  data  from  one  source  for  evaluation  provides  better 
comparability of data,  namely  in  terms  of the  way  staging  or other prognostic 
information is recorded. 
Presentation of  interval cancer data 
Interval cancers  may  be presented using a range  of indicators  (Table 3).  When 
looking at interval cancers per 1000 women screened, it is conventional to present 
data  by  screening  round  and  to  separate  the  initial  (prevalent)  round  from 
subsequent  (incident)  rounds  of  screening.  Interval  cancer  rates  should  also 
distinguish  between  in  situ  cancers  and  invasive  cancers.  In  the  UK,  it  is 
specifically  recommended  to  limit  the  analysis  of cancer  detection  rates  and 
interval  cancer  rates  to  invasive  cases  only,  as  only  these  would  have  been 
considered in  the  estimate  of underlying  incidence  (Chamberlain  et al.,  1993). 
Moreover, the age used for describing interval cancers should always be the age at 
the time of screening. 
140 Table 3.  Presentation of interval cancers 
Measure  Significance 
Interval cancers per 1000 women screened.  May be compared to screening detection 
rate to measure share of  interval with 
respect to screen-detected cancers. 
Interval cancers per 1000 women screened  Allows for comparison of  interval cancer 
at 0-11, 12-23 and 24-36 months post- occurrence within 1, 2 or 3 years after 
screening.  screening. Provide an indication of sojourn 
time of  cancers and the potential need to 
shorten or lengthen screening interval. 
Proportionate incidence of interval  Allows for comparison of interval cancer 
cancers, i.e. total number of interval  rates across different programmes. 
cancers divided by the total expected 
incidence during that period. 
Schouten et al. (1998) recommend the age standardisation of the target population 
used  as  the  denominator  in  the  detection  rates.  No  age  standardisation  was 
performed  by  any  of the  UK programme  authors  in  the  presentation  of their 
interval cancer data.  Adjustments for migration or death to the total number of 
women screened as a denominator were also not done by McCann et al.  (1998) or 
by other authors. 
Calculation of  the underlying incidence of  breast cancer 
The proportionate incidence rates for interval cancer allows comparison of interval 
cancer data across different programmes, regardless of detection rates or the size of 
the target population. To obtain this  rate,  one needs to ascertain the underlying 
incidence of breast cancer,  that is  the incidence  of invasive breast cancer that 
would have been observed in the absence of screening. Calculation of this rate is 
simple in randomised clinical  trials,  as  it can  be based on the  incidence  rates 
observed in age-matched controls. For example, in the Swedish two-county trial, 
underlying  incidence was  taken  from the control  population and data from the 
literature for women aged 50-59 and 60-69 in the trial control arm were used to 
estimate the expected incidence rate in the absence of screening for women aged 
50-69  years  (Tabar  et al.,  1992).  In  non-experimental  situations,  however,  the 
expected incidence may  only be estimated based on projections from historical 
data, with potential errors. There exists no clear consensus on what the best method 
141 is  to  estimate  the  underlying  incidence,  however,  several  methods  have  been 
described in the literature. In their analysis of the Nijmegen programme interval 
cancer rates, Verbeek et al.  assumed the underlying incidence in Nijmegen to be 
that of the adjacent population in Amhem (Verbeek et al.,  1984).1n the study in the 
Northwest Region (England), Woodman et al.  (1998) estimated the mean annual 
incidence rate of  invasive cancer in the three years preceding the onset of screening 
and used this average rate as the underlying incidence rate. This method was also 
used by Schouten et al.  (1998). Day et al. (1995) used linear extrapolation of the 
invasive cancer rates observed before the onset of screening (1976-1988), by age 
group, to estimate the expected incidence rates during the screening period ( 1990-
1993). The expected incidence in women 50-64 was taken as the summed average 
incidence rate over the period 1990-1993 of three 5-year age bands (50-54, 55-59, 
60-64 years). 
The adjustment for breast cancer incidence increases over time used by Day et al. 
(1995) has been advocated as the preferred method by several authors (Prior et al., 
1996).  However,  it  is  questionable  that  adjustment  will  account  for  large 
differences in observed proportionate incidence rates. Schouten et al.  (1998) only 
observed a difference of 1-2% in estimated proportionate incidence rates when they 
applied this adjustment (0.8% annual increase in incidence for women aged 50-69) 
to  their  data.  The  authors  of  the  Northwest  Region  study  made  similar 
observations. 
In  a publication by  a UK  special  working group  on interval cancers, Moss  and 
Blanks  (1998)  assumed  a  log-linear relationship  between  age  and  incidence  to 
calculate underlying  incidence rates  for  the  year before  the  onset of screening. 
They then extrapolated these data based on trends from  1987-1995 and used the 
midpoint of the  two estimates  (from  1987  and  1995)  to determine  age-specific 
underlying incidence during the years following screening. 
Classification of  interval cancers 
Interval cancer rates may certainly be decreased with improved sensitivity of the 
screening  process  (Day  et al.,  1995),  however,  there  will  inevitably  remain  a 
certain  number  of true  interval  cancers  that  cannot  be  detected  at  the  time  of 
screening. A number of programmes have run blinded retrospective chart review 
exercises in an effort to determine the characteristics of false negative cancer cases 
missed by  radiologists.  However,  the  following  classification  scheme  has  been 
devised to distinguish cancers based on whether they could or could not have been 
detected at the time of screening: 
142 Table 4.  Classification of  interval cancers (Adapted from Broeders et al.,  1996) 
Classification  Dermition 
True interval  Cancer that appeared negative on the screening mammogram, yet was 
radiologically apparent on the presenting mammogram at diagnosis. 
Radiological!  y 
occult 
Minimal signs 
False negative 
Unclassifiable 
Cancer that appeared negative on the screening mammogram and 
negative on the presenting mammogram at diagnosis. 
Cancer that upon rereading shows minimal signs, but was classified 
as negative on the screening mammogram; however, it appeared 
positive on the presenting mammogram at diagnosis. 
Cancer that is apparent upon rereading the screening mammogram 
and is visible on the presenting mammogram at diagnosis. 
Cancer for which no screening or presenting mammogram is 
available. 
The impact of screening on stage distribution 
The  rationale  underlying  breast  cancer  screening  is  that  it  will  allow  for  the 
detection  of cancers  at  a  more  precocious  stage.  This  should  translate  into  (i) 
favourable  distribution  of  prognostic  factors  in  screen-detected  cancers  as 
compared to cancers  detected  outside  of the  screening  programme,  and  (ii)  an 
overall increase in the total share of cancers of favourable prognosis and a decrease 
in  advanced cancers as  compared to these proportions before the introduction of 
screening. 
Obtaining staging information 
Cancer registries do not always record staging information of cancers; moreover 
the quality of  existing data has been found to vary significantly from one registry to 
another.  In  their  comparison  of cancer  survival  rates  across  European  cancer 
registries, the EUROCARE research group  originally intended to  provide  stage-
specific  survival  data,  however,  they  retracted  when  faced  by  the  formidable 
discrepancies in quality and completeness of staging data (Berrino et al.,  1995). As 
a result, a second study effort was created (EUROCARE-2) in an attempt to set out 
143 a methodology for comparing staging data across cancer registries. Even within a 
single  registry,  the  comparison  of staging  information  from  one  institution  to 
another may be biased, should one institution have more sophisticated diagnostic 
techniques.  These  differences  will  have  an  important  bearing  on  stage-specific 
survival analyses. Moreover, they may bias the comparison of recent staging data 
with that from  historical controls,  as  cancers  which may  have been described as 
localised  with  less  sophisticated  diagnostic  techniques  would  now  appear  as 
metastatic. This phenomenon is known as "stage migration". A solution chosen by 
several authors is to limit analysis to histological size as a proxy for stage. 
Stage distribution of  screen-detected versus other breast cancers 
In  order to  verify  that  screening  detects  cancers  at  an  earlier  stage,  one  may 
compare the staging properties of screen-detected cancers, cancers detected in non-
attenders, interval cancers, and cancers detected in lapsed attenders (women whose 
last  mammogram  was  negative  and  preceded  the  last  screening  round).  This 
grouping of cancers  by  detection  mode  requires  the matching  of files  from  the 
cancer  registry  and  screening  databases,  as  dates  of  screening  invitation  (if 
applicable) and diagnosis are required in addition to detection mode and prognostic 
information. Computer matching follows the same principles outlined above for the 
analysis of interval cancers. 
Of particular interest is  the  comparison  of prognostic  characteristics  of interval 
cancers to  those of screen-detected cancers.  A predominance of poor prognosis 
interval cancers indicates the failure of the screening programme to detect cancers 
at an earlier stage. It is also assumed that interval cancers are of similar or worse 
prognosis compared with cancers detected in non-attenders. Interval cancers were 
of worse prognosis than non-attender cases in the Malmo (Anderssen et al., 1988) 
and in the Bas-Rhin screening programmes (S. Wait, data on file). In East Anglia, 
the prognostic factors of interval cancers were similar to those of the unscreened 
population (McCann et al., 1998). 
One important point to consider is that the comparison of prognostic factors should 
ideally be presented as  rates per population screened, as  opposed to percentages 
amongst  screen-detected  or  non-screen  detected  cancers.  Rates  allow  one  to 
account for the actual share of cancers detected through screening. For example, 
even  if there  is  a  higher  proportion  of small  cancers  amongst  screen-detected 
cancers  than  amongst  cancers  detected  in  non-attenders,  the  overall  impact  on 
staging distribution and breast cancer mortality  will be  small, if screen-detected 
cancers  only  make  up  30%  of all  cancers  detected.  The  importance  of cancer 
registry data in the evaluation of screening programmes thus becomes paramount, 
as this linkage allows for a comprehensive perspective on the evolution of breast 
cancer prognosis in the target population for screening. 
144 The reduction of  advanced cancer incidence 
If  screening programmes are successful at advancing the diagnosis of cancer, one 
should  observe  an  overall  reduction  in  advanced  cancer  rates  in  the  target 
population, which in tum translates into a reduction of mortality from  advanced 
disease. Day described a sequential impact of screening on stage distribution in the 
following schema (Figure 2,  Day et al.,  1989).  He  suggested that differences in 
stage distribution by mode of detection will appear immediately, however one only 
begins to see an impact on advanced cancer rates approximately four years  after 
screening initiation,  followed  by  an  impact  on  mortality  some  two  years  later, 
namely six or seven years following the onset of screening. 
Day et al.  (1989) suggested that screening should cause a decrease of at least 30% 
in the rate of advanced (Stages ll-IV) tumours  after four years.  In the Limburg 
programme, a decrease of 10% in advanced cancers and of 15%  in node positive 
tumours was shown one to four years after the onset of screening (Schouten et al., 
1998). A study in East Anglia found that the increase in small cancer incidence in 
the  early  years  of screening  was  much  larger than  the  subsequent  decrease  in 
advanced cancer incidence, thus suggesting that the reduction in mortality may also 
be somewhat less than targeted (McCann et al.,  1998). An important factor is that 
the  incidence  of  interval  cancers  is  increasing  regularly  in  many  screening 
programmes, and that prognostic characteristics of interval cancers are similar to 
those of non-attenders. Moreover, the actual proportion of cancers detected through 
screening  does  not  exceed  one-third  in  many  programmes,  even  with  high 
compliance rates (McCann et al.,  1998). These factors combined suggest that the 
potential of screening programmes to  significantly reduce the rates  of advanced 
cancer detection may be less than expected, with consequent impact on reductions 
in breast cancer mortality. 
Estimating the expected rate of  advanced cancers 
The calculation of the reduction  in  advanced cancer incidence due to  screening 
requires a reliable estimation of advanced cancer incidence before the introduction 
of screening. McCann et al. (1998) explore three different methods for arriving at 
this estimate. First, they project from the advanced cancer incidence observed in 
1976-1986 to estimate this rate in 1995.  Secondly, they take the average rate of 
advanced  cancers  observed  in  1987-1988,  immediately  before  the  onset  of 
screening,  and  compare  this  to  the  1995  rate.  Finally,  they  take  the  ratio  of 
advanced to early cancers in  1989-1994 in women  who had not yet received an 
invitation to screening to generate an expected incidence rate of advanced cancers, 
and multiply this by actual number of cases in order to ascertain actual numbers of 
cases expected. Schouten et al.  (1998) used rates of advanced and node positive 
tumours in the three years preceding the screening programme as  their reference 
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 rates  and calculated a rate ratio of the incidence of advanced and node positive 
tumours detected in each year since the onset of screening as compared to the pre-
screening incidence. 
Discussion 
Despite  years  of experience  with  breast  cancer  screening,  the  true  impact  of 
existing screening programmes on breast cancer mortality remains to be elucidated 
and  has  been  the  topic  of some  controversy  in  the  recent  literature.  Existing 
screening programmes  have  succeeded in  reaching  most  targets  for  quality  and 
efficacy. However, targets for the impact on  mortality (e.g. interval cancer rates) 
based on  clinical  trial  results  may  need  to  be revised  to  account  for  evolving 
screening practices and the realities of exercising screening in uncontrolled settings 
(Moss et al., 1998). 
Randomised  clinical  trials  for  screening  are  designed  to  detect  a  statistically 
significant  difference  in  breast  cancer  mortality  between  two  age-matched 
populations (screening attenders and non-attenders). The controlled setting implies 
that treatments will be identical in the trial arms and, thus, that any difference in 
the trial endpoint (ultimately mortality) may definitely be attributed to screening. In 
operational  screening  programmes,  it  is  elusive  to  try  to  isolate  the  effect  of 
screening on breast cancer mortality, as one cannot control for the differences in 
the  patient  risk  profiles  and  in  the  treatment  modalities  received.  Moreover, 
increases  in  incidence  rates  will  also  im1--!ct  on  mortality  trends,  thus  further 
complicating the interpretation of mortality  trends  in  the target population.  Any 
comparison  between  screen-attenders  and  non-attenders  is  unlikely  to  have 
sufficient  power  to  detect  meaningful  differences  in  mortality  between  groups 
while controlling for all these other factors. While this limitation may also apply to 
the  comparison  of earlier  measures  of the  impact  on  cancer epidemiology,  the 
measure of these outcomes  is  not  subject to  the  long lag necessary  to  measure 
mortality data. All efforts should be made to allow for an unbiased comparison of 
these measures based on comprehensive data analysis for screening attenders and 
non-attenders of ongoing programmes. 
In summary, cancer registries play an essential role in the evaluation of screening 
effectiveness, both through early indicators such as prevalence, incidence, staging 
distribution and interval cancer rates,  as  well  as through later indicators  such as 
breast cancer survival and mortality. Most importantly, registry data allow for the 
calculation of the expected incidence in the absence of screening programme and 
the comparison of actual to expected trends. The development of a cancer registry 
specifically  for  the  purposes  of  evaluating  a  screening  programme  is  not 
recommended  due  to  its  incurring  high  cost.  However,  programmes  located  in 
147 areas with a reliable population-based cancer registry may benefit greatly from the 
data provided for the purposes of screening evaluation. 
Although the first  screening trials began over 30 years  ago,  there remain  many 
challenges  in  the  evaluation  of  the  impact  of  screening  on  breast  cancer 
epidemiology. Further studies based on existing screening programmes are needed 
to  fully  understand  the  value  of early  indicators  of screening  efficacy  and  to 
elucidate the true impact of screening on breast cancer incidence and mortality. 
These studies  will  rely  on the existence of high  quality,  longitudinal data from 
c~cer  registries. 
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150 Chapter 10.  Breast cancer:  modelling of mortality trends 
T. Hakulinen 
Introduction 
The main  and ultimate indicator of a success of a cancer screening programme is  a 
decrease in the mortality of the cancer in question. It is therefore natural that routine 
statistics  on  cancer mortality could be  used for  the evaluation purpose.  Changes in 
cancer incidence may also be utilised if the cancer had a sufficiently long pre-clinical 
phase and if the treatment of a pre-invasive lesion prevented its development into a 
truly  invasive  cancer.  For example,  cervical  cancer  has  such  a pre-invasive  stage, 
whereas  in  situ  lesions  of the  breast  are  less  well  defmed.  Thus,  in  breast  cancer 
screening, mostly invasive but preclinical lesions are searched for in order to decrease 
breast cancer mortality. 
Unfortunately, it is not always possible to evaluate population-based mass-screening 
activities  within  controlled  trials.  Even  if a proper  trial  has  been  introduced  it  is 
possible that public  health service screening will differ from  screening in  a trial  in 
terms  of quality and hence  in  its effectiveness (Hakama,  1982).  Compromises  may 
have to be made in service screening, and the enthusiasm and experience of the field 
staff may be decreased compared to a trial. Thus, even when a specific trial has not 
been  designed,  it  is  important  for  quality  assurance  of  any  ongoing  screening 
programme that an evaluation can be made of the activity. 
Bases for comparison 
Ideally, the screening policy should be specifically designed to facilitate evaluation. 
The Finnish breast cancer screening (Figure 1) provides a good practical example. For 
practical reasons  and due to  shortage of funding it was  not possible to  provide the 
screening  service for  the  entire  target  population  at the  beginning.  This  lead  to  a 
national recommendation to start screening the cohorts born in even years earlier than 
those born in odd years (Hakama et al.,  1999). A non-significant 24%  reduction  in 
breast cancer mortality, based on deaths among the incident breast cancer cases in the 
period  1987-1992,  was  observed for  the  birth cohorts  screened early,  compared to 
151 those screened later. The reduction was 44% and significant among women under 56 
years of age at the beginning of  the study (Hakama et al.,  1999). 
Year 
Figure 1. Finnish National Board of Health's recommendations of screening rounds in 
organised screening programme for breast cancer, by  birth cohort and calendar year 
(reproduced by permission ofBMJ Publishing Group from Hakama et al.,  J Med Screen 6:209-
216, 1999) 
The  routine  mortality  statistics  were  not  sufficient  for  such  an  evaluation.  The 
nationwide Finnish Cancer Registry provided the dates of diagnosis of the incident 
cancer cases so that an evaluation could be based on mortality related to incident breast 
cancers diagnosed during the period of study. 
If  the screening policy has not been designed to facilitate the evaluation, a prerequisite 
for an empirical evaluation is  some difference in the screening policies, either over 
time (Gibson et al.,  1997) or between geographical regions (Tornberg et al.,  _1994). 
Differences in the temporal and geographical patterns of disease incidence or mortality 
should subsequently reflect the differences in screening patterns. Thus, consistent and 
comparable information on disease occurrence and deaths among the patients should 
also be available. A population-based cancer registry may also be able to provide - in 
addition to reliable incidence statistics - improved data on cancer mortality compared 
152 with official statistics on causes of death (Saxen, 1982). The cancer registry receives 
usually a number of notifications on a cancer case prior to death and may be in a better 
position to know the appropriate cause of death than the person  signing the death 
certificate. 
Confounders may  seriously complicate the evaluation of a  screening policy,  unless 
there are documented differences in the screening policy that could be regarded as a 
non-experimental design for a study. For example, treatment is a potential confounder 
which  should be taken into  account when  using routine mortality  data to evaluate 
mammographic  screening  (Figure  2).  Treatment  with  tamoxifen  was  introduced  in 
England and Wales approximately  at the time  when  mammographic  screening was 
initiated (Quinn and Allen, 1995). Thus, it is very difficult to estimate the independent 
effect of screening. 
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Figure 2.  Age-adjusted breast cancer mortality rates in women 55-69 years of  age in 
England and Wales in 1950-1994 (reproduced by permission of BMJ Publishing Group from 
Quinn et al., BMJ 311:1391-1395, 1995) 
153 Historical developments 
The incidence and mortality rates may have existing trends and differentials before the 
screening  activity  started.  The  areas  to  be  compared  may  also  be  internally 
heterogeneous with respect to disease trends and differentials. These factors should be 
taken appropriately into account using a statistical model for the incidence or mortality. 
The part  of the  incidence  or mortality  data  that  is  not  related  to  a  period  when 
screening  was  practised may,  using  an  appropriate  model,  be extrapolated Into  the 
period of screening in order to give a hypothetical expected number of cases or deaths 
in the absence of screening (Prior et al.,  1996; Gibson et al.,  1997). If the observed 
number of cases or deaths is very much below the expected one,  screening may  be 
considered successful. Information on the screening activity may be incorporated in the 
model in order to estimate as  detailed numerical effect of the screening as  possible 
(Tomberg et al., 1994). 
Trends  in  cancer incidence  and  mortality  may  also  be caused  by  technical  issues 
(Hakulinen, 1996). Definitions, and diagnostic criteria and facilities change over time 
and  may  create  or mask  trends.  It  may  be difficult to  predict  for  how  long these 
changes may continue. 
Statistical modelling 
Although  breast  cancer  mortality  would  be the  most  useful  target  to  model,  also 
incidence rate models may give useful information (Prior et al.,  1996). Breast cancer 
screening leads to an increased incidence of the disease, at least temporarily, due to the 
fact that diagnoses are made earlier than in the absence of screening. It may also be 
possible that in some cases small tumours are detected that otherwise would never have 
surfaced as  clinical cancers. Incidence trend modelling may  help in estimating how 
much of an increase in incidence may be related to the screening activity. 
A screening is usually targeted to certain age groups only. If  the observed incidence is 
compared with a predicted incidence in the absence of screening, it is expected that the 
incidence is  increased in these age groups.  The age-specific predicted and observed 
incidence rates of breast cancer in Finland in 1989-1993 agreed fairly well, given that 
the prediction base was  1954-1983, when  there was no mammographic screening in 
Finland. There was one major exception: Mammographic screening took place in ages 
50-64 years in the years following the prediction base, and the observed incidence of 
154 breast cancer exceeded that predicted in those ages (Figure 3). Of course, the increased 
incidence is not as  such beneficial. In the years after the start of the screening,  the 
advancement of breast cancer diagnoses  should lead to  a decrease in  breast cancer 
mortality attributable to a smaller lethality of these early detected tumours (Hakama et 
al., 1997). 
Statistical  model  building  should  lead  to  a  tailor-made  product  for  the  particular 
problem considered.  The models  in the  comparisons  are  usually  based on  Poisson 
regression (Breslow and Day, 1987). They should take into account the uncertainty in 
the  model parameters due  to  the randomness in the  historical data and the  random 
variation of the observations that are made in the period of the evaluation (Hakulinen 
and Dyba, 1994; Gibson et al., 1997) . 
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Figure 3.  The predicted age-specific breast cancer incidence in Finnish females (pred) 
and that observed (obs) in 1989-1993, by age (reproduced by permission of Scandinavian 
University Press from Hakulinen, Acta Oncol 35:665-710, 1996) 
Under the assumption that the model chosen is correct, the range of likely outcomes is 
described by a confidence interval. The confidence intervals, the middle intervals of 
the  predictions  in  Figure 4,  have  been  actually  built in  such  a  way  that  only  the 
uncertainty in the historical data has been taken into account. Prediction intervals, the 
total (outer) intervals of the predictions in Figure 4, also account for the randomness in 
155 the numbers of cases themselves. Consequently, the prediction intervals are somewhat 
wider than the corresponding confidence intervals. 
Theoretically, if screening for melanoma and cancers of the colon, stomach or lung 
could be based on early detection of preclinical lesions and if  this screening had been 
started  after  1980-1985,  one  simple  way  to  evaluate its  effect  would  be to check 
whether the observed number of clinical cancers in 2000-2004 would fall below the 
4 
3 
2 
Incidence 
(/10
4 person-years) 
1960  1970 
I  Lung 
' 
Melanoma I! Colon 
~  t Stomach 
1980  1990  2000  2005 
Year 
Figure 4.  Age-adjusted incidence rates of cancers of the lung, stomach and colon and 
melanoma of the skin in females in the Stockholm-Gotland Oncological Region in Sweden 
in 1960-1984, by five-year periods, with predictions for 2000-2004 (the total interval: 95% 
prediction  interval  for  the  future  observation;  the  middle  interval:  95%  confidence 
interval for the expected value of the future observation) (Hakulinen T &  Dyba T,  1994. 
Precision  of incidence  predictions  based  on  Poisson  distributed  observations.  Stat  Med 
13:1513-1523. Copyright John Wiley & Sons Ltd. Reproduced with permission) 
156 prediction  intervals  (Figure  5).  Special  attention  should,  nevertheless,  be  given  to 
possible confounding and technical factors that may also be involved. 
It is possible to use models that preserve the age-incidence or age-mortality pattern of 
the disease in the period of prediction when calculating the theoretical expected or 
predicted incidence or mortality in the absence of screening (Dyba et al.,  1997). To 
guarantee this, Prior et al. (1996) used a model of the form 
(1) 
where Mit is the incidence (or mortality) of disease in age group i and period t, EMit is 
its expected value, and <Xi and ~ are unknown parameters. The problem with this model 
in  longer-term predictions  is  that  it specifies  an  implausible exponential incidence 
growth with time. A model without the log transformation of the EMit precludes this 
property but with cancers, the incidence  (or mortality)  rates cannot have the same 
parameter of absolute change in all ages, as the rates vary strongly by age. Thus, the 
growth parameter has to become age-dependent: 
(2) 
This model, however, as the first model tried by Prior et al.  (1996), In EMit= <Xi+~it, 
does not guarantee a plausible age-incidence pattern in the future. 
A model that both precludes the exponential future growth and guarantees a plausible 
future age-incidence pattern was recently proposed by Dyba et al. (1997): 
(3) 
This model is  non-linear in its parameters but linear with respect to time.  Figure 5 
shows a comparison of models (2)  and (3) for the skin melanoma data of Figure 4. 
Clearly,  the  future  age-incidence  pattern  is  more  plausible  and  the  age-specific 
confidence intervals are shorter for model (3). Model (3) also fits the historical data, a 
feature that is very important to check. 
Whatever model  is  used,  it  would be important to  make  it simple  for  reasonable 
prediction intervals for future observations. These intervals are important in showing 
how much confidence a particular prediction has provided that the model being used 
can be relied upon. Of course, it is quite possible that the model used for predictions is 
157 wrong even if  it fits the historical data, and the confidence interval in such cases has a 
limited value only. 
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Figure S.  Age-specific incidence rates of skin melanoma in females in the Stockholm-
Gotland Oncological Region in 1960-1984 (lower solid line) and incidence rates predicted 
for 2000-2004 as estimated by model (2) (dotted line) and model (3) (upper solid line)  with 
95%  prediction  intervals for the future observations  (total intervals)  and confidence 
intervals for the expected values of the observations (middle intervals) (Dyba et al.,  1997. 
A simple non-linear model in incidence prediction. Stat Med 16:2297-2309. Copyright John 
Wiley & Sons Ltd. Reproduced with permission) 
Incorporation of  exposure variables 
The screening variable can  be also  explicity included in the  model  as  an  indicator 
(Luostarinen  et al.,  1995)  or as  a more  elaborated score  variable  (Tomberg et al., 
158 1994). This facilitates and increases the efficiency of the formal testing of the effect of 
the screening programme and helps in estimating its effect. 
For the quality assurance of the Swedish mammographic screening (Tornberg et al., 
1994) it was of interest to check, whether the effect of the large Swedish trials could be 
demonstrated  using  routine  breast  cancer  mortality  data  and  details  about  the 
screening. The evaluation of the service screening could be considered to be based on 
routi_ne  mortality statistics.  Ideally the screening would,  as  a routine activity,  be as 
successful as the Swedish mammographic screening trials. 
A successful screening should reduce the breast cancer mortality from the predicted 
level,  based  on  trend  extrapolation.  However,  a  large  proportion  of breast  cancer 
mortality during the observation period is attributable to cases diagnosed earlier, i.e., 
before the screening was introduced. Consequently, the statistical model applied in the 
Swedish study contained an assumption that the full effect of screening can be seen 
starting from 10 years after the period the screening was initiated. From 5 to 10 years 
after the start, the effect was assumed to be only half of the full effect. No effect was 
assumed during the first five  years  after the initiation of the  screening programme. 
When the whole age group was not subject to screening, the effect of the programme 
was assumed to concern only the proportion screened. 
All the  26 Swedish counties,  with  the  exception of Gavleborg county  with  a  long 
history of service screening, were used as geographical units in the evaluation. The age 
groups considered were those of the screening, five-year categories between 50 and 75 
years  in five-year time periods between  1971  and  1990.  Deviations from  mortality 
trends were predicted to occur in the last two periods only (Table  1). The expected 
reduction was largest, 60% of the theoretical maximum effect, in Kopparberg in 1986-
1990. These proportions were called mammography scores. 
A satisfactory fit to the breast cancer mortality data was given by a Poisson regression 
model including the categorical variables age, period and county, and the numerical 
mammography  score  but  no  interaction  terms.  The  p  value  for  removing  the 
mammography score from the model was 0.08. The estimate for the mammography 
score indicated a 19%  protective effect, with 95% confidence interval from -3% to 
37%. There was no evidence that the effect of mammography score would have been 
different for different counties. 
159 Table  1.  Fractions  of theoretical  maximum  effects  (mammography  scores)  for  the 
Swedish  counties  with  mammographic  screening  trials  in  1981-1990  (reproduced  by 
permission of BMJ Publishing Group from Tomberg et al., J Med Screen 1: 184-187, 1994) 
County  Period 
1981-1985  1986-1990 
Stockholm  0  0.08 
Ostergotland  0.15  0.40 
Malmo  0.25  0.50 
Gothenburg  0  0.15 
Kopparberg  0.27  0.60 
The 19% protective effect, even if non-significant, is compatible with the 24% effect 
estimated in an overview of the Swedish trials (Nystrom et al., 1993). The modelling 
based  on  routine  mortality  data  is  of course  a  cruder  alternative  than  a  proper 
evaluation of the trials.  In  any case,  an  effect could be disclosed also using routine 
mortality data when modelling had been done. Nevertheless, it can be expected that the 
effects may end up being somewhat underestimated depending on the appropriateness 
of the  model  and  on  confounding  effect  of deaths  of patients  with  breast  cancer 
diagnosed before the start of  the trial. 
On the other hand,  it would have been possible to sharpen the model employed by 
Tomberg et al.  (1994). For example, separate mammography scores could have been 
used for different age groups in a county and the differences in the trial design could 
have been taken explicitly into account. 
Trend  extrapolations  were  based  on  a  simultaneous  modelling  of the  rates  in  all 
counties, not just making a model for each county separately. When the number of 
counties increases, multi-level modelling should be considered (Gibson et al.,  1997). 
160 In  some  countries,  trends  in  breast  cancer  mortality  in  the  age  groups  subject  to 
mammographic screening were already decreasing before any  screening programmes 
were  introduced (Coleman  et al.,  1993). When evaluating any  beneficial effects of 
mammographic  screening  on  mortality  trends,  the  existing  trends  and  particular 
screening policies should be properly taken into account. 
In any case, this kind of evaluation is very crude. Techniques exist (Chen et al., 1998) 
to base the evaluation on a number of intermediate endpoints describing the severity of 
the disease of the individual patients. Thus, there is no need to wait until the breast 
cancer patients  have  died  and  contributed to  breast cancer mortality.  However,  an 
information system, a mass-screening register (Hakama et al.,  1997), is needed for a 
successful accomplishment of such a task.  It is  advantageous to have a population-
based cancer registry to guarantee the completeness and to study the representativeness 
of the  breast  cancer  patient  series  needed  in  the  evaluation  and  monitoring  of 
mammographic screening activities in a population. 
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162 Chapter 11.  Cohort studies on breast cancer screening 
R. Sankila and E. Lynge 
Introduction 
The  first  randomised  controlled  trial  to  evaluate  the  efficacy  of mammographic 
screening for breast cancer was launched in 1963 in New York State (Shapiro et al, 
1966). Subsequently, major randomised screening trials have been performed in, e.g., 
Canada, Scotland and Sweden (Miller et al., 1992; Roberts et al., 1984; Nystrom et al., 
1993). The results have been fairly consistent, suggesting that a reduction of up to 30% 
in breast cancer mortality can be achieved among the screened women. 
Based on the results of the trials, organised screening programmes have been set up, 
first as pilot programmes, and later expanded into regional or nationwide public health 
interventions. For example, in Sweden, the first pilot study was performed in 1974, 
followed by screening trials (Nystrom et al.,  1993). In  1986, the National Board of 
Health published national guidelines on mammographic screening and, eventually, in 
1997, all counties in Sweden were providing mammography service screening (Olsson 
et al., 2000). 
Why does any doubt still exist? 
There are several reasons why the full benefits of screening, as demonstrated in the 
randomised  trials,  may  not  be  accomplished  in  real-life  settings.  Quantifying  the 
benefits in a service setting is only possible through population-based studies, using 
data before and after the launching of an organised screening programme. Due to the 
prospective nature of such studies, the relative rarity of breast cancer in the screening 
age  groups,  and  the  high  survival  rates  among  breast  cancer  patients,  the  study 
populations need to be very large for statistically significant effects on the mortality 
rates to be seen. Further, collection of data may need to continue for 10 years at least, 
as most of the randomised trials began to show a decrease in mortality only after six or 
seven years of follow-up. 
163 Cohort studies 
Although the notion of a cohort study is fairly  clear to most epidemiologists in the 
context of investigating possible aetiological factors,  in reports of studies evaluating 
screening, different types of studies have been referred to as cohort studies - or at least 
the terminology 'study cohorts' has been used. For example, the two groups of women 
in screening trials originally randomised to be screened or not may be referred to as 
'cohorts' (Alexander et al.,  1999). These cohorts may continue to be monitored even 
after the end of the trial itself (UK Trial of Early Detection of Breast Cancer group, 
1999). Possibly more conventional is the nested case-control study, in which exposure 
(in  cases  and  controls)  is  defined  as  having  actually  been  screened,  within  the 
populations of a screening trial,  in  an  organised screening programme or simply in 
opportunistic screening activities in the general population. 
In this  latter instance  (and  in  this  chapter),  the  study  cohort  is  the  entire  female 
population which is  targeted for screening. The population should be geographically 
defined, but it can be stratified according to the research needs. In the analysis phase, it 
is possible, e.g., to exclude non-attenders from the entire cohort that was intended to be 
screened.  There  should  be  a  clear  and  explicit  reason  for  any  exclusions  and 
stratifications, however. 
The principle constraint upon the classical approach of prospectively observing women 
who have and have not been screened (possibly separating screenees by the setting of 
the test (organised vs.  opportunistic,  and the number of tests  and intervals between 
them)  is  the  difficulty  in  determining  outcomes.  The  screening  registry  must  be 
organised  to  this  effect,  or,  more  plausibly,  linked  to  a  population-based  registry, 
which  can  determine  outcomes  in  the  population  comprising  the  cohort.  Record 
linkage  (between  screening  records  and  cancer  registers)  faces  challenges  from 
misconceived  regulations  on  confidentiality.  Furthermore,  if  unique  personal 
identification numbers do not exist, the linkages can be technically very challenging. 
These complexities explain why few cohort studies have been performed and why the 
existing data fall  short of producing a comprehensive picture of the entire screening 
programme. 
Although a decrease in breast cancer mortality due to the screening programme should 
be the natural outcome of a population-based cohort study, only one such study has 
been published so far (Hakama et al., 1997). Other such studies have produced results 
on a variety  of quality indicators of the screening process itself or on intermediary 
outcomes in the screened populations. 
164 Examples of  cohort studies involving population-based cancer registries 
An example of a published study evaluating the effectiveness of screening for breast 
cancer as a public health policy is the one perfonned in Finland (Hakama et al., 1997). 
Hakama has described the study in detail elsewhere in this Monograph (see Chapter 2). 
Another  example  of  a  population-based  cohort  study  evaluating  mammography 
screening  for  breast  cancer  in  Copenhagen  will  be  described  in  more  detail  here 
(Mammography Screening Evaluation Group, 1998). 
Mammography  screening for breast cancer in  Copenhagen  April 1991  - March 
1997 
Based on the results of randomised controlled trials,  women  aged 50-69 have since 
1991  been  offered  biennial  mammography  screening  in  the  municipality  of 
Copenhagen,  Denmark.  The target population  is  approximately  40 000 women.  As 
relatively  short  time  has  passed  since  start  of the  programme,  only  the  short-tenn 
indicators of its effectiveness have been evaluated and compared with the outcomes in 
other service screening programmes. 
Organisation of  mammography screening in Copenhagen 
All mammography screening in Copenhagen takes place at a special clinic. Two-view 
mammography is used in the first screening round. The radiographer checks the image 
quality  before  the  woman  leaves  the  clinic.  Women  with  dense  breast  tissue  will 
continue  to  have  two-view  mammography,  whereas  other  women  will  have 
single-view mammography in the subsequent rounds. 
Invitations to the screening are issued by K~benhavns  Kommunes IT  -Service, based on 
the. updated population register for  the  municipality.  All  women  aged  50-69  at the 
beginning of the invitation round and living in the  municipality of Copenhagen are 
invited.  The invitation register is  updated  daily  with  movements  in  and  out of the 
municipality and with deaths  (using the Central Population  Register).  The personal 
jnvitation  gives  an  appointment  at  the  screening  clinic.  This  appointment  can  be 
changed by telephone. It is also possible to infonn the clinic by telephone if a woman 
does not want to participate in this round and/or in any future rounds. A reminder with 
a new appointment is sent to women who have not contacted the clinic. 
165 Data sources 
Mammography screening data in K~benhavn Kommunes IT  -Service are stored in three · 
flies;  two with  information on the target population from  the current and previous 
invitation  rounds,  and  one  with  all  the  screening  data.  Women  developing  breast 
cancer in this population were identified through the Danish Cancer Registry (which 
has information on all incident invasive cancer cases in Denmark 1943-1994) and from 
two registers of the Danish Breast Cancer Cooperative Group,  'DBCG-invasive' with 
information  on  most  incident  invasive  breast  cancer cases  diagnosed  in  Denmark 
1978-1996, and 'DBCG-in situ' with information on most cases of carcinoma in situ 
(CIS) in the breast in Denmark 1978-1996. It proved rather difficult to determine the 
flnal diagnoses of women who screened positive and the number of interval cancers. 
All  the  available  data  were  reviewed  manually  on  a  case by  case  basis,  and  any 
inconsistencies  were  resolved by retrieving further information  from  the  pathology 
register and the clinical records. 
First invitation round 
The target population consisted of all women born between 31 March 1921 and 1 April 
1941  (N = 43 092). The frrst date of screening mammography was 4 April 1991  and 
the last date was 28 March 1995. The fmal diagnosis of the last screen-detected case 
was  made in November 1995. A total of 29 966 women tested negative in the frrst 
invitation round,  with 28 303  women  with a negative mammography,  1432 women 
with a positive mammography but with a negative assessment, and 231  women with a 
positive assessment but with a negative surgery. Among 363  women with malignant 
diagnosis at surgery,  316 had invasive breast cancer, 44 had carcinoma in situ and 
three had other cancer diagnoses. A flowchart of the results of  the frrst screening round 
is provided in Figure 1. 
Analysis of  interval cancers 
The populatign ·at risk for  c~ulation of interval cancer rates comprised women who 
tested  negative  in  a  given  screening  round.  The  negative  'test'  could  occur  at 
mammography,  at assessment ot,  at  surgery.  Theoretically, the risk period for each 
woman started from the date of the negative 'test' until the date of death, emigration, 
next screening date or two years since the previous screening date,  whichever came 
flrst.  However,  as  the  dates  for  assessment  and  surgery  were  not  systematically 
recorded, the start of the risk period was defined from the date of mammography. 
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Figure 1.  Mammography screening in Copenhagen rll'St invitation round 4 Aprll1991 -
23 April1993, women hom 31 March 1921 - 1 Aprll1941 (modified from Lynge, APMIS 
Suppl. 83, 106, 1998) 
The  expected  number  of breast  cancer  cases  in  women  who  tested  negative  was 
calculated using Danish Cancer Registry  incidence rates  for  invasive  breast cancer 
among women living in the municipality of Copenhagen in 1986-90, i.e., in the period 
immediate!  y before the start of the screening programme. The results are presented as 
proportionate interval cancer rates where the observed number of interval cancers is 
divided by the expected number. 
167 A total of 52 invasive breast cancers were diagnosed after the first screening round. Of 
these, 16 occurred within the first year after the screening date, and 36 occurred within 
the  second  year  after the screening date.  The expected number  of invasive  breast 
cancer cases was  152.25. The proportional interval cancer rate was thus 521152.25 = 
0.34. The rate was 16/77.42 =  0.21 within the frrst year, and 36/74.84 =  0.48 within the 
second year (Table 1). 
Table 1.  Mammography screening in Copenhagen. Interval cancers after fii'St invitation 
round (modified from Lynge, APMIS Suppl. 83, 106, 1998) 
Negative at  Negative  Negative  Total 
mammography  at  at surgery 
assessment 
No. of women  28 303  1432  231  29966 
After 0-11 months 
Obs  13  3  0  16 
Exp  73.10  3.72  0.60  77.42 
OlE  0.18  0.81  - 0.21 
95%CI  0.09-0.30  0.17-2.36  - 0.1-0.34 
After 12-23 months 
Obs 
Exp  34  2  0  36 
OlE  70.65  3.61  0.58  74.84 
95%CI  0.48  0.55  - 0.48 
0.34-0.67  0.07-2.00  - 0.35-0.67 
After 0-23 months 
Obs  47  5  0  52 
Exp  143.75  7.33  1.18  152.25 
OlE  0.33  0.68  - 0.34 
95%C  0.25-0.40  0.22-1.60  - 0.26-0.45 
168 Comparison  with  results  from  randomised  controlled  trials  and  other  service 
programmes 
Key indicators for the outcome of the first invitation round are presented in Table 2 
together with data from other service screening programmes (Thurfjell and Lindgren, 
1994;  Hakama  et  al.,  1995;  Lenner  and  Jonsson,  1997;  NHS  Breast  screening 
programme,  1997;  Sundhedsstyrelsen,  1997;  Fracheboud  et  al.,  1998).  The 
participation rate was low in the Copenhagen programme compared with that of other 
service programmes. The Copenhagen municipality is a completely urbanised area. A 
regional gradient in participation rates is  observed in other countries as  well.  In the 
Netherlands, the participation rate was 69% in strongly urbanised areas compared with 
82%  in  not  urbanised  areas  (Fracheboud  et  al.,  1998).  In  England,  a  marked 
geographical gradient from a participation rate of 60% in North West Thames Region 
to 83% in Northern Region during the prevalence screening round almost disappeared 
during the incident screening rounds (NHS  Breast screening programme, 1997). The 
gradient in the participation rate in Denmark from 71  %in Copenhagen to 88% in Fyn 
county  during  the  prevalence  screening  round  is,  thus,  in  accordance  with  the 
experience in other countries. 
There is a marked difference between the programmes in the percent of participants 
recalled for assessment, with England and Copenhagen at the top of the list. There is 
clearly a wider difference between the recall rates than between the incidence of breast 
cancer in the various regions. The differences in recall rates  will  therefore result in 
differences in the proportion of women with false positives results, and potentially also 
in different interval cancer rates. 
Copenhagen has the highest detection rate of 11.8 per 1000 in the first invitation round. 
However, the detection rate in Fyn, at 9.8 per 1000, is close to that in Copenhagen, and 
the  difference between these two  Danish  areas  is  compatible with  the  overall  15% 
regional difference in breast cancer incidence (Andreassen et al.,  1994). Twelve per 
cent of the cases detected in the Copenhagen programme were CIS. This proportion is 
relatively low compared with other screening programmes, and it reflects a deliberately 
conservative attitude towards supposedly benign microcalcifications. 
Outcome measures 
While data on breast cancer mortality continue to be unavailable, the potential outcome 
of a screening programme must be assessed from short-term surrogate measures (Day 
et  al.,  1989).  The  detection  rate  in  the  screening  programme  compared  with  the 
background breast cancer incidence is a first indicator of the success of a programme. 
169 Table 2.  Results from the first invitation round in selected populations based on service 
screening programmes with mammography (modified from Lynge, APMIS Suppl. 83,  106, 
1998) 
Copen- England  Holland  Uppsala  Finland  Nordbotten 
hagen  Vaster-
Norrland 
Screening age group  50-69  50-64  50-69  40-69  50-59  50-69  (years) 
First invitation round  1991-93  1994-95  1990-95  1988-89  1987-88  1991-93 
Reference  1  2  3  4  5 
Participants in  71%  75%  79%  87%  88%  89%  percent of  invited 
Percent of  participants  6.8%  7.2%  1.3%  4.6%  4.5%  2.1%  recalled for assessment 
Percent of  participants  2.0%  0.7%  1.0%1  0.9%
2  0.9%  NA  with surgery 
Detected me + CIS 
11.8  5.9  6.8 1  4.8  4.7 
3  NA  per 1  000 participants 
CIS in percent of  12%  19%  14% 1  11%  - NA 
ffiC+CIS 
Percent of  recalled  17%  8%  48%
1  10%  8%  NA 
withffiC+CIS 
Percent of  women 
with surgery with  60%  59%  66% 1  53%  42%  NA 
ffiC+CIS 
Percent of  false  5.6%  6.6%  0.7%
1  4.1%  NA  positive  -
!.  These results refer to first screened women commg from different InVItation rounds 
2  Aspiration cytology only 
3Defined in original paper only as 'cancers'. 
References : 
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1 NHS Breast Cancer Screening Programme, 1997 
2 Fracheboud et al., 1998 
3 Thurfjell and Lindgren, 1994 
4 Hakama et al., 1995 
5 Lenner and Jonsson, 1997 
6 Sundhedsstyrelsen, 1997 
Fyns 
Amt 
50-69 
1993-95 
6 
88% 
2.7% 
1.3% 
9.8 
16% 
36% 
74% 
1.8% In the WE-trial these ratios were 3.09 for women aged 50-59 years and 4.59 for women 
aged 60-69 years (Day et al.,  1989). Table 3 shows the detection rates for invasive 
breast cancers and carcinoma in situ cases in Copenhagen compared with the incidence 
of invasive breast cancer in the period prior to the screening programme. The ratios 
between the two sets  of rates  varied from  about 3 to  about 6 for  all  age  groups of 
women screened for the first time. 
Table 3. Detection rates in the Copenhagen mammography screening programme 
compared with the breast cancer incidence in Copenhagen prior to screening (modified 
from Lynge, APMIS Suppl. 83, 106, 1998) 
Age group (years)  50-54 
Rate 
(per 10
4
) 
Incidence of me  21 
Copenhagen 
1986-90 
Detection IBC +CIS 
First screen 
-first IR 1991-93  72 
- second IR 1993-95  41 
- third IR 1995-97  52 
Detection IBC+ CIS 
Second screen 
- second IR 1993-95  47 
- third IR 1995-97  25 
Detection ffiC+ CIS 
Third screen  671 
-third IR 1995-97 
ffiC: Invasive breast cancer 
CIS: Carcinoma in situ 
IR: Invitation round 
OlE 
(1) 
3.4 
2.0 
2.5 
2.2 
1.2 
3.21 
1Based on less than 5 observed cases 
55-59 
Rate 
{per 104) 
24 
100 
112 
921 
38 
79 
53 
60-64  65-69 
OlE  Rate  OlE 
Rate  OlE  {per 104)  (per 104) 
(1)  29  (1)  27  (1) 
4.2  127  4.4  154  5.7 
4.7  172  5.9  114
1  4.i 
3.81  1311  4.51  203  7.51 
1.6  70  2.4  77  2.9 
3.3  561  1.91  214  7.9 
2.2  78  2.7  51  1.9 
The  participation  rate  is  a  second  key  indicator  for  the  potential  success  of a 
programme. It is common practice to calculate the participation rate as the number of 
screened  women  as  a  percentage  of those  invited.  However,  in  Copenhagen  it  is 
171 possible for women to ask not to be invited. The participation rate of concern for the 
potential reduction in breast cancer mortality in Copenhagen is therefore rather the 
number of screened women as a percent of the target population. Table 4 shows that 
the participation rate calculated, using the invited women  as  the denominator,  has 
remained stable at about 70% throughout the three invitation rounds. 
Table 4.  Participation rates in the Copenhagen mammography screening programme 
(modified from Lynge, APMIS Suppl. 83, 106, 1998) 
Participants as  Participants as  Participants as 
Percent of invited,  Invitation round  percent of  target  percent of invited  'regularly screened' 
1 
population  women 
1  71%  71%  71% 
2  65%  69%  83% 
3  63%  70%  90% 
1 'regularly screened': those who participated in all previous rounds 
Table 5 shows the proportionate interval cancer rates between the frrst  and second 
invitation rounds from selected progranimes. The data from the WE study in Sweden 
(Tabar et al., 1992) are from the randomised trial, while the data from the two areas in 
England (Day et al., 1995; Woodman et al., 1995; McCann et al., 1997) and from the 
Netherlands  (Schouten  et al.,  1998)  are,  like  the  Copenhagen  data,  from  service 
screening programmes. The WE trial had a proportionate interval cancer rate of 0.24 
within the first two years after the screening, at a  'cost' of 4.4%  women with false 
positive results. The Copenhagen service programme did worse on both indicators, as 
the proportionate interval cancer rate was 0.34, at a  'cost' of 5.6 %  false positives. 
However, compared with the English service programmes, Copenhagen did relatively 
well. 
Population flow 
In  the evaluation of the prospects for a later reduction in breast cancer mortality in 
Copenhagen, the continuous flow in and out of the target population should be taken 
into account. The major part of this is of course due to the inclusion and exclusion of 
different birth cohorts in successive invitation rounds. In the long term, this would, 
172 Table 5. Proportionate interval cancer rate and false positive percent in first invitation 
round of  selected mammography screening programmes (modified from Lynge, APMIS 
Suppl. 83, 106, 1998) 
Proportionate interval cancer rate 
0-11 
Type of  Location  Ref.  Age  months 
programme  years 
Service  Copenhagen  50-69  0.21 
Trial  Sweden WE  1  50-69  0.17 
Service  England,  2  50-64  0.24 
EastAnglia 
Service  England,  3  50-64  0.31 
N.  Western 
Service  Limburg, The  4  50-64  0.31 
Netherlands 
References:  1 Tabar et al., 1992 
2 Day et al., 1995, McCann et al., 1997 
3 Woodman et al., 1993 
4 Schouten et al., 1998 
12-23  0-23 
months  months 
average 
0.48  0.34 
0.30  0.24 
0.59  0.42 
0.52  0.42 
0.60  -
False 
positive 
% 
5.6 
4.4 
5.0 
-
-
however, not affect the programme as all women would be offered 11  screens between 
their 50th and 70th birthdays. There is, however, an additional population flow due to 
movements in and out of Copenhagen and due to deaths. To illustrate the size of this, 
we  have looked at  women born between  1 April  1925  and  1 April  1941  and,  thus, 
potentially included in the target population for all three invitation rounds. 
In  total 34 405 women were born between 1 April 1925 and 1 April  1941  and were 
included in the target population for either the first, the second or the third invitation 
rounds. Among these women,  27  894, equal to 81%,  were included in all the three 
173 target populations.  The remaining 6511  women  were  present in the municipality of 
Copenhagen for only part of the six years from April 1991 to March 1997. Of the 27 
894 women, 15 898, equal to 57%, were screened three times. At the third invitation 
round, the 15  898 women who had been screened three times constituted 53% of the 
target population of women born between 1 April 1925 and 1 April 1941. 
The relatively low participation rate, combined with the population flow explain why 
many of the breast cancer cases diagnosed in women aged 50-69 in Copenhagen after 
April  1991  do  not  come  from  the  screening  programme.  Table  6  shows  a  cross 
tabulation  of the  incident  invasive  breast  cancer  cases  detected  in  the  screening 
programme and the incident invasive breast cancer cases diagnosed in Copenhagen in 
the age groups and periods which were the target of the screening programme.  We 
have included here only the two frrst invitation rounds, because we wanted to use the 
data from the Danish Cancer Registry in order to ensure that all incident cases were 
included in the comparison. By the time of the study, the Danish Cancer Registry was 
only fully updated for 1994. 
Table 6.  Incident invasive breast cancer cases in women aged 50-69 in Copenhagen April 
1991 to May 1995 by status in the screening programme (modified from Lynge, APMIS 
Suppl. 83, 106, 1998) 
Status in the Danish 
Cancer Register 
Before April 1991 
April1991-April19913 
May 1993-May 1995 
After May 1995 
Missing 
Total screen detected 
me 
me: Invasive breast cancer 
CIS: Carcinoma in situ 
.. :  Not relevant 
174 
me in first  me in 
invitation  second 
round  invitation 
round 
7  6 
290  3 
16  122 
0  6 
3  9 
316  146 
Screen  Not  Total 
detected  screen 
CIS  detected 
..  ..  .  . 
6  188  487 
5  116  259 
..  ..  .  . 
..  ..  .. 
..  ..  .. Cancer register data 
Table 6 shows that the majority of the screen detected cancers were found among the 
cases recorded in  the same  time  period in  the  cancer register.  A  small  number of 
women with screen detected cancers were registered in the cancer register with a date 
of diagnosis before screening. These are women with two primary breast cancers, and 
their second cancer detected at screening. As expected, a small number of women with 
screen detected cancers were found in the cancer register with dates of diagnosis after 
the end of their invitation round, due to delay in assessment and surgery. Finally, some 
screen-detected cancers were missing in the Danish Cancer Registry especially from 
the  second invitation round which  ended in  May  1995.  In total,  61  % of the  487 
incident invasive breast cancers diagnosed in women aged 50-69 in Copenhagen at the 
time of the first  invitation round  were  screen  detected,  and 55%  of the  259  cases 
diagnosed at the time of  the second invitation round. 
Data from the Danish Cancer Registry was used to identify second primaries among 
the screen detected cancers, to calculate detection rates for each screening round, to 
calculate proportionate interval cancer rates and to measure the screen detected cancers 
as  proportion of all breast cancers diagnosed in the area. Thus, this cohort study would 
not  have  been  possible  without  access  to  long  term  data from  a  population-based 
cancer registry.  However, the relatively slow process of producing complete cancer 
registry data for a calendar year was a problem and independent clinical databases with 
more up to date data were used in addition. 
A cohort study of  breast self-examination 
A  cohort  of women  who  took  part  in  the  'Mama'  breast  self-examination  (BSE) 
screening program in Finland from 1973 through 1975 (with BSE used for screening, 
and mammography for diagnosis) was  studied (Gastrin et al.,  1994). In total, 28785 
women who returned calendars recording their practice of BSE over a 2-year period 
were followed by linkage with the  records  of the Finnish Cancer Registry  through 
1986.  The incidence  of and  mortality  from  breast cancer was  compared  with that 
expected in the Finnish population, based on a model incorporating Finnish national 
data for breast cancer incidence and case fatality. 
In the study cohort, breast cancer incidence was higher than  expected (a rate ratio of 
1.19 over all ages). The stage distribution of  cases was not different from that expected 
from Finnish Cancer Registry data for 1980, but breast cancer mortality was lower than 
expected (a rate ratio of0.75). 
175 The authors state that the reduction in mortality from breast  cancer in the study cohort 
was  consistent  with  an  effect  of  BSE,  though  selection  bias,  inherent  in  any 
observational study of screening, provides a plausible alternative explanation for the 
findings.  The participants  (as  in  other studies of breast cancer screening compliers) 
came from  higher social classes and  had  a higher educational  status  than  the non-
participants or the general population. All cause mortality among the participants was 
lower than that among comparable general population (rate ratio 0.70). Thus, the lower 
breast cancer mortality among the participants (rate ratio 0.75) is difficult to ascribe to 
the screening. The conclusions have been challenged by another Finnish study using 
the survival analysis approach (Auvinen et al.,  1996).  Another large  study reported 
negative results in relation to BSE practice, as reported by 548 000 US women in 1959 
(Holmberg et al., 1997) 
Conclusion on cohort studies assessing breast cancer screening 
Breast cancer screening programmes  are  being implemented and planned in  several 
countries.  Population-based cancer registries  will  provide essential background data 
and later they will be involved in the monitoring of the programmes. The launching of 
a new programme provides an opportunity to plan large-scale population-based cohort 
studies. Thus, cancer registries should be active in the early design and planning phases 
of screening  programmes,  and  seriously  examine  the  possibilities  of prospective 
(cohort) studies of outcome at the population level. Such studies can provide important 
information  on  the  performance  of the  programme  in  a  service  setting,  thereby 
suggesting  the  need  for  modification  or  improvement  of  different  aspects,  and 
justifying (or otherwise)  the  expenditure of funds  on the  programme.  However,  in 
addition to complete registration (so that all incident breast cancer cases are detected), 
and  effective  linkage  to the  screening register (to  distinguish  screen detected from 
interval cancers),  cancer registries  will  generally  have to  improve  upon the routine 
mechanisms for recording size and stage of registered cases. They will, in  addition, 
have  to  devise  methods  for  producing  timely  results  with  enhanced  case-finding 
mechanisms for the cancer(s) of interest, and preparation of interim analyses before the 
usual  "Annual  Report",  often  delayed  until  reporting  of all  cancers  is  virtually 
complete. 
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179 Chapter 12.  Cancer registries in monitoring, evaluating and planning 
breast cancer screening programmes 
D. Stockton and J. McCann 
The  aim  of breast  screening  programmes  is  to  reduce  breast  cancer  mortality 
through early detection of breast cancers, which has been shown to improve the 
chance of successful treatment. Cancer registries can help ensure that a programme 
has  every  opportunity to  achieve  the  mortality  reduction  by  being  involved  in 
identifying problems in the programme at an early stage so that remedial action 
can be taken. 
When a screening programme is introduced the anticipated mortality reduction will 
not be seen for a number of years but will depend largely on three aspects of the 
programme (Day et al., 1989): 
a)  the compliance rate 
b)  the rate of interval cancers 
c)  the distribution of prognostic indicators among screen-detected and interval 
cancers 
The routine monitoring of screening performance cannot easily be undertaken by 
cancer  registries  because  of the  time  lag  between  diagnosis  and  registration. 
However, cancer registries can play a large role in evaluating the programme both 
looking at interim indicators and end point indicators of success (Figure 1). 
The importance of the cancer registry is that it provides information on the whole 
population  of women  invited  for  screening  - not  just  those  who  accept  the 
invitation. Thus it provides information on the population impact of screening. 
The following chapter looks at tools used to monitor and evaluate breast cancer 
screening programmes, with particular attention to areas  where cancer registries 
can make a contribution. 
181 REGISTRY 
FUNCTIONS 
Figure 1.  The key cancer registry functions in evaluating screening programmes 
Monitoring compliance 
Even though it is usually not the role of the cancer registry to monitor compliance 
of women attending screening, it is important when evaluating a programme to be 
aware  of compliance  rates  as  programme  success  relies  on  consistently  high 
compliance over progressive screening rounds. 
The non-compliers (or non-attenders) will include women who did not receive an 
invitation to come for screening due to administrative errors (wrong address details 
etc.) and those who chose not to attend. In  the latter group there are those who 
have never attended screening and those who have attended a screening test but 
subsequently stopped attending. 
Administrative errors 
These can be minimised, particularly by checking population lists for accuracy. 
Never attender 
It has been widely seen that non-attenders have a worse prognosis than unscreened 
control populations (Duffy et al., 1991). This may be due, in part, to women who 
already have symptoms not attending screening due to denial or fear.  Other non-
attenders may not appreciate the importance of regular mammography and they 
should be encouraged by providing more information on the benefits of screening, 
sending  out  appointment  reminder  letters,  and  by  having  a  more  flexible 
appointment system (Lidbrink et al., 1995). 
182 It has been shown that compliance can be improved by re-inviting, either with an 
open or fixed appointment, women who did not attend their initial invitation in a 
particular screening round, particularly if the letter is sent via or signed by their 
personal physician (Dinnes et al.,  1997). Specific groups of women may need to be 
targeted  in  different  ways,  for  example,  one  study  found  that  variations  in 
compliance by general practice were closely related to social deprivation and there 
was some evidence that contact with a female GP was beneficial (Gatrell et al., 
1998). 
Monitoring interval cancers 
Interval cancers are related both to the sensitivity of a screening programme (i.e. 
how good the programme is  at picking up cancers) and the length of the inter-
screening interval (frequency with which screening is performed). The monitoring 
of interval cancers requires the results of, at least, the second round of screening in 
order to define the results over an entire screening round, i.e. interval cancers from 
just after  the  prevalence  screen  to just before  the  second  screening,  plus  the 
cancers detected at the second  screening.  This  group of cancers is termed the 
'unbiased set' (Tabar et al., 1992). The initial prevalence screen must be excluded 
due to length bias, i.e.,  the detection,  at screening, of a  large number of good 
prognosis  cancers  which  might  never  present  symptomatically  in  a  woman's 
lifetime (Morrison, 1992). 
The cancer registry is essential for identifying interval cancers. Sensitive record 
linkage  between  the  cancer registry  and  screening programme  is  necessary  to 
ensure that cases are not missed.  It should be possible to categorise all cancers 
registered at the cancer registry, in women in the screening age range, into one of 
the following categories of interest (McCann et al., 1998): 
a)  Screen-detected cancer 
b)  Interval cancer 
c)  Cancer in non-attender 
d)  Cancer in lapsed attender 
e)  Cancer in woman not yet invited 
The  sensitivity  and  specificity  of  the  record  linkage  should  be  continually 
assessed, as it is  important to accurately categorise the cancers, particularly the 
screen-detected and interval cancers, otherwise monitoring and evaluation of the 
programme will be compromised. Problems will arise if the registry does not have 
high  case ascertainment or does  not cover the whole  screened population.  For 
example,  if the  registry  case  ascertainment  is  in  general  quite  low  but  the 
183 ascertainment of screen-detected cases is high (due to good information exchange 
between the registry and screening programme), bias will be introduced making 
the rate of screen-detected cancers look artificially high in comparison to the rate 
of cancer in the other categories. The screening programme may also link to death 
records,  hospital  admission  and  discharge  records  or pathology  laboratories  to 
ensure that no cases are missed. 
Once all the identified cancers have been assigned to one of the above-mentioned 
categories, the rate of interval cancers can be calculated using woman-years at risk 
as  the denominator. Three different methods for calculating the woman-years  at 
risk have been compared by the Scottish breast screening programme (Everington 
et al., 1999): 
Method 1: Number of women screened negative. 
Method 2: Adjusting the number of women screened negative at three time periods 
(1,  2 and 3 years  after the last screen)  by  removing  women  who  had been re-
screened  or diagnosed  with  cancer  before  that  time  period.  Thus,  all  women 
contribute one, two or three years to the woman-years at risk. 
Method 3: Person-time elapsed between the date of the last negative screen and the 
date of re-screening or diagnosis of cancer, truncated at 3 years if this occurs later 
than 3 years. 
They estimated the underlying incidence rate by (a) extrapolating 1978-87 trends 
within  each  age  band  up  to  1991  and  then  using  the  1991  estimate  for  all 
subsequent  years,  and  (b)  using  an  age-period  Poisson  regression  model.  The 
number of cancers expected in the absence of screening was then calculated using 
the three estimates of the person-years and the two estimates of the underlying 
incidence rates. 
In their analysis, they found that the expected number of cancers estimated by the 
computationally  intense  methods  (methods  2  and  3  with  age-period  Poisson 
regression models) were not substantially different from those obtained by method 
1 with trend extrapolation (Table 1  ). 
The definition of an interval cancer can have an important effect on the calculated 
interval cancer rates. If a programme is falling behind in  the invitation schedule 
and  re-inviting  women  beyond  the  agreed  screening  interval,  should  interval 
cancers  that  occur  during  this  "slippage  time"  (i.e.  beyond  three  years)  be 
included? In  evaluating the overall success of a screening programme, it would 
seem  appropriate  to  include  interval  cancers  arising  in  slippage  time.  This  is 
because slippage may be seen as a failure of the programme. 
184 Table 1.  Comparison of the Scottish results for women screened in 1991-1992 using 
the different methods of  calculating the underlying incidence (method a or b) and 
person-years at risk (methods 1, 2 or 3) 
Methods (as  0- <12 months  12 - <24 months  24 - <36 months 
described in text)  since last negative  since last negative  since last negative 
screen  screen  screen 
Rate  Exp.  Rate  Exp.  Rate  Exp. 
1 and a  4.6  182  11.5  182  12.3  182 
2 and a  4.6  181  11.8  178  12.7  176 
2 and b  4.6  183  11.8  183  12.7  186 
3 and a  4.6  179  11.8  176  13.5  165 
3 and b  4.6  179  11.8  181  13.5  175 
The interval cancer rates per 10 000 women years at risk are shown in bold and the 
expected number of  cancers are shown in italics 
However,  when  evaluating  the  effectiveness  of a  screening  test  in  detecting 
cancers, it may  be important not to include interval cancers arising outside the 
screening interval. Round slippage will vary between screening programmes (Faux 
et al.,  1998) and so it is important to study the interval cancers occurring both in 
the  agreed  interscreening  interval  and  in  slippage  time  when  evaluating  the 
appropriateness of the screening interval. 
If  interval cancer rates are higher than expected, based on set standards
1
,  special 
studies  should be performed to evaluate the  extent to  which this is  due to low 
sensitivity of the programme (e.g., the quality of mammography, the experience of 
the radiologist, or the problems when women are recalled for assessment) or the 
screening interval being too long. Alternatively, it may be necessary to revise the 
standards (Moss and Blanks, 1998) 
1 
Current standards are derived from screening trials rather than population-based screening programmes and 
may be artificially high. Now that population-based screening programmes have been running a number of  years 
these standards should be refined. 
185 Monitoring tumour characteristics 
If  cancer registries are to help monitor a screening programme, it is very important 
that  they  collect information  on  tumour  pathology  including  histological  type, 
grade, size and nodal status. It is advantageous if this has also been collected for 
cases diagnosed before the screening programme began. 
Tumour characteristics that determine breast cancer survival have been identified. 
Comparison  of  the  distribution  of  these  characteristics  between  the  cancers 
diagnosed over a screening cycle and those diagnosed in an unscreened population 
gives a direct estimate of the effect of screening in improving prognosis. If  there is 
a shift towards a more favourable distribution of these tumour characteristics, then 
it is likely that screening will have the desired effect of reducing mortality. 
Duffy et al.  (1991) investigated which prognostic factors recorded in the Swedish 
two-county study had the largest effect on survival, using multivariate analysis. 
They  showed  that  the  favourable  prognosis  of screen-detected  (not  including 
prevalent  screen)  cancers  could  be  largely  accounted  for  by  three  tumour 
characteristics: size, nodal status and grade. 
High interval cancer rates indicate that a screening programme is not performing 
as well as  it could be. However, comparing the tumour characteristics of interval 
cancers with those in the other categories, especially those among women in the 
'not  yet invited' category,  should indicate  whether a screening programme  with 
high interval cancer rates might still be successful in reducing mortality. Burrell et 
al.  (1996) compared the size, grade and lymph node status of interval cancers in 
their programme with  cancers in  an  unscreened control group  and  with  screen-
detected cancers over the same time period. They found that the interval cancers 
had  a significantly worse distribution of tumour characteristics than the  screen-
detected cancers but a similar distribution to the control group cancers, indicating 
that the interval cancers are no worse than those that would arise in the absence of 
screening. Their programme should, therefore, have some impact on mortality, but 
not as  great as  would be the case with a lower interval cancer rate. Frisell et al. 
(1992)  reported  that  interval  cancers  in  their  programme  also  had  a  similar 
distribution of prognostic indicators to those in  an unscreened control group, but 
the overall survival by stage was consistently higher among the patients diagnosed 
with  interval cancers compared with those in  the control group.  In  the  Swedish 
two-county  study,  the patients  with  interval  cancers had  slightly  better survival 
rates than the controls (Duffy et al., 1991). 
Collins et al. (1998) investigated whether the survival rate for women with interval 
cancers in their programme was different from the rates for women diagnosed with 
186 cancer in an  unscreened population.  Interval  cancer rates  had been  higher than 
expected and it was of interest to determine what effect this would have on the 
reduction in mortality in the population invited for screening. When choosing an 
unscreened population to use as controls, they first ruled out two groups (1) non-
attenders, because they had been shown to have a worse outcome than controls in 
the Swedish two-county study, and (2) historical cases, because of recent advances 
in managing breast cancer.  Due to the phased introduction of screening in their 
programme, they  were  able  to  use  women  not yet  invited to  screening as  their 
control  group.  They  found  no  significant  difference  in  survival  between  the 
patients  with  interval  cancers  and  the  controls,  again  indicating  that,  in  their 
programme, the interval cancers were not a subset of more aggressive tumours. 
As well as monitoring interval cancers, it is important to study the distribution of 
tumour  characteristics  in  other categories.  However,  care  must  be  taken  when 
reporting analyses  by  prognostic  categories.  For example,  in  the  first  round  of 
screening a wide variety of tumour types and sizes are picked up and it is expected 
that many small and fairly benign tumours will be detected that would either not 
have presented clinically until  a long time  into the  future  or might  never have 
presented  at  all  (so  called  'length  bias').  For  this  screen,  studying  the  size 
distribution of tumours would give an artificial appearance of a big reduction in 
large tumours. Until the screening programme is stable, i.e. the overall incidence 
rate has come back down to a level approaching the expected underlying incidence 
rate (although it might be a bit higher due to a "detection age shift" - older women 
with  higher incidence being  detected  at  an  earlier  age),  tumour characteristics 
should not be monitored using proportions. 
Furthermore,  when  investigating  the  distribution  of prognostic  indicators,  one 
needs  an  overall  picture  of how  the  programme  is  performing.  Therefore,  in 
evaluating a specific screening round, sufficient time should be allowed, i.e. up to 
the  next  screening  round,  so  that  all  interval  cancers  can  be  included  in  the 
analysis. There may be a very favourable distribution of prognostic indicators in 
the screen-detected cancers, but this will not give a good indication of how the 
programme is performing, if interval cancer rates are high or these cancers have a 
particularly poor prognosis. As  screening will detect slow-growing cancers with 
good  prognosis,  whereas  fast-growing  cancers  will  become  apparent  between 
screens,  we  would  expect  the  distribution  of prognostic  indicators  to  be  very 
different between the screen-detected and interval cancers. 
In Table 2, the incidence rates by TNM stage are shown, both prior to and during 
screening,  for  the  East  Anglian  programme,  UK  (McCann  et al.,  1998).  The 
programme  was  phased  in  from  1989  and  most  women  had  been  invited  for 
screening for  the  first  time  by  the  end  of 1993.  By  1995,  virtually  the  entire 
population of women aged 50-69 would have received at least one invitation to 
187 screening. As the table shows, during the first screening round the rates of early 
and advanced stage cancers are difficult to interpret, particularly with the effect of 
the staggered introduction; thus, comparing the proportions would be misleading. 
In  1995  most  women  were  undergoing  their  second  screening  but  the  total 
incidence for the 50-69 year olds  was  still quite a bit higher than the expected 
underlying incidence (see next section) so the data should still be interpreted with 
caution. 
The rate of advanced cancer obtained with the screening programme in place can 
be compared with the expected underlying incidence rate of advanced cancer (see 
next section) to evaluate how the programme is performing. If  the programme is to 
be successful in  reducing mortality, an  early indicator would be a lower rate of 
advanced  cancer  compared  with  the  estimated  underlying  incidence  rate  of 
advanced cancer. 
Table 2.  Incidence rates of  invasive breast cancer by TNM stage in the 50-69 year age 
group. Rate per 100 000 women in the East Anglian region 
Year of  1981- 1987- 1989  1990  1991  1992  1993  1994  1995 
diagnosis  1986  1988 
Early stage  55.5  76.1  89.1  141.0  159.8  141.9  123.6  141.3  118.8 
(stage 1) 
Advanced  131.4  162.1  158.9  140.5  129.2  109.9  133.7  135.4  131.8 
(stages 2,3,4) 
Total (incl.  196.4  245.0  256.2  288.8  297.3  257.4  262.8  281.7  253.3 
unknown 
stage) 
Proportion of  70%  68%  64%  50%  45%  44%  48%  49%  53% 
advanced 
Schouten et al.  (1998) found that, immediately after the introduction of screening, 
the annual number of breast cancer diagnoses increased by almost 50% and then 
188 decreased  to  previous  levels  after  completion  of  the  first  screening  round. 
Evaluating  cases  diagnosed  in  the  second  screening  round,  they  compared 
incidence by prognostic factor with that seen in a period directly before screening 
began (1987-1990). They found that the incidence of node positive tumours was 
1%  lower  in  1994  and  15%  lower  in  1995,  indicating  that  the  screening 
programme was having the desired effect of improving prognosis, which  should 
lead to a mortality reduction. 
Hakama et al.  (1995) compared size, nodal status and histological type of breast 
cancers in a population of women invited to screening with those diagnosed among 
unscreened controls. They designed the study to  avoid length bias by excluding 
cancers detected in the first screening round. They found that the cancers detected 
in the population invited to screening (screen-detected, interval and non-attend.er 
cancers  combined:  the  unbiased  set)  had  a  better prognosis  than  the  controls, 
indicating  that  their programme  should  also  bring  about  a  reduction  in  breast 
cancer mortality. 
Monitoring and interpreting time trends 
An estimate of what the incidence of breast cancer would have been in the absence 
of screening (the underlying incidence rate) is  essential in  order to  evaluate the 
performance of a breast screening programme. For example, in order to estimate 
the magnitude of a reduction in late stage cancers, an estimate of what the rate of 
late stage cancers would have been in the absence of screening is needed. In order 
to calculate the proportionate incidence of screen-detected and interval cancers, an 
estimate of what the overall rate of breast cancer would have been in the absence 
of screening  is  required.  Cancer  registries  are  very  important  for  evaluating 
screening programmes that do  not have  a contemporaneous  unscreened control 
group since they can estimate the ''underlying" incidence rates.  The three  most 
widely used methods for estimating the underlying incidence are: 
a)  Extrapolating pre-screening trends in incidence using statistical modelling 
procedures. 
b)  Using, as fixed, the rate of breast cancer seen directly before screening began, 
i.e. assuming that incidence in the absence of screening would have been 
static. 
c)  For programmes with a phased introduction of screening, using the rate of 
cancer seen in women of screening age who have not yet been invited to 
screening. 
Of these, the  most commonly  used method is  (1)  as  it can be  adopted  by  any 
registry that has collected numerous  years  of accurate data prior to the  start of 
189 screening. If  trends by tumour characteristics are to be extrapolated, then complete 
information about these must also have been collected historically by the registry. 
If  the incidence rates do not increase equally in all age groups, the trends must be 
analysed separately for each age  group or a more complicated model should be 
adopted. 
Before the introduction of screening, an upward trend in the incidence of breast 
cancer was observed in many countries. Some studies suggested that cohort, rather 
than calendar period, effects are the cause of this upward trend (Quinn et al. 1995). 
If  it is known that strong cohort effects were in force, trend extrapolation will not 
be valid. However, many years of data are needed to demonstrate cohort effects 
and,  as  this quantity of data is not always available, most studies still use trend 
extrapolation to estimate the underlying incidence rate. 
Prior et al.  (1996) used an age-period model to predict the underlying incidence 
rate. The age-specific rates were fitted using Poisson regression models with the 
population as  a weighting factor,  and a year by age interaction term was added. 
Prediction intervals were calculated to reflect the statistical uncertainties that arise 
when extrapolating beyond the range of available data. From their analysis, they 
concluded that the rate of breast cancer was increasing prior to the introduction of 
screening  and  that  the  use  of one  incidence  rate  for  all  age  groups  was  not 
appropriate since the rate of increase in incidence varied between age groups. The 
observed and predicted underlying incidence of breast cancer from their analysis is 
shown in Figure 2. 
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Figure 2.  Oberved and predicted underlying incidence of breast cancer in the UK 
(Prior et al.,  1996, J Med Screen 3:119-122; by permission ofBMJ Publishing Group) 
190 The importance of "exploring" the data before performing trend analyses cannot 
be stressed enough.  The genuineness of increasing trends in  incidence must be 
established since observed increases could actually be due to improved reporting 
to the registry or a change in the diagnostic procedures. If  there is any doubt about 
the validity of the data, trend extrapolation must not be used. 
McCann et al. (1998) found a marked and unexplained increase in the incidence of 
advanced  and  total  breast cancer in  the  two  years  prior to  the  introduction of 
screening in East Anglia, UK, compared with only a slight upward trend seen over 
the preceding 10 years. This complicated their trend extrapolation. The difference 
between the trends when including and excluding the data for these two years is 
shown in Figure 3. 
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Figure 3.  Extrapolated trends (1976-86 and 1976-88) showing the possible range of 
the underlying incidence rate of advanced breast cancer in women aged 50-69 in East 
Anglia 
In this study, the analysis of the data using methods (2) or (3) described earlier was 
also  complicated  by  the  increase  in  incidence  in  1987  and  1988  since  it  was 
unclear whether the increase was  real  (and so  would have continued) or was  an 
artefact. Indeed, looking at the predicted rate of advanced cancers using the three 
191 methods above, the predicted rates using data for 1987 and 1988 are very similar, 
whilst the predicted rate excluding 1987 and 1988 shows a different picture (Table 
3). Which is correct? Interpretation of results is not always simple and analyses 
should be embarked upon with caution! 
Table 3.  Predicted rate of advanced cancer in 1997 in East Anglia using the three 
methods to calculate the estimates 
Method  Description of method  Observed  Expected  Percent 
rate  rate  reduction 
(%) 
1  Extrapolating advanced cancer  129.3  136.5  5.3 
incidence trends from 1976-86 
1  Extrapolating advanced cancer  129.3  162.8  20.6 
incidence trends from 1976-88 
2  The proportion of advanced cancer in  129.3  162.5  20.4 
1988 applied to the 1997 cases 
3  The proportion of advanced cancer in  129.3  163.5  20.9 
women  not  yet  invited  to  screening 
applied to the 1997 cases 
In  conclusion, routine monitoring of breast screening programme performance is 
largely undertaken by the programme itself due to the inevitable time lag between 
cancer diagnosis and registration, and the restricted number of data items collected 
by cancer registries. However, cancer registries can and do play a very important 
role in evaluation, particularly of the impact of screening in the whole of the target 
population. 
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194 Chapter 13.  Population-based trends of  prostate cancer in the 
United States before and after widespread use of  PSA 
R.A. Stephenson 
Introduction 
In the late 1980s, physicians in the United States and elsewhere began to recognise 
the  potential  usefulness  of prostate  specific  antigen  (PSA)  in  the  detection  of 
prostate cancer (Catalona et al.,  1991; Crawford and DeAntoni.,  1993; Catalona et 
al., 1994  ). Based on the promise of enhanced prostate cancer detection, use of PSA 
testing  rapidly  gained  acceptance  and  widespread  use  in  the  United  States.  A 
substantial literature now clearly demonstrates improved prostate cancer detection 
with  the  addition  of PSA  testing  to  previously  available  detection  methods 
(Catalona et al.,  1991; Crawford and DeAntoni, 1993; Catalona et al., 1994). PSA 
based detection is now widely prevalent in the United States (Potosky et al., 1995). 
In some regions of the United States by the mid 1990s, nearly 50% of all men over 
the age of 40, and 70% of men over age 70 had undergone PSA testing (Mansfield 
et al., 1991; Close et al., 1998). 
Subsequent to widespread use of PSA based detection unprecedented changes in 
prostate cancer incidence rates  were  observed.  These  changes  in  incidence  had 
substantial effects on the characteristics of diagnosed prostate cancer cases through 
lead time  and perhaps  length  time  effects.  The  magnitude  of these  changes  in 
incidence  are  unique  in  the  history  of modem  oncology.  While  PSA  based 
community screening was  a part of early prostate cancer detection efforts,  most 
PSA based detection is now part of the routine pattern of care for men in the US 
Clearly,  despite  these  trends  in  the  United  States,  no  convincing  evidence  is 
available to support or refute PSA based detection strategies for prostate cancer. 
Population-based  mortality  effects,  and  survival  analyses  from  randomised 
screening  trials  are  not  currently  available.  Unfortunately,  we  are  left  with  a 
situation in which the appropriate role of PSA testing remains to be defined. In this 
setting  of  persisting  uncertainty,  different  philosophies  for  detection  and 
management of prostate cancer have emerged from different regions of the world. 
The United States  is  notable for  proactive PSA based detection  and  aggressive 
treatment,  while  Scandinavian  countries  are  notable  for  minimal  use  of PSA 
detection and largely conservative treatment approaches. 
In  this  paper,  population-based  temporal  trends  in  prostate  cancer  incidence, 
diagnosis,  grade,  stage,  age,  and  mortality data obtained from  the  Surveillance, 
195 Epidemiology and End Results  (SEER)  Program are being used to describe the 
effect of widespread use of PSA testing in the United States (Stephenson,  1998; 
Stanford et al., 1999). 
Incidence 
As seen in Figure 1, the incidence of prostate cancer rose gradually in the United 
States from the inception of the SEER Program in  1973  through the late  1980s 
(Stephenson,  1998; Stanford et al.,  1999). This gradual rise in incidence can be 
attributed either to changing environmental risk factors within the US  population, 
or to gradual improvement or increased use of diagnostic methods. Rates of TURP 
(transurethral resection of the prostate) diagnosed prostate cancer rose  gradually 
through  1987  in  the  United  States  (Merrill  et  al.,  1999).  The  rise  in  TURP 
diagnosed prostate cancer was  due to  increasing use  of TURP for  treatment of 
benign prostatic hypertrophy (BPH). Historically, 10 to 20% of BPH cases treated 
with  TURP  will  have  incidental  prostate  cancers  identified  in  the  removed 
pathological material (Newman et al.,  1982). Merrill and colleagues indicate that 
TURP diagnosed cancers account for nearly all of the increasing incidence rates of 
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Figure 1.  Prostate cancer. Incidence rates. SEER Program 1973-1995 
196 prostate cancer from 1973 through 1987 (Merrill et al.,  1999). After 1987 the role 
of TURP in the diagnosis of prostate cancer has  steadily declined. The rise and 
decline in TURP diagnosed prostate cancer rates are probably related to the rise 
and decline of TURP utilisation for treatment of BPH.  While the rise in TURP 
utilisation through  1987  likely  relates  to  increasing urological  manpower in  the 
United  States,  the  decline  in  TURP  utilisation  probably  relates  to  partial 
replacement  of TURP by effective pharmacological  treatments for BPH or less 
invasive  surgical  procedures  that  do  not  generate  pathological  material  for 
examination. 
Beginning in 1988 or 1989 prostate cancer incidence rates rose dramatically in the 
United States (Figure 1). These years are coincident with the rapid acceptance and 
use of PSA in screening and routine clinical detection. Incidence rates peaked in 
1992 and declined rapidly to rates approaching those prior to the widespread use of 
PSA. A change in incidence of this magnitude has never been previously observed 
for any cancer. While the increased prostate cancer incidence rates of 1988 to 1992 
are  probably  related  to  increased  use  of PSA,  the  reasons  for  the  decline  in 
incidence after 1992 are less clear (Figure 1). Factors related to declining PSA rates 
appear to include: (1) a cull phenomenon where fewer PSA detectable cancers are 
identified in repeatedly screened individuals and populations;  (2)  enthusiasm for 
continuing screening among  practitioners may  have declined as  they  recognised 
declining prostate cancer case yields among populations which were substantially 
contaminated by  previously screened,  low  prostate cancer yield individuals;  (3) 
screening activity in the United States may also have been inhibited by publications 
in  the  lay and  professional  media which  questioned  the  wisdom  of PSA based 
prostate cancer detection; and (4) little may  have been done to reach individuals 
who were not inclined to seek PSA testing or other forms of health care, resulting 
in a large fraction of the population in whom PSA testing was never performed. 
The relative contributions of these four factors and others are yet to be adequately 
measured and described. 
Grade 
Figure  2  shows  temporal  trends  in  prostate  cancer  grade  (Stephenson,  1998, 
Stanford et al.,  1999). In the SEER Program Gleason Scores are assigned in the 
following fashion: Gleason Scores 2-4 - good differentiation, Gleason Scores 5-7 -
moderate  differentiation  and  Gleason  Scores  8-10  - poor  differentiation.  A 
remarkable trend toward moderate differentiation is  seen as  the PSA era moves 
forward.  Approximately  75%  of the  increased  incidence  of the  PSA  era  are 
accounted for by moderately differentiated tumours, while only 8% of the increase 
were due to well-differentiated tumours. Even after 1992 when incidence rates 
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Figure 2.  Prostate cancer. Incidence rates by grade. SEER Program 1973-1995 
were in decline, the fraction  of cases  with moderate differentiation continued to 
increase.  This  predominance  of moderate  differentiation  during  the  PSA  era 
suggests  that PSA is  largely  unable  to  detect  the  large  prevalent pool  of well-
differentiated prostate cancer. Low-grade misclassification of tumours by relatively 
inexperienced pathologists in the 1980s would have had a negligible effect on the 
overall observed PSA era changes in incidence rates  by  grade.  Only  8%  of the 
increase in incidence of the PSA era were due to well-differentiated tumours, with 
roughly 1/3 of those classified as well differentiated. Even if all low-grade cancers 
were  incorrectly  graded  in  the  1980s  the  contribution  to  the  overall  increased 
incidence by well-differentiated tumours in the PSA era would have increased by 
only a few percentage points. While poorly differentiated cancers were detected in 
increased  numbers  during  the  PSA  era  the  magnitude  was  small  relative  to 
moderately differentiated tumours. This is probably due primarily to the  s~aller 
prevalence of poorly differentiated tumours in the population. 
These trends in prostate cancer grade are somewhat counter-intuitive with respect 
to length time issues. Typically during screening, cancers of even lower biological 
potential are detected due to repeat screening effects where slower growing cancers 
are more easily identified. As measured by grade no such effect is evident in SEER 
grade data. TURP diagnosed cancers of the pre-PSA era were commonly assigned 
well differentiated (typically designated by the stage Al category).  Such cancers 
198 are uncommonly identified in the PSA era. PSA appears to do the ideal thing by 
identifying cancers of greater biological significance while concurrently identifying 
these  cancers  at  time  points  when  they  are  more  amenable  to  therapy.  It  is 
important  to  state  that  grade  is  only  an  approximate  or  surrogate  indicator  of 
biological relevance or potential. It is highly likely that many cancers of the PSA 
era have  been  identified  which  have  insufficient biological  potential  to  require 
treatment. 
Stage 
Distant stage rates  have  declined by  more than  50%  in the PSA era (Figure  3) 
(Stephenson, 1998; Stanford et al.,  1999). Distant disease stage rates have declined 
in all age categories. Node positive rates (stage Dl) are also declining according to 
data from the Utah Cancer Registry (Mansfield et al., 1996). Concurrently, rates of 
local  and  regional  stage  have  increased  substantially.  Unfortunately  SEER 
abstraction rules make separating local and regional stages difficult. Nevertheless, 
rising  SEER prostate cancer incidence rates  taken  together with  falling  rates  of 
distant  stage  indicate the  presence  of substantial  trends  toward  early  diagnosis 
during the PSA era. Whether this documented stage migration results in beneficial 
lead  time  effects  where  early  diagnosis  leads  to  more  effective  treatment,  or 
whether  it  results  in  lead  time  bias  where  no  impact  on  mortality  is  observed 
remains to be resolved with future mortality data. 
Declining distant prostate cancer stage rates  may  be due to  a cull phenomenon 
where distant cases are either removed from the prevalent population, or, due to 
early detection do not reach  distant  stage  at diagnosis,  or both. It may  also  be 
possible that health care providers during the PSA era have become less inclined to 
screen  elderly  men  who  are  more  likely  to  have  distant  disease  at  diagnosis. 
However, data from the Utah SEER registry reveal that elderly men are more likely 
to undergo PSA testing than younger men (Mansfield et al., 1997). This indicates 
that disinclination to screen older men is not a significant factor in declining distant 
stage rates. 
Declining distant stage rates are a necessary but insufficient condition to be certain 
of future declines in mortality. Nevertheless, the fall of distant stage rates suggest 
that future declines in prostate cancer mortality are quite likely. 
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Figure 3.  Prostate cancer. Incidence rates of  distant stage. SEER Program 1983-1995 
Age 
Age at diagnosis has fallen sharply in the PSA era (Figure 4) (Stephenson,  1998; 
Stanford et al.,  1999).  An abrupt fall  in  age  began  in  1990  and  has  continued 
through  1995,  the  last  year  for  which  information  is  available.  Mean  age  at 
diagnosis  has  declined by  2.9  years  from  71.9  to  69.0 years  of age.  As  in  the 
staging  data  presented  above,  declines  in  mean  age  at  diagnosis  reveal  that  a 
substantial lead-time effect has occurred in the United States during the PSA era. 
As can be seen in Figure 4, mean age at diagnosis is likely to continue to fall in 
coming years based of the steep slope of present mean  age curves  1990 through 
1995.  In  a large cohort of men  with  serially  banked sera prior to  the PSA era, 
retrospective  analysis  of  PSA  testing  and  prostate  cancer  rates  established 
estimated lead time effects of approximately 4 to 5 years with use of PSA (Gann et 
al., 1995). 
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Figure 4.  Prostate cancer. Mean age at diagnosis. SEER Program 1983-1995 
Treatment 
The majority of patients diagnosed in the PSA era received aggressive treatment 
(radical prostatectomy, radiation therapy) (Figure 5)  (Stephenson,  1998; Stanford 
et al.,  1999). Radical prostatectomy became the most common type of treatment 
for  local  and  regional  prostate  cancer  in  1991.  Figure  6  demonstrates  how 
treatment choice is related to age in the US.  Choice of radical prostatectomy is 
inversely  related  to  age,  while  no  treatment  and  hormone  therapy  are  directly 
related to age. Choice of radiation therapy is biphasic with a peak in its use among 
men in their 70s. There is little evidence for a left or right shift in age of treatment 
choice when comparing years 1988-89 to 1993-94, suggesting that the decision tree 
for treatment as a function of age has not changed significantly during the PSA era 
in the US. 
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Figure 5.  Prostate cancer. Incidence by treatment of localised and regional stages. 
SEER Program 1988-1994 
Mortality 
Age-adjusted  US  mortality  rates  peaked  in  1991  and  declined  7.3%  by  1995 
(Figure 7) (Stephenson, 1998; Stanford et al., 1999). For men dying at ages of 75 
or  less,  mortality  rates  declined  by  15%  during  the  same  time  interval.  The 
magnitude of  the decline in mortality is currently quite small. It is not expected that 
the large number of early stage prostate cancers which have been diagnosed and 
treated in the PSA era will have a substantial impact on mortality for several more 
years. It is clear that during the PSA era large numbers of men were diagnosed with 
prostate cancer and received treatment. It is unknown what fraction of these men 
were overtreated (therapy had no impact on outcome), or what fraction needed and 
benefited from therapy. The steepness of the decline in future mortality rates will 
be a measure of the relative number of cases from these two sub-populations. 
202 1988  - 1989 
1  00 
Percent of Cases 
80  --------------------------------------------
No Treatment 
60 
40 
20 
0~~~~~~~~~------~==~ 
J>-<,;,  ~OJ ~~  ~<,;,OJ  ~~  ~roOJ  \:f~'t>.  ,_~OJ  ~#  ~x 
b'  'J  '::)  <a  (()  "\  ~".)  '0'"'  qj 
·Age of Diagnosis 
1993  - 1994 
1  00 
Percent of Cases 
80  ---------------------------------------------
60 
40 
20 
0~,--~--~--~--~~------~--~==~ 
~<o ~OJ  r;y~  ~<oOJ r;s~  ~roOJ \:!~~ <d~OJ ~~  co<ox 
~  'J  ':)  ~  <o  ~  '\  '0 
Age of Diagnosis 
Figure 6.  Prostate cancer. Distribution of cases by age and treatment for localised and 
regional stage. SEER Program 1988-1989 and 1993-1994 
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Figure 7.  Prostate cancer. US mortality rates 1973-1995 
Conclusions 
Several important observations can be garnered from SEER prostate cancer data: 
(1) Prostate cancer incidence rapidly rose and fell during the PSA era (1988-1995) 
in the United States. The magnitude of those incidence changes is unprecedented in 
the history of oncology and is  a reflection of enthusiastic use of PSA as  a new 
detection  method  for  prostate  cancer  in  the  United  States.  (2)  Moderately 
differentiated tumours became the predominant grade in the PSA era. Fortuitously, 
this  suggests that PSA is unable to detect the large prevalent pool of low-grade 
prostate cancer.  (3)  Distant  stage rates  fell  by  over 50%.  This  observation  is  a 
necessary  but,  by  itself,  insufficient precondition  to  observe certain  declines  in 
mortality rates in the future.  (  4)  Age at diagnosis fell by  more than three years. 
Taken  together  with  stage  migration  effects,  these  age  effects  demonstrate  a 
powerful  lead  time  effect  of PSA.  (5)  Large  numbers  of men  with  local  and 
regional stage disease received aggressive therapy for prostate cancer in the US. (6) 
Mortality  rates  have  fallen  by  only  a  small  increment  to  date.  Based  on  the 
204 prolonged  natural  history  of  prostate  cancer,  any  substantial  effect  of  PSA 
detection on mortality is not yet expected. 
These observations raise interesting questions regarding how to deal with problems 
of incomplete information and persisting uncertainty. In the case of PSA, enhanced 
detection of prostate cancer has been clearly demonstrated, but improved mortality 
outcomes are yet to be observed. How should individuals and societies approach 
such problems? Decision-making must often be made using inherently incomplete 
information in combination with the hopes and fears of the society's members. As 
examples, the societies of Sweden and the United States have arrived at distinctly 
different approaches  to  the problem of prostate cancer detection  and  treatment. 
While  many  argue  that  resolution  of  the  uncertainty  regarding  PSA 
detection/screening can only be achieved by means of randomised screening trials, 
it is possible that convincing differences will be seen in population-based mortality 
data from regions with distinctly different management strategies. This is similar to 
the case with Pap smear testing  where randomised  screening trials  were  never 
performed, but convincing population-based mortality data were used to justify the 
use of Pap testing (Johannesson et al.,  1978; Laara et al.,  1987; Benedet et al., 
1992; Sigurdsson, 1993). It appears likely that prostate cancer mortality data from 
these two countries and others will give clear answers to these troubling questions 
long before results from randomised screening trials are available. 
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206 Chapter 14.  Evaluation of  screening for prostate cancer 
F  .E. Alexander 
Commentary 
Stephenson  acknowledges  in  his  detailed  evaluation  of  prostate  cancer  (PC) 
incidence and mortality trends from the US  SEER database that the US  prostate 
cancer experience is very different from the European: in Europe opinion is much 
less favourable towards PSA screening and PC mortality rates continue to increase. 
At present we have insufficient scientific evidence to determine whether these two 
are causally associated. 
There are,  potentially, three types of evidence on  which a conclusion that PSA 
screening reduces  PC mortality  may  be based:  (ij randomised  controlled  trials 
(RCT);  (II) other epidemiological studies - case-control and cohort studies  and 
temporal and/or geographical comparisons; (III) the consensus of expert scientific 
opinion. These are not equivalent but represent a hierarchy with (ij being the gold 
standard. 
I write as  a European epidemiologist who  has been actively involved in the era 
where evaluation of breast cancer screening by RCTs has pioneered research into 
cancer screening (Wald et al., 1993; Nystrom et al., 1993; Alexander et al., 1999); 
this  experience  leads  me  to  emphasise  the  necessity  for  the  firmest  evidence 
regarding PSA screening - that  which comes  from  RCTs.  On the  basis  of the 
evidence  from  RCTs,  over  22  countries  have  organised  programmes  of 
mammographic screening (Shapiro et al.,  1998). Several of these countries (e.g., 
Quinn  and  Allen,  1995;  Smith  et al.,  1998)  have reported reductions  in  breast 
cancer mortality but the  authors  are,  justifiably, doubtful  whether these can  be 
attributed to the use of screening; for example, the reductions occur earlier than 
would be expected from an  effect of screening as appears possible for the recent 
US reductions in prostate cancer mortality. 
Substantial over-diagnosis from prostate cancer screening (i.e. men diagnosed and 
treated who, if unscreened, would have died of other causes before symptoms of 
PC emerged) is virtually certain from existing data (McGregor et al., 1998; Zappa 
et al.,  1998;  Alexander,  1997).  Of 100  men  with  prostate  cancer  detected  by 
screening up to age 70, only 16 would have died from PC before their 85th birthday 
(McGregor  et al.,  1998).  It is  clear  that  the  human,  social,  psychological  and 
economic  costs  of population-based  screening  programmes  will  be  large.  It  is 
207 essential that the benefits be quantified rigorously. RCTs, alone, can do this (Miller 
and Alexander, 1999). 
Two RCTs of prostate cancer screening are in progress: the European Randomised 
Screening for Prostate Cancer (ERSPC)  and the  US  Prostate,  Colon,  Lung  and 
Ovary  (PCLO)  screening trial  (Auvinen  et al.,  1996;  de  Koning  et al.,  2000). 
Together they have now randomised 160 000 men.  The first  analysis of ERSPC 
mortality data has been planned for 2008 when 120 000 men will have completed 
10 years of follow-up. It is necessary to have this follow-up completed because PC 
often develops  slowly;  population-based series  of locally confined disease  have 
reported >75%  survival at 10 years from diagnosis (Lu-Yao and Yao,  1997). The 
end-point  for  these  trials,  as  for  other  trials  of screening,  is  disease  specific 
mortality. Since the expected number of prostate cancer deaths in the trials is small, 
accurate classification is essential.  Reviewing all deaths is  clearly impracticable; . 
relying  on  death  certificates  alone  may  be  unreliable.  A  sensible  middle  way 
involves cause-of-death review of all deaths, which may involve prostate cancer-
those of known PC cases and those with PC on the death certificate. The assistance, 
here, of good quality cancer registration is invaluable since it allows accurate and 
unbiased ascertainment of prostate cancer cases in the two arms of the trial. Cancer 
registries  are  assisting  ERSPC  in  several  countries,  including  the  Netherlands, 
Sweden and Finland. 
RCTs of screening can, also, determine which 'process measures' are reliable early 
indicators  of future  mortality  benefit.  For  breast  cancer  (Tabar  et  al.,  1985) 
cumulative incidence of 'distant' disease were less predictive than rates of disease 
of more modest stages  G~:pT2 and/or pN1).  We do not yet know which benchmark 
will  be  appropriate  for  PC but the  declining  rates  of distant  stage  disease  (see 
Figure 3 in Chapter 13  of this volume) need not be as promising as frrst appears. 
Two things are, however, clear: firstly, Stephenson is absolutely correct in avoiding 
the temptation to base his arguments on increasing proportions of good prognosis 
cases  and,  secondly,  ascertainment  from  cancer  registries  of cases  in  the  trial 
populations is a prerequisite of scientific investigation of process measures. 
Stephenson's data on grade (Figure 2) are particularly interesting. Typically, due to 
length biased sampling, initial (prevalence) screening detects large numbers (and 
high proportions) of cancers with markers of low biological aggressiveness (Tabar 
et al.,  1992a;  Anderson et al.,  1991;  Roberts  et al.,  1987).  Subsequent cancers 
arising between  screens  and detected  at  later screens  are,  when  taken  together, 
relatively free of length bias though their diagnosis has  been moved forward in 
time.  They  have,  therefore,  favourable  characteristics  for  the  so-called 
'chronological  factors'  (e.g.,  size  and  node  status).  Whether  mammographic 
screening can be expected to  lead to lower rates of high grade cancers has been 
controversial (Alexander et al., 1997; Hakama et al., 1995) but Tabar et al.  (1992b) 
argue strongly that advancing the diagnosis should achieve this. Stephenson's data 
208 suggest that PSA screening can advance the diagnosis to times when cancers are 
moderately but not well differentiated. He believes this to be 'ideal'; we shall in 
future know from the RCTs of screening what targets for grade should be applied 
in  population  screening  programmes  - if,  that is,  the  trial  results justify  such 
programmes.  Meanwhile,  the  key  message  to  the  scientific,  public  health  and 
urological  communities  is  that  the  ERSPC  and  PLCO  trials  are  of enormous 
importance.  It  is  not unreasonable  to  expect  that,  when  their  mortality  results 
become available, analyses of their subsidiary data will enable future clinicians to 
have at their disposal scientifically valid criteria to select, for curative therapy, a 
minority  of cancers  detected  by  PSA  screening.  If so,  the  benefits  (if  any) 
demonstrated in the RCTs can be obtained at much reduced cost. 
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211 Chapter 15. Evaluation of  screening for colorectal cancer 
J. Faivre, A.M. Benhamiche and M.A. Tazi 
Colorectal cancer fulfils the conditions required for mass screening. It is a major 
cause of morbidity and mortality in industrialised countries. However, it can be 
cured by the detection of early stage cancers and even prevented by the removal of 
adenomas. This situation has prompted considerable research efforts over the last 
15  years to evaluate the ability of screening tests to decrease colorectal cancer 
mortality. Over the last five years more and more results have been published that 
suggest the benefits of screening. Cancer registries have been of great importance 
in planning and evaluating population-based studies. The purpose of this paper is 
to report their role in the planning, evaluation and monitoring of mass screening 
programmes for colorectal cancer. 
Use of cancer registries in planning screening programmes 
Descriptive epidemiological data provided by cancer registries proved useful in 
designing screening programmes for colorectal cancer. Data from cancer registries 
helped to indicate that colorectal cancers represented a major health problem and 
to focus attention on it. It is a major cause of illness in North America, Western 
Europe, Australia and New Zealand (Parkin et al., 1997). Japan is now also among 
the high-risk areas. Incidence data supplied by the European Network of Cancer 
Registries  enable  us  to  estimate  the  number of new  cases  per year  at  around 
198000 in the 15 member states of the European Union in 1995 (EUCAN, 1999). 
Colorectal cancer is  uncommon  before the  age  of 50 (less  than  6%  of cases). 
Incidence  increases  rapidly  from  this  age  onwards.  Thus  the  average  risk 
population was defined as  subjects over age 50. Considering these data and the 
results  of  screening  trials  it  was  recommended  to  implement  screening  in 
asymptomatic  adults  aged  50 and  over by the  European  Group  for  Colorectal 
Cancer Screening (1999).  Data from  Cancer registries  indicate that in  Western 
Europe the risk of developing a colorectal cancer before the age of 74 is nearly 
4.1%  and  2.6%  among  males  and  females  respectively  (EUCAN,  1999).  The 
cumulative risk of colorectal cancer in first degree relatives of a patient having a 
colorectal cancer before 50, or having two first-degree relatives affected, has been 
estimated to be over 10% (Benhamiche, 1998). On this basis the French consensus 
conference  on  colorectal  cancer  concluded  that  a  screening  colonoscopy  was 
advisable for this population (Conference de consensus, 1998). In the event of a 
213 colorectal cancer after the age of 60 (with a risk slightly higher than in the general 
population) no advice was given about screening strategy, given the present state 
of knowledge. 
Screening methods 
Several tests and procedures have been proposed for the screening of colorectal 
cancer.  The most commonly used is  the faecal  occult blood test.  Most of these 
tests  are  guaiac-based  tests,  which  are  intended  to  detect  the  peroxidase-like 
activity of haemoglobin. The most extensively evaluated test is the Hemoccult II 
(Smith  Kline  Diagnostic,  California).  Two  slides  are  prepared  from  three 
consecutive stool samples with or without dietary restrictions. This test is easy to 
perform, without great inconvenience to the individual, and is inexpensive. If  any 
of the slides are positive, a complete colonoscopy is recommended. Sensitivity in 
detecting cancer with a non-rehydrated test and biennial screening in populations 
over 50 is situated between 50 and 60%  for cancers (Young and StJohn, 1992) 
and between 20 and 30% for adenomas larger than 1 em in diameter (Bertario et 
al.,  1988; Macrae and StJohn, 1982). The true positive rate is between 40 and 
50%. Rehydratation increases sensitivity but also decreases specificity, so that the 
predictive  accuracy  of a positive  test becomes  very  low  (Young  and  St John, 
1992). 
More  complex  faecal  occult  blood  tests,  particularly  immunochemical  tests 
specific for human haemoglobin, have been developed. They are more sensitive, 
but their specificity at a population level is  not well established. They are more 
expensive and not as suitable for a mass screening procedure. 
Periodic sigmoidoscopy has been recommended by some organisations,  whereas 
colonoscopy is rarely considered for individuals at average risk.  The theoretical 
advantages  of endoscopic  screening  include  its  high  diagnostic  sensitivity  and 
specificity. However, it is unpleasant for the individual, has the risk of perforation, 
is expensive and compliance is not known. It does not fulfil the criteria generally 
required for a mass  screening procedure. On-going studies in England and Italy 
will  indicate  the  effectiveness  of screening  with  sigmoidoscopy  (Atkin  et al., 
1993). Double contrast barium enema has the same drawbacks  as  endoscopy as 
well as lower sensitivity and specificity. The rest of this article will be confined to 
results from the faecal occult blood test. 
214 Case-control studies 
Six case-control studies have been conducted is order to estimate the efficacy of 
screening with faecal occult blood tests on colorectal cancer mortality. Three of 
them were population-based: one in Italy in the province of Florence (Zappa et al., 
1997), one in Germany, in Saarland (Wahrendorf et al.,  1993) and one in France in 
Burgundy (Faivre et al.,  1999a) (Table  1  ).  Cases  were  less likely to have been 
screened than  controls.  Two  studies  indicate  a  significant protective  effect for 
those  screened  within  three  years  of case  diagnosis  compared  with  those  not 
screened. No reduction in risk existed when considering longer screening intervals. 
Such findings lie behind current screening recommendations and suggest that the 
faecal  occult blood test should be repeated at  least every two years.  The Italian 
study suggests a reduction in colorectal cancer mortality of 40% and the French 
study, a reduction of 33%. In the German study, in which results were reported by 
sex,  mortality  reduction  was  57%  for  females  and  8%  for  males  for  those 
asymptomatically screened 6-36 months before the reference date (Table 1). This 
difference in the protective effect of the faecal occult blood test between males and 
females was not reported in the other two studies. The reason for the discrepancy 
seen in Saarland has not been explained. 
Table 1. Results of  population based case-control studies 
Proportion screened 
Cases  Controls  Odds Ratio 
Florence  22%  29%  0.6 (0.4 - 0.9) 
Burgundy  49%  61%  0.  7 (0.5 - 0.9) 
Saarland 
Males*  13%  14%  0.9 (0.5 - 1.6) 
Females*  16%  29%  0.4 (0.3 - 0.  7) 
* Asymptomatically screened only 
The  main  advantage  of these  population-based case-control  studies,  performed 
with the data from cancer registries, is the opportunity to include all deaths from 
colorectal cancer in a defmed population and to hold information of similar quality 
on the history of participation in screening campaigns for both cases and controls. 
215 Matching cases and controls by sex and birth year as well as by place of residence 
decreased the effect of socio-demographic and lifestyle risk factors that could have 
exaggerated the efficacy estimates. Prior screening can be a confounding factor in 
such studies, however before the studies began, no cancer screening programme 
existed in  the  study  areas  and  faecal  occult  blood tests  were  not  available  to 
individuals. Cases and controls were unlikely to have been screened previously. 
Bias towards an apparent benefit of screening might operate when individuals with 
a lower risk of developing colorectal cancer are more likely to be screened. Data 
from the controlled part of the Burgundy  study  indicate little difference in  the 
incidence of colorectal cancer between non-participants and the control group. It is 
thus unlikely that selection bias of this type accounts for a substantial part of the 
reported effect of screening. However, the difficulty in accounting for all relevant 
confounding factors could still limit the accuracy of case-control studies. We must 
not forget that as case-control studies compare participants with non-participants, 
they provide an indication of reduction in risk, which is independent of compliance 
rates. This means that the results are valid for 100% compliance. 
Population-based controlled studies 
There are four European controlled trials that compare colorectal cancer mortality 
between the study and the control group (Hardcastle et al.,  1996; Kronborg et al., 
1996;  Kewenter et al.,  1994; Tazi et al.,  1997) (Table 2).  Data from the cancer 
registries covering the area represented one source of information on diagnosed 
colorectal cancers. In  Burgundy the researchers from the cancer registry were in 
charge of the design, set-up, collection of the data and analysis of the controlled 
trial. 
The Funen, Nottingham and Gothenburg trials randomly allocated individuals or 
households identified from general practitioners records or population registers, to 
receive an  invitation to participate in screening with Hemoccult, or to a control 
group.  In  the  Burgundy  trial,  people  from  small  administrative  areas  called 
«cantons» were allocated either to  the screened or to the controlled population. 
The Minnesota study is not presented here as it was performed in volunteers. 
Together with the efficacy of the screening test, compliance is a major determinant 
in the effectiveness of a screening programme. In Nordic countries and in England, 
the test is mailed with one or two reminders if required. In  France this strategy 
resulted in a low compliance. It had to be combined with the active participation of 
primary care physicians  who  recommend the test to  their patients.  Compliance 
with the first screening campaign was 67% in Funen, 66% in Gothenburg, 53% in 
Burgundy and in Nottingham. The proportion of the population screened at least 
216 once  was  67%,  68%,  69%  and  60%  respectively.  In  total,  46%  completed five 
screenings  in  Funen,  31%  in  Burgundy.  In  Nottingham  38%  completed  all 
screenings,  i.e.,  three  to  six  according to  period of recruitment.  Screening  was 
limited to two rounds in Gothenburg. 
Table 2.  Population-based trials of  Hemoccult screening for colorectal cancer 
Funen  Nottingham  Gothenburg  Burgundy 
Denmark  England  Sweden  France 
Study population  61933  152 850  68 308  91553 
45-74 years  50-74 years  60-64 years  45-74 years 
Screening test  Hemoccult  Hemoccult  Hemoccult  Hemoccult 
unhydrated  unhydrated  most  unhydrated 
biennially  biennially  rehydrated  biennially 
2 rounds 
Complete  67% did at  60% did at  68% did at  69% did at 
screening  least 1 screen,  least 1 screen,  least 1 screen,  least 1 screen, 
46% completed  38% completed  60% completed  37% completed 
5 screens  all (3-6)  the 2 screening  5 screens 
screens  rounds 
Positivity rate  1st screen  1st screen  1st screen  1st screen 
1.0%  2.1%  6.3%  2.1% 
Positivity  12.2%  11.5%  4.7%  11.4% 
predictive 
value for 
colorectalcancer 
Proportion of  Screen  22%  Screen  20%  Screen  29% 
colorectal cancer  Control  11%  Control  11%  Control  21% 
TNM Stage 1 
Years of trial  10  median 7.8  median 8.3  9 
follow-up 
Relative risk  0.82  0.85  0.88  0.86 
(95% Cl) of  colo·  (0.68 - 0.98)  (0.74- 0.99)  (0.69 - 1.12)  (0.71 - 1.03) 
rectal cancer 
death with 
screening 
217 The variation of positivity rates according to trials was related to the method of 
slide preparation. The positivity rate of the Hemoccult test in the initial screening 
was  1.1% in Funen where the test was  performed with diet restriction,  2.1%  in 
Nottingham  and  Burgundy,  where  there  was  no  diet  restriction,  and  6.3%  in 
Gothenburg where 80%  of the tests were rehydrated. The proportion of positive 
tests in subsequent screenings was between 1% and 1.5% with the non-rehydrated 
Hemoccult test and 5.6% with a rehydrated test. The positive predictive value for 
the non-rehydrated test was about 10% for colorectal cancer and ranged between 
30 and 40% for adenomas. 
Cancer registries were useful in obtaining information on newly diagnosed cases 
of colorectal cancers in screening participants and in the control group. They were 
of particular importance to ensure complete ascertainment of incident colorectal 
cancers. In all four studies the proportion of Dukes A among cancers detected by 
screening was around 40%. The non-responders presented at a later stage than the 
controls.  There  was  an  intermediate  situation for  interval cancers,  with  a  stage 
distribution  between  that  of  cases  detected  by  screening  and  that  of  non-
participants. 
The shift towards a less advanced stage of the disease was maintained, when the 
test group as  a whole  (intention to  screen)  was  compared to the control group. 
There was  also a significant survival advantage for individuals in the screening 
group over those in the control group. But these data do not represent a sufficient 
argument in favour of the effectiveness of screening. There are a number of biases. 
Slow-growing cancers are more likely to be detected by screening (length bias). 
Screening hastens the diagnosis of incurable cancers, giving a longer lifespan to 
the  disease  without  actually  lengthening  it  (lead  time  bias)  and  subjects  who 
participate in screening can be at lower risk (selection bias). 
The effectiveness of the screening programme should be evaluated in terms of the 
number of cancer deaths prevented. The Funen trial reported an  18% (RR=0.82, 
95% CI: 0.68-0.98) reduction in colorectal cancer mortality with a 10 year follow-
up, the Nottingham study a 15% reduction (RR=0.85, 95% CI: 0.74-0.99) with a 
median follow-up of 7-8 years, the Burgundy study a 14% reduction  (RR=0.86, 
CI:  0.71-1.03)  with  a  9  year follow-up  trial  and  the  Gothenburg  study  a  12% 
reduction (RR=0.88, 95% CI:  0.69-1.12) after 8 years of follow-up (Kronborg et 
al., 1996; Hardcastle et al., 1996; Faivre et al.,  1999b; Towler et al.,  1998). These 
four studies provide evidence that biennial screening with a Hemoccult test can 
reduce mortality from colorectal cancer. These findings can be extrapolated to the 
general population if the conditions of the screening programme active in these 
areas  were  to  be  reproduced.  To  be  effective,  a  mass  screening  programme 
necessitates a rigid organisation with a call-recall system for individuals. 
218 Monitoring of mass screening programmes 
Screening for colorectal cancer by faecal occult blood tests began in Germany in 
1977  as part of an annually offered cancer check-up.  Because of confidentiality 
problems only a limited evaluation of this programme was  performed (Gnauck, 
1995). In particular, data from cancer registries could not be used. 
Most available data concerning screening with Hemoccult II are provided by pilot 
studies in limited populations. This is because the scientific evidence for reduction 
in  mortality  from  colorectal  cancer  by  screening  the  stools  for  blood  and 
performing colonoscopy to detect the source of bleeding, has only been provided 
recently.  Cancer  registries  have  been  used  in  France  to  monitor  screening 
programmes in Calvados (Normandy) and in Isere (Alps). In Calvados, the cancer 
registry  was  in  charge  of organising  and  evaluating  the  screening  programme 
(Launoy et al.,  1996). The Hemoccult test was offered to 170 000 subjects aged 
between  45  and  74.  In  case  of  a  positive  screening  test,  information  on 
complementary investigations, as well as on treatment of diagnosed lesions were 
actively collected from GPs and specialists. The cancer registry routinely collected 
data on treatment and stage at diagnosis, and also provided data on interval cancers 
and on cancers in non-participants. These data were used to estimate the sensitivity 
of the Hemoccult test (Launoy et al.,  1997). In Isere (Exbrayat et al.,  1996) the 
screening programme was limited to 84 000 women between 50 and 69 (who were 
proposed a mammography,  a Pap smear and  Hemoccult test by  their GP).  The 
cancer registry data are used to identify interval cancers. It was recently decided to 
carry out two large pilot studies in  the  United Kingdom in  order to  verify  the 
reproducibility of the Nottingham study. Other European countries will probably 
also implement such policy. Cancer registries will be of great importance in the 
evaluation of such programmes. 
Conclusion 
Data from cancer registries have been used to plan screening trials and to evaluate 
mass screening for colorectal cancer. They were used to provide data on colorectal 
cancers, both in case-control studies evaluating the efficacy of faecal occult blood 
tests  and  in  controlled  studies  evaluating  the  effectiveness  of such  tests.  The 
results of these studies will probably provide a basis to implement screening in 
larger populations. In the future, cancer registries will be important in monitoring 
these programmes. 
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222 Chapter 16.  Cancer registries in early detection of 
cutaneous malignant melanoma 
J. W. W. Coebergh and H.J. van der Rhee 
Introduction 
Cutaneous malignant melanomas (CMM) account for 2 to 8% of all new malignant 
tumours in industrialised countries, but for only 1 to 2% of all cancer deaths. The 
lifetime cumulative risk of dying from CMM is less than 0.5% in most fair-skinned 
populations (Parkin et al., 1997). In the European Union about 31 000 new patients 
with CMM were diagnosed in 1995 and about 8000 deaths occurred (Ferlay et al., 
1999). About 44 000 new patients are expected in the USA in 1999 and about 7000 
deaths (Ries et al.,  1999). Because CMM is a visible tumour, a variety of screening 
efforts (Elwood, 1994) has been undertaken during the 80's and 90's in response to 
the marked rise of incidence rates since the 60's (Coleman et al.,  1993). Thanks to 
earlier detection, mortality has risen to a lesser extent, or even stabilised in middle-
aged  women  and  young  adults  in  most  countries  (LaVecchia  et  al.,  1999). 
Melanoma awareness has certainly increased in many countries and is linked with a 
more  precise  knowledge  of  the  aetiology,  largely  intermittent  UV  radiation 
(Armstrong and Kricker, 1993). 
The  pressure  to  implement  secondary  and  primary  prevention  has  become 
considerable, not only due to the above mentioned scientific factors. There may be 
an emotional component in the medical reaction to the rising incidence, influenced 
by  the  experience  of seeing  young  and  middle-aged  patients  die  from  CMM. 
Cancer societies  have  also  become  more  active  in  devising  campaigns  against 
avoidable dangers. 
Cancer registries have played a vital role in alerting the medical profession and 
public to the melanoma epidemic. Until now, their data have mainly been used in 
describing  the  impressive  changes  in  incidence,  by  subsite  and  sometimes 
according to thickness,  in  a  variety  of industrialised countries  (Armstrong  and 
Kricker,  1994)  Some  registries  have  also  reported  impressive  changes  in  the 
incidence of the more frequent basal cell carcinoma (BCC) (Coebergh et al.,  1995; 
Gallagher et al., 1990). 
Early detection campaigns for CMM have largely been evaluated by monitoring of, 
for example, changes in incidence rate according to stage or thickness, sometimes 
also taking trends in mortality into account (MacKie et al.,  1997; van der Rhee et 
223 al.,  1999).  Occasionally  have registries  been used to  identify the possible false 
negative  or interval  tumours  (Rampen  et al.,  1995),  and  few  campaigns  were 
continuous. If effects of screening had been assessed using mortality rates, they 
would probably have been small, or become manifest so much later that they could 
also be attributed to other influences. Assuming that no conclusive screening trials 
will  be conducted  in  the  near future,  this  chapter  considers  only  the  minimal 
requirements of the monitoring role of registries in support of medical and public 
health policies aimed at early detection and primary prevention. 
Frequency: time trends and variation in mortality and incidence 
Mortality rates from CMM have doubled or even tripled since the 50's (Coleman et 
al.,  1993; Armstrong and Kricker,  1994), although there is  some overestimation 
due  to  under-registration  and  misclassification  of  skin  tumours  in  the  past. 
Incidence rates have also been rising dramatically since the 60's and 70's in the 
predominantly  fairly  skinned  populations  of Europe,  at  first  in  Northern  and 
Central Europe, later in Eastern and Southern European countries. In Australia the 
most marked rises in incidence and mortality have occurred among people with 
recreational  sun  exposure,  and  among the sun-adoring Caucasian immigrants  of 
Northwest  European  origin,  especially  when  they  migrated  during  childhood 
(Armstrong et al.,  1982). Marked rises in incidence (of 5 to 7% annually) have also 
been observed among whites in the USA (Glass and Hoover, 1989). These analyses 
also show that incidence figures started plateauing, and period-cohort analyses of 
incidence and mortality showed deceleration of the increases in generations born 
after 1950, sometimes even after 1920 (Chen et al.,  1994). Figures 1 and 2 show a 
worldwide overview of the incidence of CMM in the period 1988-92. The current 
south-north and east-west gradients (from low to high) in Europe will probably be 
reduced in the future,  because rates are still rising in low-incidence populations, 
while they are tending to stabilise in higher risk countries. The absolute lifetime 
risk of CMM hardly exceeds 1% in most European countries and the risk of death 
remains below 0.3% (Ferlay et al.,  1999). Incidence curves usually start rising after 
the age of 20, but flatten beyond 50 to 60 years. In most countries incidence in 
females  is  some  25  to  50%  higher  than  in  males,  whereas  the  differences  in 
mortality  are  smaller or even reversed;  this  is  largely  due to  a  less  favourable 
distribution  of tumours  with  respect to  subsite  and  stage  in  men  (Streetly  and 
Markowe, 1995). 
Deaths from CMM comprise up to 2.5% of all mortality in Dutch women up to age 
40,  when  overall  death  rates  are  very  low,  but  this  proportion  declines  with 
increasing age, in spite of a steep increase of  the death rate (Figures 3-4). 
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Figure 2.  Worldwide age-adjusted incidence of cutaneous malignant melanoma in 
age-group 35-74 years, females, 1988-1992 (Parkin et al., 1997) 
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226 It seems likely that increased awareness of melanoma leads to earlier detection. To 
assess its potential, one might frrst consider how often a general practitioner (GP) 
or dermatologist is confronted by a new patient with CMM. 
In the Netherlands, with medium to high incidence rates of CMM, a GP (with an 
average practice of about 2500 people) is confronted with a new patient with CMM 
every 4-6 years and a dermatologist (one for every 50 000 inhabitants) once in 2-3 
months (Coebergh et al.,  1995). If  the melanoma-predictive value of suspect, but 
unclear, skin signs varies from 2-10%, a Dutch GP would be confronted with a new 
patient every  2  months. If the  predictive  values  lay  between 5  and  10%  for  a 
dermatologist (who only receives referred patients), a new patient would attend for 
a diagnostic procedure every week. These frequencies would be modified in areas 
where (plastic) surgeons are active in skin cancer detection. 
Concerning follow-up screening, an average GP in Holland would have about two 
prevalent patients (after removal of a CMM) in his practice, who may benefit from 
some surveillance (for another melanoma rather than for recurrence),  whereas a 
dermatologist  would  have  some  25  to  50  such  (former?)  patients,  and  gives 
attention to recurrence. The prevalence of dysplastic naevus syndrome, primarily in 
dermatologist practices, varies with definition and awareness. Such calculations (to 
be adapted by registries in every country) can also be made for BCC and SCC. The 
substantial prevalence of suspected lesions would at least underscore the need for 
sound dermatological training for GP'  s. 
Stage distribution, survival and screening 
Tumour stage, or thickness  according to Breslow (Breslow,  1970) is the major 
determinant of recurrence and survival. CMM can be detected early at most sites, 
because they are readily visible. As a rule, patients with CMM of <1.5 mm thick 
have a  very good prognosis, the cumulative relative  10-year survival rate being 
over 90%.  Data on melanoma thickness  are,  however,  rather sparse,  since few 
registries have recorded this for more than 15 years (Coebergh et al.,  1995; Roder, 
1998; Thorn et al.,  1994; Levi et al.,  1998). In  many studies stage-distribution is 
more favourable (thickness <1.5 mm) in women compared with men, in younger 
and middle-aged subjects, and in tumours on the extremities, rather than the trunk 
or the head and neck area. 
Tumours  have  been  increasingly  detected  at  early  stages  since  the  1970's, 
especially in European countries with good access to specialised care, leading to an 
impressive  improvement  of  relative  survival  (Smith  et  al.,  1998).  As  a 
consequence, the mortality/incidence ratio for melanoma has decreased in these 
countries and in the USA from 0.6 to 0.2, whereas unfavourable ratios still exist in 
eastern and southern Europe (Coleman et al.,  1993; Armstrong and Kricker, 1994). 
227 Beginning  in  the  United  States,  early  detection  has  been  promoted  by 
dermatologists and cancer societies, a pattern sometimes followed in Europe. There 
have  been  primarily  exercises  in  raising  awareness  of the  public  and  general 
practitioners, and there have been few  attempts at systematic evaluation. In fact, 
detection  rates  for  CMM  appear  to  have  increased,  and  stage  distribution 
favourably  influenced.  Effects  on  population-based  mortality  are  hard  - if not 
impossible - to assess, because they would only become manifest after a long time. 
Marked changes are anyway unlikely, because the populations most at risk of fatal 
melanoma  - such as  men of middle and older age with the thicker melanomas -
are often not reached by such campaigns. A shift in the classification of malignant 
behaviour may  have  occurred,  although  a  systematic  study  in  Europe  did  not 
provide any evidence of this during the 1970's and 80's (van der Esch et al.,  1991). 
In any case, mortality has not risen as much as incidence, and has even started to 
decrease in women after various campaigns in Scotland (MacKie et al.,  1997) and 
in Connecticut (Khlat et al.,  1992). However, the same thing happened in southern 
and western Holland without any or very limited screening effort (Coebergh et al., 
1995;  van  der  Rhee  et  al.,  1999).  The  only  documented,  albeit  still  indirect, 
evidence of a positive effect of early detection comes from a skin self-examination 
(SSE) campaign in the state of Connecticut at the end of the 1980's. Although only 
practiced by 15% of the population, SSE occurred more frequently in patients with 
thin melanomas than in those with advanced or lethal lesions, the odds ratios for a 
protective effect being 0.7 to 0.5 (Berwick et al.,  1996). 
Role of the cancer registry in melanoma prevention 
In developed countries, it is  quite likely that cancer control policies will  include 
primary and secondary prevention of CMM (Marks, 1995; Kroon et al.,  1999). The 
latter will always include close surveillance of the small number of families with 
dysplastic  naevi  syndromes  (DNS)  (MacKie  et  al.,  1993).  With  respect  to 
promoting early detection among the general population, cancer registry reporting 
can support the setting of targets by  indicating the room for improvement in the 
thickness distribution according to  sex and age  (Table 1).  For example, a target 
statement can  be formulated  that more  than 70 to  80%  of the CMM'  s in male 
patients below 60 years must be <1.5 mm and 60 to 70% in those over 60 years. In 
monitoring  how  closely  such  targets  are  approached,  deficiences  (such  as 
subgroups  which  are  insufficiently  reached)  can  be  identified.  Of course,  the 
targets  must  be  realistic.  Collection  of data  on  tumour  thickness  may  require 
retrospective reviews, with assistance of pathologists. Reports on survival can be 
particularly  useful,  particulary  if the  determinants  can  be  explored  using 
multivariate analysis (Levi et al.,  1998). 
228 Table 1.  Function of  cancer registry for melanoma prevention: intelligent monitoring 
1.  Public health trends of: 
Mortality by sex and age-group 
Incidence according to: 
Sex and age-group (0-19, 20-39,40-59, 60-69, 70+ yrs) 
Histological type (SSM/nodular, lentigo maligna) 
Stage, preferably Breslow thickness (<1.50, 1.51-3, 3+ 
mm) 
Subsite (ICD-0, 4-digit) 
Ratio in situ/invasive 
2.  Clinical evaluation of: 
Summary 
Relative survival according to: 
Sex and age-group 
Breslow thickness (in mm) 
Subsite 
Quality of care: Diagnostic process 
- Review of  diagnosis 
- Reexcision rate 
- Referring and diagnosing specialty (according to subsite) 
The epidemic of skin cancer is still continuing among fair-skinned populations in 
most industrialised countries,  although  it may  be  on  the  decline in  some.  With 
respect to prevention of CMM, public awareness is most important, especially if 
focussed on risk groups.  For primary prevention, these  are  largely children and 
young  adults  and  for  secondary  prevention,  people  at  middle  and  old  age. 
Continuous screening campaigns are unlikely to have much added value.  Cancer 
registries  have  primarily  a  monitoring role  in  reporting  of trends  according  to 
subsite and of thickness. Registries should try to support health policies aimed at 
controlling the CMM epidemic, which will also create opportunities to get involved 
in  studies of aetiology and quality of care. Wherever possible, registries  should 
report incidence trends of BCC and SCC by subsite. 
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232 Chapter 17.  Lessons learned from neuroblastoma screening 
R. Sankila 
Introduction 
The  history  of screening  for  neuroblastoma  is  a  very  good  lesson  for  anyone 
involved in the planning, evaluation, or monitoring of screening programmes. As 
described below, general population-based cancer registries have had a limited role 
in the studies concerning the effects of screening for neuroblastoma. At the time 
the  screening  programmes  were  launched  in  Japan,  there  were  rather  few 
population-based cancer registries. Several studies in Europe and North America 
have relied upon data from  hospital-based registries or collaborative groups,  and 
some have used data from specialised childhood cancer registries. 
Background 
Neuroblastoma is the second most common solid tumour among children in Europe 
under 5 years of age, following astroglial brain tumours (Parkin et al.,  1988). The 
prognosis is much better among children diagnosed at less than one year of age 
compared with older children, whose tumours more often are of advanced stage at 
diagnosis (Figure  1).  About 90% of patients with neuroblastoma secrete elevated 
levels  of  catecholamine  metabolites  (vanillylmandelic  acid,  VMA,  and/or 
homo  vanillic acid,  HV  A)  in urine (Woods and Tuchman,  1987). The urine can, 
e.g., be easily blotted from the diaper and analysed later in a laboratory. 
In the  1960s  and  1970s,  pioneering  work was  performed in  Japan  by  Sawada, 
establishing the feasibility of early diagnosis of neuroblastoma by screening babies 
at the age of six months for elevated urinary levels of VMA/HV  A (Sawada et al., 
1971). In 1973, a mass-screening programme was started in Kyoto, Japan, and in 
1985, it was extended to a nationwide programme throughout Japan (Sawada et al., 
1991). 
After a period of optimism, doubts began to rise (Miller et al., 1990, Murphy et al., 
1991). Finally, in December 1998, the Consensus Conference on  Neuroblastoma 
Screening concluded that  neuroblastoma  screening  under  seven  months  of age 
cannot  be  recommended  as  a  public  health  policy,  nor  do  new  screening 
programmes  in  that  age  group  appear  to  be justified  on  the  basis  of current 
evidence (Consensus Conference on Neuroblastoma Screening, 1999). 
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Figure 1.  5-year cumulative survival rates for 257 neuroblastoma patients (all stages) 
diagnosed in Finland in 1953-1986, by age and period of diagnosis (reprinted  from 
Sankila R &  Hakama  M,  1992.  Survival  trends  for  neuroblastoma  patients  in  Finland: 
negative  reflections  on  screening.  Eur  J  Cancer  29A:122-123;  with  permission  from 
Elsevier Science) 
Prerequisites for screening 
From reports written in English, one cannot find documentation on how systematic 
the  planning  process  was,  when  the  programme  for  screening  children  for 
neuroblastoma at 6 months  of age  was  initiated in  Kyoto  in  the early  1970s.  It 
seems  now,  in  retrospect,  that  our  current  understanding  of many  aspects  of 
neuroblastoma is  based largely on the  results  of research originating from  these 
pioneering  screening  efforts.  What  is  also  evident,  is  that  evaluating  and 
monitoring the original Japanese screening exercises was  very  difficult, because 
there were no population-based cancer registries. These problems become obvious 
when reading the excellent review of all published Japanese studies (Parker and 
Powell, 1998). 
The first prerequisite for any screening programme is some evidence of potential 
benefit  from  screening.  Conclusive  evidence  can  ultimately  only  be  acquired 
through a well-designed randomised trial.  Since no  such trial  was  conducted in 
Japan, the potential benefits were based on clinical knowledge of the disease. In a 
very  simple model of the disease, it was  observed that neuroblastoma was  more 
234 common among children less  than one  year of age than  among  older children. 
Further, children diagnosed before the age of one  year had proportionally more 
localised disease, and their overall survival rates were much better than those of 
older children (Figure 2). On the other hand, children diagnosed after one year of 
age had often stage 3 or 4 disease, and their prognosis was dismal (Tables 1 and 2). 
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Figure 2.  Survival since diagnosis by Evans stage of neuroblastoma (from Bernstein et 
al. , 1992. A population-based study of neuroblastoma incidence, survival, and mortality in 
North America. J Clin Oncol10:323-329; by permission of  Lippincott Williams & Wilkins) 
It seemed obvious, that there might be a time window during which children with 
subclinical neuroblastoma could be diagnosed and treated curatively before their 
tumours advanced leading to inevitable death of the patients. However, there are 
two exceptional biological aspects complicating our understanding of the natural 
history of neuroblastoma. First, it is evident that neuroblastoma-like tissue is often 
found in organs of foetuses  and new-borns (Acharya et al.,  1997). Furthermore, 
there is a special type of metastasised neuroblastoma (Stage 4S), which regresses 
spontaneously,  matures  into  non-malignant  ganglioneuromas,  or  is  cured  with 
minimal treatment, with very high survival rates (Brodeur et al., 1988, Figure 2). 
The second prerequisite is a test that could be used for mass screening. In the case 
of neuroblastoma, a test was  available, since the tumours excrete catecholamine 
metabolites, which can be detected as elevated levels in urine. However, some 10% 
of the  patients  are  non-secretors  at time  of clinical  diagnosis.  Testing  was  first 
started with a qualitative spot test for VMA, with further improvements in testing 
235 with  enzymatic  immunoassay  or,  quantitatively,  with  high-performance  liquid 
chromatography,  and  by  including  HMA  and  creatinine  concentrations  in  the 
analysis  package.  Finally,  a  method  using  stable  isotope  dilution  gas 
chromatography-mass  spectrometry  provided  the  most  sensitive  and  precise 
analysis (especially)  for control  samples from children  whose  frrst  samples  had 
proven positive. 
Table 1.  Stage distribution (%)  of all neuroblastoma cases (N=452) in Germany in 
1987-1991,  by age (modified  from  Schilling  et al.,1998.  German  neuroblastoma  mass 
screening study at 12 months of age: statistical aspects and preliminary results. Med Pediatr 
Oncol 31:435-441; reprinted by permission ofWiley-Liss, Inc., a subsidiary of John Wiley 
& Sons, Inc.) 
Age 
Stage  < 1 year  1 year and above  Total 
1-III/1-3  63%  37%  48% 
N/4  15%  64%  42% 
NS/4S  21%  9% 
False-positive results 
After the initiation of the mass screening programmes at age of 6 months in Japan, 
very  promising  results  were  published.  The  test  was  feasible,  it  was  easy  to 
perform by the mothers Gust requiring a drop of urine in filter paper to be mailed to 
the laboratory),  and generally, the compliance was  very  good.  The test-positive 
children were retested, and, following clinical examination, neuroblastomas were 
diagnosed and treated. The stage distribution of the tumours was very favourable, 
and survival of  the patients was excellent. 
236 Table 2.  5-year survival rates (%) of all neuroblastoma cases (N=452) in Germany in 
1987-1991, by stage and age (modified from Schilling et al., 1998. German neuroblastoma 
mass screening study at 12 months of age: statistical  aspe~ts and preliminary results. Med 
Pediatr Oncol31 :435-441; reprinted by permission ofWiley-Liss, Inc., a subsidiary of  John 
Wiley & Sons, Inc.) 
Age 
Stage  < 1 year  1 year and above  Total 
I-IW1-3  95%  74%  85% 
IV/4  69%  22%  28% 
IVS/4S  81%  81% 
Total  82%  38%  56% 
The monitoring  of screening programmes  in  Japan  was  difficult,  because there 
were  no population-based cancer registries  and,  at the  beginning,  the results  of 
screening  were  published  for  each  prefecture  separately,  often  based  on  small 
numbers of patients from different time periods. The screening programmes were 
started without considering the need to  obtain data on clear-cut end-points,  and 
there  was  no  reliable  population-based  information  on  the  incidence  of  and 
mortality from neuroblastoma in Japan. As  a consequence, later attempts to draw 
conclusions based on the original reports are challenging and imprecise. However, 
it soon became obvious that the detection rate in the screened population was much 
higher than  would  have  been  expected  based  on  incidence  data  with  no  mass 
screening.  With  improvements  in  the  laboratory  methods,  the  detection  rates 
increased from 5.1  to 24 per 100 000. The incidence rate among those who  were 
intended to be screened, but were not,  was  about 50%  lower.  The incidence in 
Sapporo City among the screened population doubled.  Similar results have been 
seen elsewhere in Japan,  and in the  largest screening trial in  Northern America 
(Bessho, 1996; Nishi et al., 1997; Woods et al., 1998). 
There were children with false-positive test results (between 28 and 53 per 100 000 
screened children). For the lucky ones, after non-invasive clinical examinations at a 
hospital and repeated control urine samples (often for a period of several months), 
no  other signs  or symptoms  of the disease  were  found.  If, however,  a  clinical 
237 tumour was revealed, at least a diagnostic operative procedure was performed. It is 
only in recent  years  that a  "wait-and-see" approach  has  become the choice for 
patients  less  than  one  year  of age  with  screen  detected  tumours,  but  with  no 
apparent signs of aggressiveness, and with a potential for regression or maturation 
(Ladenstein et al.,  1998). 
The possibility of actually diagnosing something that looks like a neuroblastoma, 
but  would  never  have  become  a  clinical  tumour,  is  further  supported  by  the 
extremely good prognosis of patients with screen detected neuroblastoma. Of the 
more than 800 cases detected by screening in Japan, only 10 have died (Parker and 
Powell, 1998). 
Missing evidence of benefit 
The early reports describing the effects of neuroblastoma screening in Japan were 
based on such process indicators as  sensitivity and specificity of the test, shifts in 
age and stage distributions, and the improvement in the survival rates. The end-
points that should have been provided, but never were, included a decline in the 
incidence  of (advanced  stage)  neuroblastoma  after  the  frrst  year  of life,  and 
crucially, a decline in the overall and age-specific mortality from neuroblastoma. 
Without complete catchment of all neuroblastoma patients and individual follow-
up,  any incidence, mortality,  and  survival calculations  are  inaccurate. Thus,  the 
experiment in Japan never had any chance of proving the effect of screening for 
neuroblastoma at age of 6 months as a public health intervention. It is unfortunate 
that  the  unreliable  reporting  of the  test-negative  cases  and  their  incomplete 
individual  follow-up,  hamper  any  further  attempts  to  learn  from  the  Japanese 
experience. 
Based on the results of screening trials outside of  Japan, it has become evident that 
mass  screening of children at 6 months  of age finds  children  with tumours that 
resemble clinical neuroblastomas. However, these tumours have favourable stage 
and other biological features. In recent years, it has become possible to ''wait-and-
see" with these patients, and regression of tumours has been observed. On the other 
hand, patients that were not detected by the screening programme, but were later 
clinically  diagnosed  with  neuroblastoma,  often  have  advanced  stage  and  other 
biological  markers  of unfavourable  prognosis  (for  review,  see  Brodeur  et al., 
1998).  Further,  there  is  no  evidence  of  a  decrease  in  the  incidence  of 
neuroblastoma after the age of one year, nor of a decrease in overall neuroblastoma 
mortality (Woods et al., 1997). 
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In its consensus statement in December 1998, the Jury found no support for mass 
screening  for  neuroblastoma  as  a  public  health  policy  at  any  age  (Consensus 
conference on Neuroblastoma Screening,  1998). The results of current screening 
trials must be awaited before any further guidelines can be considered on screening 
for  neuroblastoma  at  a  later  age  than  at  6  months.  It  has  been  proposed  that 
screening at  a later age  might decrease the number  of false  positive cases,  and 
increase  the  efficacy  of detecting  older  patients  with  unfavourable  biological 
markers and poor prognosis (Kerbl et al., 1997, Schilling et al.,  1998). However, it 
is not clear whether these tumours can actually be found by screening at any earlier 
stage, nor if they can be curatively treated. It is  also possible that the on-going 
trials may not be able to answer these questions due to limitations in their size and 
design. 
A  small  decrease  in  mortality  can  not be ruled  out,  but even  if it existed,  the 
hideous adverse effects of mass  screening for neuroblastoma at 6 months of age 
outweigh any benefits. It is apparent that the early experiments have provided a lot 
of data for further research on the natural history of neuroblastoma, and opened 
many unanswered questions regarding the consequences of screening.  However, 
with current know ledge, it is far less obvious that all necessary precautions were 
taken into account to minimise potential harm, and, e.g., to provide the parents with 
adequate,  neutral,  and  understandable  informed  consent  forms.  Serious 
consideration  must  be  given  to  the  ethical  issues  related  to  any  screening 
programme involving healthy children. It is likely, that parents will be willing to 
enrol their children in screening programmes offering potential benefits. However, 
the  enthusiasm  of the  screeners  may  limit  their  willingness  to  provide  critical 
information  on  the  adverse  effects  and  false  negative  results.  In  the  case  of 
screening for neuroblastoma, it is still unclear how much morbidity  - physical or 
psychological - is produced as a consequence of false positive test results. Nor has 
it been possible to estimate the number of healthy children (with spontaneously 
regressing subclinical neuroblastoma tissue), who have been exposed to invasive 
diagnostic and therapeutic procedures, some with fatal outcome. 
As  cancer  registries  become  involved  in  evaluating  and  monitoring  screening 
programmes,  emphasis  must  be  given  to  collecting  data  on  side  effects.  Any 
screening trial or programme must be considered as an entity that not only includes 
assessing the biological and classic public health outcomes, but also issues related 
to ethics, quality of life, health economics, and keeping the public up-to-date with 
relevant information. 
One of the major lessons learned from  the neuroblastoma experience is that any 
cancer registry should be involved as early as possible in the planning phase of a 
screening programme, in order to provide a clear picture of how and what data can 
239 be  expected  to  be  collected.  Further,  providing  background  data  for  power 
calculations and other estimates of the expected numbers and rates should be the 
responsibility of the cancer registry as well as - based on these figures - the neutral 
and sensible interpretation of  the feasibility of any planned programme. 
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242 Chapter 18.  Cancer registries and genetic screening 
L. Tryggvadottir 
Dermitions 
Germline mutations - Mutations that have arisen in germ cells. They segregate in 
families and are carried by all cells of the individual who inherits the mutation. 
Somatic mutations - Spontaneous mutations that arise in  somatic cells,  such as 
tumour cells.  They  are  therefore  confined to  the  tissue  of their origin  and  not 
transmitted to the descendants. 
Genetic testing - There is more than one definition of genetic testing. In this text it 
means testing individuals for germline mutations. Almost any kind of body tissue 
can be used for this purpose.  Usually, DNA from lymphocytes is used.  Another 
definition  of genetic  testing,  not  applied  here,  includes  testing  individuals  for 
somatic mutations. The DNA must in this case be extracted from the tissue where 
the mutations are supposed to have arisen. 
Predictive genetic testing- Testing unaffected individuals for germline mutations 
that are known to increase the risk of a disease. This can be done decades before 
the onset of disease. 
First degree relatives - Relatives th~t can be expected to share 50% of their genes 
with each other. Those are siblings, parents and offspring. 
Familial cancer- Increased risk of cancer in the family. Definitions vary, but most 
demand at least two cases that are first degree relatives to each other. Often young 
age at diagnosis is included in the definition. Familial cancer is not necessarily due 
to  inherited  factors.  Other  explanations  can  be  chance  or some  environmental 
factors shared by family members. 
Hereditary cancer - Increased risk of cancer in the family,  due to predisposing 
genetic  alterations  (germline  mutations),  usually  in  tumour  suppressor  genes. 
Hereditary cancer is a subset of familial cancers. 
Proband - The first individual in a family in whom a familial syndrome has been 
manifest,  e.g.  a  person  diagnosed  with  FAP  after  presenting  with  colorectal 
symptoms, thus leading to the surveillance of his first degree relatives. 
243 Genetic screening for cancer- Testing for inherited mutations in cancer related 
genes. To date, the target population consists of families that fulfill certain criteria, 
e.g. first-degree relatives of a proband. 
Famlly  cancer  screening  - A  programme  of screening  for  defined  precursor 
lesions or early  stages of cancer in  members  of families  with  increased risk of 
cancer, e.g.  a programme consisting of colonoscopy every other year for  young 
first  degree  relatives  of FAP  patients.  In  recent  years,  genetic  screening  is 
increasingly being included in family screening programmes. 
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I Introduction 
In  recent  years  the  rapid  development  of  molecular  genetics  has  opened 
possibilities  for  genetic  screening  for  cancer.  New  information  on  high  risk 
mutations is accumulating fast and this development is likely to be even further 
stimulated by a recently started programme of The National Cancer Institute, which 
aims  to  define  all  genes  that  are  relevant to  all  cancer (NCI,  Cancer Genome 
Anatomy  Project).  As  hereditary  cancer  is  a  rare  phenomenon,  any  genetic 
screening programme is destined to have very limited, if any, public health impact 
on  a  population  level.  On  individual  and  family  levels  the  benefits  from  such 
programmes  may  be  substantial.  Thus,  genetic  screening  for  cancer cannot  be 
recommended in the general population, and is  currently confined to individuals 
with family history of certain cancers. 
This chapter deals first with the benefits and hazards of using familial and genetic 
information for surveillance and preventive purposes while at the same time trying 
to protect individuals from possible harmful effects of disclosure of sensitive data. 
Secondly,  there  is  an  overview  over the  three  most  common  and  best  studied 
cancer syndromes and finally, there is discussion of the role of cancer registries in 
screening programmes for inherited predisposition to cancer. 
Potential health benefits of genetic testing and the rights to personal 
privacy 
The  ability  to  identify  inherited  genetic  aberrations  that  are  associated  with  a 
markedly increased risk of cancer offers possibilities of preventive measures and 
early treatment to individuals carrying certain inherited mutations. However, at the 
same  time,  the prospect of being able to do  so  has  given  rise to  many  ethical 
questions and concerns. 
The main concerns relate to the familial nature of the data and the sensitive nature 
of information based on DNA research. The participation of one family  member 
involves  not only  himself,  but usually  also  demands  the  involvement  of other 
members of the family. Furthermore, the results from one individual are indicative 
of the  status  of other close relatives.  The genetic  test  may  reveal  an  inherited 
mutation that is indicative of a very high risk of a particular disease, even decades 
before the onset of any  symptoms, and this poses a psychological burden on the 
tested individual. On the other hand, the results from genetic tests will free 50% of 
those who are suspected of carrying a dominant mutation from their worries. It has 
been suggested that, for such important information to be sought and disclosed, a 
245 process with three well-defined stages should be offered to family members. Those 
are: the information stage, the test stage and the stage of interpretation and support 
(Harper,  1997).  Counselling should be offered not just to  the  proband  seeking 
advice, but to the rest of  the family. 
A  further  complication  with  genetic  testing  is  that  the  results  are  of potential 
financial interest for insurance firms, employers and private health care institutions. 
Disclosure of testing results may thus lead to discrimination against those tested. 
There is also the danger of stigmatisation of individuals or whole families if they 
are known to carry a detrimental mutation. 
Genetic tests have already become commercially available for diseases for which 
there are still serious uncertainties of the efficacy of  recommended surveillance and 
management procedures, e.g., for breast and ovarian cancer. Therefore results are 
urgently  needed  from  high  quality  studies  of  the  effects  of  the  currently 
recommended procedures on survival and quality of life. This uncertainty calls for 
careful education and counselling of individuals with family history (V  asen, 1998) 
and for a conservative approach with respect to genetic tests. 
The sensitive nature of genetic testing calls for strict precautions, and special rules 
have been formulated for the handling of data and for approaching relatives, the 
most important rule being that of asking for informed consent from the individuals 
being  tested.  In  Britain,  the  "Advisory  Commission  on  Genetic  Testing" 
(Government response to the third report of the House of Common, 1996) and in 
the  United  States  the  "Task Force  on Genetic  Testing"  (1995)  have  published 
extensive rules concerning genetic testing. 
The American Society of Clinical Oncology (ASCO) (1996) review of the main 
benefits and hazards of genetic testing recommends rules for oncologists regarding 
this complicated task. The statement stresses the clinical importance of identifying 
high-risk families and offering genetic counselling. It acknowledges the need for 
performing  genetic  testing  in  the  setting  of  long-term  outcome  studies  with 
appropriate  confidentiality.  The  role  of informed  consent  is  stressed,  and  the 
importance of providing adequate information to the patients on possible risks and 
benefits  of the  detection  of a  high-risk  cancer  gene  and  of the  prevention 
modalities. Also, the importance of studying the psychological impact of genetic 
testing  is  pointed  out.  ASCO  supports  legislation  and  other  efforts  aimed  at 
hindering that results of genetic testing being used in  a  discriminatory  way  by 
insurance companies or employers. 
246 Candidates for genetic screening for cancer 
Family  screening programs  that include  genetic  testing  have  to  fulfil  the  same 
criteria  as  other  screening  programs.  The  number  of commercially  available 
genetic tests is rapidly increasing, and this too calls for high-quality research into 
the effects of presumed, but not proven, benefits of the recommendations given. 
Some of these are quite dramatic, such as the prophylactic removal of the breasts of 
women carrying mutations in BRCAJ/2 genes. It is not likely that randomised trials 
can be used to evaluate genetic screening and surveillance programs, but evaluation 
is possible by comparing the experience of groups of potential carriers of high risk 
mutations that have participated in screening and surveillance programs, with the 
experience of groups that have not participated. 
In the report from ASCO ( 1996) three categories of tests are defined for cancer 
predisposition testing. One of those categories consists of tests where the medical 
benefits are still not apparent, e.g. tests for mutations in the gene associated with 
Ataxia-Telangiectasia. The other two categories are described below. However, it 
must be borne in mind that new tests will become available, and regrouping of  tests 
will occur, along with advances in molecular biology and according to results from 
research of  the effects of screening. 
The first category consists of tests for well-defmed syndromes for which either a 
positive  or  negative  result  will  change  medical  care.  These  are  Familial 
Adenomatous  Polyposis  (F  AP),  Multiple  Endocrine  Neoplasia  2a  and  2b, 
Retinoblastoma and Von Hippel-Lindau Syndrome. 
The second category consists of tests for hereditary syndromes, where the medical 
benefits of the identification of a mutation carrier are less well established. The 
syndromes  concerned  are  Hereditary  Non-Polyposis  Colon  Cancer  (HNPCC), 
Hereditary Breast and Ovarian Cancer and Li-Fraumeni Syndrome. In the future, a 
prostate  cancer syndrome  might  be  included  in  this  category  (Gronberg  et al., 
1997) 
F  AP, HNPCC and hereditary breast and ovarian cancer 
For three of the above syndromes, extensive registration of families and clinical 
screening for precursor lesions or initial stages of the diseases have been ongoing 
for many  years.  These syndromes are FAP, HNPCC  and Hereditary Breast and 
Ovarian  Cancer.  Family  screening  and  counselling  has  been  the  traditional 
approach, and only recently has it become possible to offer genetic testing as a part 
of the programmes. The first indication of the localisation of a gene associated with 
one of the syndromes, the F  AP syndrome, came in 1987 (Bodmer et al.,  1987). In 
247 1991  the gene for this  syndrome,  the APC gene,  was  identified (Kinzler et al., 
1991). The first gene associated with HNPCC was localised and identified in 1993 
(Peltomaki et al.,  1993; Fishel et al.,  1993; Leach et al.,  1993) and the BRCAJ gene 
was identified in 1994 (Miki et al.,  1994). The family registries for FAP, HNPCC 
and  Hereditary  Breast  and  Ovarian  Cancer  have  made  it  possible  to  identify 
individuals at high risk of those syndromes, as judged from their relationship with 
affected family  members and to  offer them screening and treatment. Also, these 
registries  have  proved  to  be  a  very  important  source  of family  information, 
essential for the linkage analyses that have led to the identification of the genes. 
FAP 
Familial adenomatous polyposis (FAP) was first described in 1882 (Cripps, 1882) 
and the risk of malignant transformation of the adenomas  was  first discussed in 
1925  (Lockhart-Mummery,  1925).  FAP  is  a  rare  dominantly  inherited 
susceptibility to colorectal cancer (CRC), with an estimated incidence of between 
115000  and  1110  000.  The  disease  is  characterised  by  the  formation  of up  to 
thousands  of adenomatous  polyps  in  the  large  bowel  of affected  individuals. 
Patients  with  polyps  almost  inevitably  develop  colorectal  carcinoma  (Jarvinen, 
1992). 
Registration  of F  AP  has  now  been  ongoing  for  several  decades  and  in  many 
countries (Bulow et al.,  1993; Rhodes et al., 1991). In  1985, national and regional 
FAP registers from all over the world formed the "Leeds Castle Polyposis Group" 
as  an  international  research  forum  (Thomson,  1988).  Since  1989  the  European 
Commission has fmancially supported a concerted action on familial cancer with 
special emphasis on FAP (EuroFAP). The aim is to increase the identification and 
registration ofF  AP patients in all countries of the European Union and to facilitate 
molecular genetic research (Bulow et al., 1993). 
For individuals with a family history of FAP, the management offered has been 
regular bowel examination with colonoscopy every two years between the ages of 
10 and 40, and then with less intensity up to the age of 60 (Bulow et al.,  1993). 
Prophylactic  colectomy  is  the  recommended  treatment  for  newly  diagnosed 
patients with polyps. Several F  AP-registry based studies have reported beneficial 
effects of regular colonoscopy screening of family members at risk. FAP patients 
detected by  screening of family  members  (call-up patients)  have been shown to 
have  a  considerably  lower  incidence  of  colorectal  carcinoma  than  patients 
presenting with symptoms (probands) (Bulow et al.,  1995; Jarvinen et al.,  1992; 
Rhodes et al.,  1991; Vasen et al.,  1990). Survival after the diagnosis of FAP has 
been found to  be considerably better for call-up patients than  for  probands,  but 
lead-time bias will play a role here. Even though life expectancy has been found to 
be increased in call-up patients relative to probands (Jarvinen, 1992; Nugent et al., 
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risk of dying in the call-up patients (Nugent et al.,  1993). A study based on the 
population-based Finnish Cancer Registry in the years 1961 to 1990 indicated that 
the proportion ofF  AP among all cases of colorectal cancer in Finland had declined 
from 0.53% to 0.14%, which might be partly attributed to the preventive effects of 
family screening (Jarvinen, 1992). 
The APC gene, responsible for FAP, identified in 1991  (Kinzler et al.,  1991), is a 
tumour suppressor gene localised on chromosome 5q21. Spontaneous mutations in 
the gene appear to account for between a tenth and a third of patients, whereas the 
rest of the patients have inherited mutations. Heterogeneity between families has 
been manifest by a marked variation in age of onset of polyposis and the number 
and  size  of adenomas.  Commercially  available  genotyping  for  FAP  became 
available in  1994 and may become a regular part of family  screening programs. 
The test has been reported to detect an APC gene mutation in approximately 80% 
of FAP families (Cromwell et al.,  1998), but it has nearly  100% sensitivity and 
specificity when the mutation in the particular pedigree is known. 
HNPCC 
Hereditary nonpolyposis colorectal cancer syndrome (HNPCC) or Lynch syndrome 
(Lynch et al.,  1988) was first described in 1913 (Warthin, 1913) and re-discovered 
in  1971  by  Lynch  and  Krush  (Lynch  and  Krush,  1971).  It  was  estimated that 
HNPCC  may  account  for  between  1  and  5  percent  of all  cases  of colorectal 
carcinoma, but the true prevalence may be lower (Aaltonen et al.,  1994; Marra et 
al.,  1995; Evans et al.,  1997; Fante et al.,  1997; Riegler et al.,  1999). HNPCC is 
characterised by an autosomal dominant mode of inheritance, early-onset colorectal 
cancers predominantly located in the proximal colon and the occurrence of various 
other cancers, such as cancer of  the endometrium (Aarnio et al.,  1999). 
The syndrome has since 1971 been registered and described in many countries. In 
1990 an international group (ICG-HNPCC)  was  formed,  aiming at collaborative 
studies on the prevalence, natural history and clinical expression of the HNPCC 
syndrome (Vasen et al.,  1991a). The group agreed on a set of minimum criteria for 
recruitment  of patients  to  the  collaborative  studies,  the  so-called  Amsterdam 
criteria (Vasen et al.,  1991b). The criteria refer to number of affected near relatives 
and young age at diagnosis. 
Several  genes  have  been  identified,  mutations  in  which  predispose to HNPCC. 
They  are  hMSH2,  hMLHJ,  hPMSJ,  hPMS2 and  hMSH6/GTBP (Miyaki  et al., 
1997; Bronner et al.,  1994;  Nicholaides et al.,  1994; Papadopoulos et al.,  1994; 
Fishel et al.,  1993; Leach et al.,  1993; Peltomaki et al.,  1993). The genes play a 
role in mismatch repair function, and the tumours are characterised by replication 
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risk of over 80 % of developing CRC and an increased risk of other cancers (V  asen 
et al., 1996). However, this estimate is based on high-risk families. It remains to be 
studied whether the risk is  lower in unselected mutation carriers  (Aarnio  et al., 
1999).  To date,  more  than  120 germline  mutations  have been  identified in  the 
mismatch repair genes. A database of mutations was established in 1994 by ICG-
HNPCC (Peltomaki and V  asen, 1997}, aiming at facilitating research that can help 
decide on mutation detection strategies. 
Clinical screening of patients fulfilling the Amsterdam criteria has been ongoing 
for several years, and more recently also the genetic screening of suspected carriers 
of  mutations.  Cancer  screening  among  HNPCC  family  members  is  more 
demanding than for F  AP. In the absence of clear preceding clinical markers (such 
as multiple polyps), full colonoscopies are needed and the screening has to go on 
for the rest of the life among the mutation carriers and in  HNPCC-like families 
where mutations cannot be found (Syngal et al.,  1999; Jarvinen et al.,  1995). It is 
therefore very important to investigate whether the screening has beneficial effects. 
This is best done by comparing tumour stages, incidence and especially mortality 
from  CRC,  between  screened  and  unscreened  HNPCC  family  members  or 
suspected  mutation  carriers.  A  non-randomised  Finnish  prospective  study 
compared  two  groups  of asymptomatic  at-risk  members  of 22  families  with 
HNPCC (Jarvinen et al.,  1995). One group of 133 study subjects had screening at 
3-year intervals; the other group consisted of 118 controls without screening. CRC 
occurred in six (  4.5%) of the study subjects and in 14 (11.9%) of the controls, a 
reduction of 62% in the screened group. In the screened group, the tumour stages 
were more favourable  and there were no deaths caused by CRC, compared with 
five deaths among the 14 cases in the control group. The follow-up was partially 
based on data from the population-based Finnish Cancer Registry. 
A  cost-effectiveness  analysis  of  colorectal  cancer  screening  among  HNPCC 
mutation carriers has been made (Vasen et al.,  1998a). This study used estimates of 
the lifetime risk of developing CRC among mutation carriers (V  asen et al.,  1996), 
and comparisons of survival rates  between sporadic  CRC  patients  and HNPCC 
patients (for most of whom mutation status was known). The other estimates used 
in the  cost-effectiveness  analysis  were  based on  studying  members  of HNPCC 
families  with  unknown  mutation  status.  The  comparison  involved  the  stage 
distribution between patients from HNPCC families who were under surveillance 
and who were not (V  asen et al.,  1995}, CRC stage-specific relative survival rates 
(Sankila et al.,  1996}, and the above estimates of the effectiveness of surveillance 
(Jarvinen  et  al.,  1995).  The  results  indicated  that the  surveillance  of mutation 
carriers led to an increase of seven years in the average life expectancy. Also, the 
costs of surveillance appeared to be less than the costs of no CRC surveillance. 
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effectiveness  of clinical  family  screening  and  genetic  testing.  However,  more 
research is  needed, especially on results from genetic screening and on  how the 
screening  and  preventive  measures  affect  the  quality  of life  and  psychological 
status of family members. 
Hereditary breast and ovarian cancer 
Research on familial breast cancer and collection of high-risk families  has been 
going on for several decades and many studies have confirmed that familial breast 
cancer is characterised by young age at onset and increased risk of bilaterial cancer 
(Bishop  1992;  Tulinius  et  al.,  1992).  In  1989,  the  Breast  Cancer  Linkage 
Consortium was established. It is an international collaboration, initially aimed at 
conducting linkage analyses of breast cancer families with increased risk (Bishop, 
1995). 
Two breast cancer genes, BRCAJ and BRCA2 were located to chromosomes 17q21 
and 13q12-q13 in 1994 and 1995, respectively (Tavtigian et al.,  1996; Wooster et 
al.,  1995; Miki et al.,  1994). The prevalence of mutations in these genes  varies 
considerably  between  populations.  In  relatively  inbred  populations,  such  as 
Ashkenazi Jews and Icelanders, the prevalence in unselected breast cancer cases 
has been found to be 12%  (mutations in BRCAJ and BRCA2) and 8%  (BRCA2) 
respectively  (W  amer et al.,  1999,  Thorlacius  et al.,  1998).  Lower  prevalence 
estimates have been reported in unselected patients in other populations such as 
from USA (North Carolina)  and UK,  or 3,3% (BRCAJ)  and 2-3%  (BRCAJ  and 
BRCA2) respectively (Newman et al.,  1998; Peto et al.,  1999). However, the .UK 
prevalence estimate may be somewhat too low, because it is partly based on the 
high penetrance (or cumulative risk) estimate of 84% by age 70 years in carriers of 
BRCA2 mutations, derived from the Breast Cancer Linkage Consortium (BCLC), 
using high-risk families (Ford et al.,  1998). Estimates of cumulative risk by age 70 
years are considerably lower when based on unselected breast cancer patients, or 
between  28%  and  37%  in  carriers  of BRCA2  mutations  (Warner  et al.,  1999; 
Thorlacius  et al.,  1998)  and between 36%  and  56%  when  BRCAJ  and  BRCA2 
mutations  are  considered  together  (Hopper  et  al.,  1999;  Fodor  et  al.,  1998; 
Struewing et al.,  1997). The risk appears to vary considerably between families, 
even if they carry the same mutation (Thorlacius et al., 1996). This indicates other 
important determinants of risk in mutation carriers  - inherited, environmental or 
both. Carriers of BRCAJ mutations also have an increased risk of ovarian cancer 
(Miki et al.,  1994). Heterogeneity of risk has also been demonstrated for ovarian 
cancer (Claus and Schwartz, 1995). 
To  date,  hundreds  of different  germline  mutations  have  been  reported  in  the 
BRCAJ/2 genes and genetic testing is now frequently included in family screening 
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population. The benefits and costs of screening Ashkenazi Jewish women  (who 
have  a  much  higher  prevalence  of BRCAJ  mutations  than  other  European 
populations) were discussed in a recent paper (Grann et al.,  1999), concluding that 
genetic screening in this population may prolong survival, but that the results need 
confirmation through prospective studies. 
There are  still  many  questions unanswered  with respect to  the  surveillance and 
management  of  breast  cancer  families.  A  European  collaborative  group  of 
clinicians specialising in familial breast cancer was formed  in  1996. In  a survey 
among  16  family  cancer clinics participating in this collaboration,  most centres 
recommend surveillance of the breasts if the lifetime risk exceeds 15-20% 0/asen 
et al.,  1998b  ).  The  surveillance  protocol  that  is  generally  advised  comprises 
monthly breast self  -examination, examination by a specialist every 6 months and 
annual  mammography,  all  starting  from  an  age  between  25  and  35  years. 
Surveillance of the ovaries is  recommended in BRCAJ/2  gene mutation carriers. 
Prophylactic mastectomy is considered for proven mutation carriers in half of the 
centres. Most of those recommendations are based on experts' opinion, and studies 
of the efficacy are urgently needed. 
The efficacy of prophylactic  mastectomy  has  been evaluated by  comparing the 
incidence of breast cancer in groups of women with family history of breast cancer 
who underwent bilateral mastectomy,  with the expected incidence in the group. 
Results from a recent, well-conducted study indicated a significant reduction in the 
incidence of breast cancer after mastectomy  (Hartmann  et al.,  1999).  However, 
critics have pointed out that bias could account for some of the observed beneficial 
effects and that results from familial patients may not apply for mutation carriers. 
Furthermore,  it  must  be  considered  that  this  disfiguring  and  potentially 
psychologically damaging operation on a large group of women is a high price paid 
for the prevention of relatively few cancers and fewer deaths (Eisen and Weber, 
1999). 
Large scale follow-up  studies  are needed,  where groups of suspected or proven 
mutation  carriers  under  surveillance  are  compared  with  similar  groups  without 
surveillance,  with  respect  to  tumour  stage,  incidence,  mortality,  stage  specific 
relative survival and quality of life. As is apparent from the above-cited European 
survey, the clinical management of a woman with family history depends on her 
estimated lifetime  risk.  Therefore,  precise risk estimates are  critical.  They  may 
differ between families (Hopper et al.,  1999; Thorlacius et al.,  1996) and should 
therefore be viewed in the context of  the extent of family history of the woman. 
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The important task of evaluating the efficacy  of family  screening programmes, 
with or without genetic screening, is totally dependent on close co-operation of two 
kinds of registries. These are the cancer family registries and the cancer registries. 
This co-operation is also important for other aspects of family screening, such as 
recruitment of probands and confirmation of  cancer diagnoses in family members. 
Cancer family registries 
As described above,  a large number of family registries and other collections of 
cancer-prone families have been in existence for some time. These registries have 
collected information on probands and relatives, usually offering family screening, 
with a view to early diagnosis and prophylactic treatment. Genetic counselling has 
become  an  important part of their activities  as  well  as  active  research into the 
efficacy  of family  screening,  often  in  close  collaboration  with  classical  cancer 
registries. The information collected on high-risk families in the family registries 
formed  the  basis  for  the  linkage  analyses  that  led  to  the  identification  of the 
currently known cancer suppressor genes. Presently, genetic screening for cancer is 
not done in  the general population, but is  confined to individuals with  a family 
history. There are two main reasons for this: first, the mutation detection rate can 
be expected to be extremely low in the general population. Second, because a large 
number of mutations are known for each syndrome, the interpretation of results 
from genetic testing must be done in the context of test results from other family 
members. The sensitivity and specificity of the genetic test are much lower if  the 
mutation segregating in the family is not known. 
Cancer registries 
The ideal design for studying the efficacy of programmes of family screening and 
surveillance, also including genetic screening, would be the randomised controlled 
trial. Trials are not likely to be conducted for this purpose, because the estimated 
risk for  individuals  with  a family  history  is  too  high,  and because of the  high 
degree of anxiety associated with belonging to a high-risk family. As pointed out 
by Vasen et al.  (1995), the next best design is a comparison of the incidence and 
mortality between a screened group and a control group of family members who 
have not been under surveillance. Population-based cancer registries can be utilised 
for this purpose, because of access to information on the incidence and mortality in 
both groups. As summarised below, evaluating family screening programmes and 
genetic  testing can  be performed  in  collaboration  with  population-based cancer 
registries. 
253 1.  In  a research setting, the identification of young cases of a particular cancer 
type  from  a  cancer registry  is  a  practical  way  of collecting  data  on  putative 
probands  into  a  family  registry,  especially  if  the  study  is  aimed  at  being 
nationwide. 
2.  Confirmation  of cancer  diagnoses  in  relatives  of the  probands  is  much 
facilitated  where  there  is  access  to  a  cancer registry  covering  the  entire  study 
population. 
3.  When it comes to the important task of evaluating the results of family and 
genetic screening for cancer, access to population-based cancer registries is crucial. 
The cancer registries can provide unbiased follow-up information when comparing 
the  incidence,  stage  distribution,  morphology,  mortality  and  relative  survival 
between  screened  and  unscreened  groups  of individuals  in  the  putative  cancer 
families. The comparisons are the only sound method of evaluating the efficacy of 
current procedures, and they form a basis for cost benefit analyses. 
4.  Another important role for the cancer registries is in estimating the cancer risk 
associated with mutations in cancer suppressor genes. Unbiased estimates can only 
be derived  from  population-based  cancer registries,  along  with  information  on 
unselected mutation carriers. The risk estimates are critical, because they form the 
basis for decision making of clinicians on an individual basis with respect to the 
choice of surveillance and management procedures.  Some of the risk estimates 
currently used are based on high-risk families  and are likely to apply only to a 
selected subgroup of mutation carriers. The risk estimates also form an important 
basis for estimates of  costs and benefits of screening and surveillance procedures. 
5.  The cancer registries can further provide unbiased estimates of the proportion 
of all cancer of a particular type that is attributable to known mutations. Studies of 
changes  in  this  proportion  with  time  can  be  indicative  of  effectiveness  of 
surveillance  programmes  in  reducing  the  incidence  of the  particular  inherited 
cancer. 
6.  Finally, cancer registries are often research institutions where state-of-the-art 
epidemiological methodology is in every day use. Thus, cancer registry personnel 
can have important roles in providing consultation on epidemiological methods, 
standardisation  of defmitions  of cancer  syndromes  and  co-ordinating  research 
methods between institutions, to facilitate the combination of  data for collaborative 
studies with high statistical power. 
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261 Chapter 19.  Conclusions and recommendations 
R. Sankila, L.J. Schouten and D. M. Parkin 
Cancer registries play a key role in the process of evaluating and monitoring mass 
screening programmes. By providing timely analyses of the trends in incidence and 
tumour characteristics, and through linking the cancer registry database to that of 
the mass screening programme, they can contribute to a variety of analyses of the 
screening programmes. 
By  studying trends  in  the  incidence  of the  target  cancer,  a cancer registry  can 
provide insight into the effects of mass screening. A good example is the decrease 
in the incidence of cervical carcinoma in Western European countries. It is  very 
likely that screening contributed greatly to this development (see Chapter 6 in this 
book). Studies in Scandinavia showed that the decrease in incidence of this tumour 
varied widely between countries and that the incidence decreased most rapidly in 
countries with well-organised mass screening programmes (see Chapters 5 and 6 in 
this volume). At the start of a new screening programme, it is possible to measure 
the effect of the screening by studying regional differences. Hakama (see Chapter 2 
in this volume) demonstrated how to evaluate the effects when a breast-screening 
programme  was  introduced.  Trends  in  incidence  and  survival  have  also  been 
studied in Finland based on  data which  were obtained at different locations and 
from  women  of varying  ages  who  had been  invited for  their first  screening  at 
different times. 
The case of screening for neuroblastoma has shown how much of a disadvantage it 
can be not to have a cancer registry.  Screening was introduced in  some parts of 
Japan, but because there were no cancer registries in the regions concerned, it was 
not clear how large its (probably negative) impact was. It seems likely that a large 
number of abnormalities were detected and treated, which would have otherwise 
regressed  spontaneously (see Chapter  17  in  this  volume).  Indeed,  in  the  era of 
evidence-based medicine,  no  screening programme  should be launched  without 
intensive collaboration with the population-based cancer registry. 
Variables 
The value of a registry in the evaluation of screening is greatly enhanced if it is 
able to collect data on the stage at diagnosis, and possibly also on other relevant 
indicators, such as tumour size, grade and treatment. On the basis of data from the 
American SEER registry, Stephenson (see Chapter 13 in this volume) showed that 
263 there had been a huge increase in the registrations of prostate cancer, followed by a 
subsequent  decrease.  This  trend  in  America  was  caused  by  large-scale 
opportunistic  screening using the PSA test.  It  also  became clear how  the  stage 
distribution of the prostate cancer cases registered differed before and during the 
PSA era'. 
To be able to follow trends in tumour stage, a cancer registry must have complete 
and reliable data on this  item (see Chapters 4 and  9 in  this  volume).  This  is  a 
problem for many cancer registries, but it is hoped that new recommendations from 
the ENCR for recording stage in terms of 'binary TNM' will improve the situation. 
In order to be able to better estimate the influence of such trends in diagnosis, it is 
valuable to separate cancers detected by screening examinations, and those found 
by other means. Ideally, this can be done by linking data from the cancer registry 
with  the  databank  of the  mass  screening  programme.  If this  is  not  possible, 
registries could utilise a variable 'method of detection' to capture this information 
(see  Chapter 4  in  this  volume).  However,  it  is  not  clear how  reproducible  the 
results  would  be  using  such  a  variable.  Further,  this  item  does  require  further 
defmition, depending on the reason why data are being collected. For instance, the 
category  of patients  who  present for  a  screening  examination  because  of non-
specific  symptoms  pose  a  considerable  classification  problem.  If a  tumour  is 
detected, should it be considered that it was screen-detected or that it was detected 
because of the symptoms? 
Indicators of effect 
Since  early  detection  of invasive  cancers  aims  to  increase  the  effectiveness  of 
treatment, the most objective indicator of success is a reduction in  deaths  (other 
benefits,  such  as  improved  quality  of life,  are  more  difficult  to  quantify).  For 
screening programmes, which aim to detect (and ensure treatment of) pre-invasive 
cancers, a reduction in the incidence of invasive disease is the target, as for cancer 
of the cervix, and, in part, for colon cancer (see Chapter 15 in this volume) and oral 
cancers. Generally, however, when detecting early invasive cancer, the idea is to 
improve  the  effectiveness  of treatment,  and  hence  reduce  mortality.  Naturally, 
survival is increased by early detection, which is a necessary condition for lower 
mortality, but not a guarantee (see Chapter 3 in this volume). In any case, survival 
data  will  rarely  be  available  before  mortality  rates.  Improved  quality  of life 
between diagnosis and death might also be considered a legitimate endpoint for 
evaluation and one that could be investigated through cancer registries. 
It should be noted that incidence of cancer will  not be reduced by screening for 
early  cancers,  but it may  be  increased.  This  effect  will  certainly  be  seen  after 
screening is introduced and asymptomatic prevalent cases are discovered. If  earlier 
264 diagnosis  were  the  only  consequence  of screening,  then  the  final,  cumulative 
incidence should be unaffected.  However,  the possibility that cancers are  being 
detected  which,  in  absence  of screening,  would  never  have  surfaced  clinically 
(overdiagnosis)  implies that  incidence, especially that of small cancers,  may  be 
permanently higher in screened than in unscreened populations (see Chapters 9 and 
13  in this volume). It is, therefore, more useful to monitor the incidence of large 
and  metastasised  cancers,  since  a  decreased  incidence  of these  cancers  is  a 
necessary condition for a lowered death rate, although, again, not a guarantee (see 
Chapter 2 in this volume). When studying trends by stage, it is important to use 
incidence rates instead of proportions. If  screening causes a sharp increase in the 
diagnosis  of small  tumours,  there  will  be  a decrease in the percentage of large 
tumours,  even though there has been no  actual decrease in the number of large 
tumours. 
To clarify the effects of screening on  mortality,  the cancer registry  data can be 
combined with the data from the death certificates (see Chapter 2 in this volume). 
Often the cancer registry data are more detailed regarding the cancer diagnosis than 
reports  available to the clinician by the time he writes the death certificate. For 
example, many cervical cancer deaths have been allocated to  'uterus unspecified' 
in the death certificates. Further, only cancer registries can link mortality data to 
the  respective  dates  of diagnoses.  This  is  necessary  in  evaluation  screening 
programmes,  as  they  can only  affect the  mortality  of cases  diagnosed  after the 
launch of the programme. 
A cancer registry becomes even more useful if  its database can be linked with those 
from mass screening programmes on a record level. However, this linkage is only 
possible  if both  registries  have  sufficient  identification  data  or have  a  unique, 
identical and  permanent patient number (see Chapters 4  and 8 in  this  volume). 
Such  linkage  provides  a  great  deal  of information  about  the  impact  of mass 
screening (see Chapter 9 in this volume). Trends can be studied in the number of 
screen-detected malignancies (if the screening organisation is  able to retrieve this 
information), the number of interval cancers and the number of malignancies in 
people who do not participate in the screening or who do not belong to the target 
group. A complete population-based cancer registry usually forms the major means 
of identifying the interval cancers. The number of interval cancers is considered to 
be  one  of the  most  important  early  indicators  of the  quality  of a  screening 
programme. By providing feedback for the  screening organisation about 'missed' 
cases, it is possible to adjust the detection criteria and referral pattern. 
If  the cancer registry has data on treatment, then this information can be useful for 
cost-benefit analyses on the screening. In case of neuroblastoma screening, the full 
cost of the screening could be assessed by including estimates of the unnecessary 
follow-up and treatments. Further, PSA screening undoubtedly causes unnecessary 
treatment,  which,  however,  might  be judged  financially  acceptable  if there  is 
265 readiness to pay for the unknown, but potential, benefit and for the treatment of the 
evident side-effects. 
Collaboration with screening organisations 
Evaluation of mass screening can be one important reason to start and maintain a 
population-based cancer registry. Cancer registries should therefore be prepared to 
contribute to the evaluation of mass screening. One condition, however, is that the 
cancer registry data are complete, accurate and valid and that the data are rapidly 
available (see Chapters 4 and 7 in this volume). As a general rule, but only as far as 
feasible, a cancer registry should be willing to collect data that enable worthwhile 
evaluation of mass screening. 
The cancer registry should be in contact with the organisation planning to start a 
screening programme. It is important to start the collaboration as early as possible 
during the planning phase. Often at the beginning, there is little understanding of 
what the evaluation and monitoring of such a programme requires. It is therefore 
necessary  to  explain  the  available  data  sources  as  well  as  the  feasibility  of 
collecting extra data items. In  this  way,  the registry personnel can avoid future 
confusion when unrealistic expectations regarding the possibilities of evaluation 
may arise. It is also important to consult the screening organisation regarding the 
way their database is handled. Due to their experience in processing and linking 
databases,  the  cancer registries  should  be the  best  sources  of advice  for  this 
purpose. 
The  design  and  analytical  methodology  used  in  any  evaluation  or monitoring 
exercise must  always  be decided  after  considering  the unique  aspects  of each 
setting. The evaluation of the screening programme may require specially designed 
studies, which may or may not be incorporated in the day-to-day operations of the 
screening programme and those of the cancer registry.  On the other hand,  the 
periodical monitoring of the programme should be organised as a simple routine. 
The structure of the screening database, the delays  in the  data flow  and in the 
linkages  with  other registers,  e.g.  the  population  register,  will  be  the  limiting 
factors  in the monitoring process. These issues may not always be clear to the 
screening organisers, clinicians and public health professionals. Thus, the cancer 
registry should keep the other parties involved fully informed about the feasibility 
and requirements concerning the monitoring process. 
In  the  planning phase,  the  cancer registry  may  have to consider adapting  new 
methods of data collection and follow-up to fulfil the expectations on timeliness. 
Further, the monitoring of the screening programme may require extra data items 
to be collected. If  judged feasible, some of these items may be added to the cancer 
registry database, e.g. method of detection. However, a separate screening registry 
266 dataset  may  be more  feasible  as  it may  contain  extra items  necessary  for  the 
screening programme only, e.g., invitation data, technical data concerning the test 
and its results as  well as data concerning re-screening and diagnostic procedures. 
Finally, once the programme is running, the monitoring process itself may reveal 
that modifications to the data collection procedures, data flow, and items collected 
may become necessary.  Indeed,  these special operations may be focused  on the 
target cancer only, e.g., the data processing of breast cancer cases could be given 
special  priority to  provide rapid accumulation of data needed for  monitoring  a 
mammographic screening programme. 
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